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Abstract 
Angiogenesis, a process that enables the growth of blood 
vessels from a pre-existing vasculature and is common to all 
solid tumours greater than 1 mm3 in size (Gacche and 
Meshram, 2014). The angiogenic process is heavily promoted 
by vascular endothelial growth factor (VEGF). Compounds able 
to inhibit VEGF signalling have been shown to reduce cancer 
mass (Arjaans et al., 2016). However, VEGF receptor tyrosine 
kinase inhibitors (RTKIs), a class of anti-VEGF treatment, have 
been shown to cause cardio-toxicity, with hypertension being a 
commonly reported, and often severe, side effect (Eskens and 
Verweij, 2006; Widakowich et al., 2007; Abi Aad et al., 2015). 
Depending on the nature of the study, the incidence of 
hypertension in the VEGF RTKI patient population ranges from 
23% to 90% (Hamberg et al., 2010; La Vine et al., 2010; 
Aparicio-Gallego et al., 2011; Bible et al., 2014). Due to the 
increasing incidence and seriousness of hypertension observed 
in oncology clinics, it is clear that there are important 
cardiovascular issues relating to the use of RTKIs, particularly 
those that target VEGF, that require further exploration. This 
body of work set out to determine the in vitro potencies of 
vandetanib, pazopanib, cediranib and sorafenib at VEGFR2, 
alongside the in vivo cardiovascular haemodynamic and 
vasoactive profile of vandetanib and pazopanib, two VEGF 
RTKIs shown to cause hypertension in approximately 32% 
(Wells et al., 2012) and 33%-40% of the patient population, 
respectively (Bible et al., 2014). 
In NFAT luciferase assays cediranib, sorafenib, pazopanib and 
vandetanib were shown to inhibit, in a non-competitive 
fashion, VEGF165 mediated signalling in vitro. In 
haemodynamic studies, using Doppler flowmetry and 
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telemetry methodologies, both vandetanib and pazopanib 
caused significant hypertension (P<0.05, in comparision to 
vehicle). Pazopanib and vandetanib lead to significant 
vasoconstriction of the mesenteric and hindquarter vascular 
beds, pazopanib also produced significant vasoconstriction in 
the renal vascular bed (P<0.05, in comparision to vehicle). 
None of the variables measured in the haemodynamic studies 
significantly differed between the 30 mgkg-1day-1 pazopanib 
and 25 mgkg-1day-1 vandetanib groups. In chronic 
radio-telemetric studies, vandetanib was shown to cause a 
significantly greater but more transient increase in mean 
arterial blood pressure in comparison to pazopanib (P<0.05). 
Vandetanib was also shown to inhibit VEGF and ACh-mediated 
vessel dilatation in pressure myography experiments. Finally, 
vandetanib and pazopanib were shown to induce 
vasodilatation in the presence of a vasoconstrictor (U46619), a 
previously unseen finding. 
In conclusion, the body of work undertaken here has given 
novel insight into the ability of non-competative anti-VEGF 
RTKIs to inhibit VEGF-mediated signalling and vessel dilatation 
as well as produce direct effect of vessel diameter in the 
absence of VEGF. It has also produced a validated method of 
hypertension in a rat model, both in the short and long term. 
These models have shown that different anti-VEGF RTKIs have 
different regional haemodynamic and post-treatment 
hypertensive side effect profiles. These findings are important 
for understanding the mechanisms behind the therapeutic and 
non-therapeutic effects of VEGF RTKIs and allow for further 
research into the signalling mechanism involved in VEGF RKTI-
mediated hypertension and the potential therapeutic 
treatments that could treat this.  
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Chapter 1 : General 
Introduction  
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1.1 General Introduction 
Cancer is a complex group of diseases, with over 100 different 
known classifications (Stewart, 2014). It is a leading cause of 
morbidity worldwide, with 14 million newly diagnosed cases 
and 8.2 million cancer related deaths in 2012 (Stewart, 2014; 
World Health Organisation, 2016). The development and 
progression of cancer involves multiple changes and/or 
mutations in gene expression, leading to up- or 
down-regulation of specific signalling pathways (Hanahan and 
Weinberg, 2011). Common to all solid tumours is the ability to 
induce angiogenesis, a process that enables the growth of 
blood vessels from the pre-existing vasculature (Gacche and 
Meshram, 2014). Increasing blood flow to the tumour mass is 
a requirement for tumour growth beyond 2-3 mm3 in size 
(Folkman, 1971). Pathological angiogenesis results in the 
development of blood vessels that are unstructured, tortuous 
and innately leaky (Ferrara, 2001). The resultant enhanced 
vessel permeability facilitates the escape of tumour cells from 
the tumour mass as well as their transportation to distant 
sites, wherein secondary metastases may form (Wong et al., 
2015). One of the key, and most potent, mediators of 
angiogenesis is vascular endothelial growth factor (VEGF). The 
inhibition of tumorigenic processes, such as angiogenesis, is 
critical to preventing cancer progression. The recent 
development of several anti-angiogenic drugs that target 
VEGF, or its receptors, has highlighted the important 
relationship between the cardiovascular system and the 
tumour microenvironment. This relationship has become one 
of the main focuses of oncology and cardiovascular research. 
VEGF is important for cell survival, proliferation, increased 
vascular density and vasodilatation (Liang et al., 2013; 
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Domigan et al., 2014). Neutralisation or blockade of VEGF 
signalling, either by inhibiting the VEGF ligand directly, i.e. 
with the humanised monoclonal antibody bevacizumab that 
prevents the VEGF ligand from interacting with the receptor, 
or by targeting the associated VEGF receptor 2 (VEGFR2) 
signalling pathway, generally with receptor tyrosine kinase 
inhibitors (RTKIs), has been shown to decrease these events 
(Liang et al., 2014). There are several RTKIs such as 
vandetanib (ZactimaTM), pazopanib (Votrient®), sorafenib 
(Nexavar®) and cediranib (RecentinTM) (Knosel et al., 2014) 
that are currently used or are in late Phase trials as adjuvant 
treatments alongside current chemotherapeutic agents (Herbst 
et al., 2010; Arjaans et al., 2016).  
VEGF RTKIs are a multi-targeted drug class. This approach 
was first designed to reduce the likelihood of drug resistance 
(Huang and Kauffman, 2013). However, it has been shown 
that anti-angiogenic/anti-VEGF treatments can lead to 
cardio-toxicity, with hypertension being a commonly reported 
and severe side effect (Eskens and Verweij, 2006; Widakowich 
et al., 2007; Abi Aad et al., 2015). Depending on the nature of 
the study, the incidence of hypertension in the clinical setting 
ranges from 23% to 90% of the patient population (Hamberg 
et al., 2010; La Vine et al., 2010; Aparicio-Gallego et al., 
2011; Bible et al., 2014), with approximately 32% of the 
patient population taking vandetanib (Wells et al., 2012) and 
33%-40% of the patient population prescribed pazopanib 
(Hamberg et al., 2010; Bible et al., 2014) developing 
hypertension. Moreover, the development and escalation of 
pre-existing hypertension in these patient populations has 
been linked to multiple severe complications including venous 
or arterial thrombo-embolisms, acute heart failure, 
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intracerebral haemorrhage and reversible posterior 
leukoencephalopathy syndrome (Govindarajan et al., 2006; 
Chu et al., 2007; Pouessel and Culine, 2008; Eschenhagen et 
al., 2011). The resultant hypertension caused by treatment 
with VEGF RTKIs has proven difficult to treat clinically, as 
many patients appear to be resistant to conventional 
anti-hypertensive therapies, including angiotensin converting 
enzyme inhibitors, calcium channel blockers, beta blockers and 
thiazide diuretics; all of which appear to have little or no 
effectiveness in this patient population (Kruzliak et al., 2013).  
VEGF blockade, by therapeutic compounds such as RTKIs, has 
been shown to produce cardiotoxic effects. To date, the role of 
VEGF in the cardiovascular system is poorly understood, under 
both normal and pathophysiological conditions. A better 
understanding of the mechanisms by which hypertension 
occurs in the absence of VEGF signalling would help to 
improve the side effect profile of current and future 
anti-angiogenic treatments.  
1.2 VEGF 
VEGF represents a ligand family of dimeric polypeptides, of 
approximately 46 kDa, which propagate pro-survival and 
pro-angiogenic signals (Liang et al., 2013).  
In the early 1970’s, J. Folkman first reported that a secreted 
tumour factor, initially termed tumour angiogenesis factor 
(TAF), was required for the initiation of tubule formation 
(Folkman, 1971; Folkman, 1972). TAF was shown to induce 
angiogenesis and allow tumour growth past 2-3 mm3 in size 
(Folkman, 1971). Several years later, TAF was isolated and 
partially purified (Senger et al., 1983), in a study that 
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demonstrated its role in vascular permeability. Thereafter, it 
was termed vascular permeability factor (VPF). Subsequently 
TAF and VPF were recognised to be the same factor and it was 
ultimately renamed as VEGF by Ferrara, who fully sequenced 
the human and bovine VEGF in 1989 (Senger et al., 1983; 
Senger et al., 1986; Leung et al., 1989; Ferrara and Henzel, 
1989).  
The mammalian VEGF family consists of 5 members, namely, 
VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental-derived 
growth factor (PIGF) (Olsson et al., 2006). VEGFs propagate 
their signal through binding to VEGF receptors. The VEGFR 
family of receptor tyrosine kinases (VEGFR1, VEGFR2, VEGFR3 
and soluble (s) VEGFR1) are structurally comprised of a 7 
immunoglobin like (Ig) extracellular domain, a linked 
hydrophobic transmembrane domain and multiple intracellular 
kinase domains (Koch et al., 2011). However, the soluble form 
of VEGFR1 (sVEGFR1) comprises of only the extracellular 
domain of the receptor. The intracellular portion of 
VEGFR1, VEGFR2 and VEGFR3 contain a juxta-membrane 
domain, a kinase insert domain, an ATP binding domain, a 
phosphotransferase domain and a C-terminal domain (Figure 
1.1) (Stuttfeld and Ballmer-Hofer, 2009; Brozzo et al., 2012). 
VEGF ligands have differing affinities for different members of 
the VEGF receptor family (Woolard et al., 2009) as well as for 
heparan sulphate glycoproteins (HSG) and neuropillin (NP) (a 
130-140 kDa co-receptor which also interact with semaphorin) 
(Soker et al., 1998). There are two NPs, namely, NP1 which is 
able to bind to VEGF-A, -B and PIGF and is found in arterial 
endothelial cells (ECs) and NP2 which is able to bind to 
VEGF-A, -C and -D and is found in venous and lymphatic ECs 
(Djordjevic and Driscoll, 2013).  
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Figure 1.1 Diagrammatical representation of VEGFR1 and VEGFR2 
receptor structure, their corresponding ligands and signalling 
pathways. The VEGFR comprises of 7 immunoglobin like (Ig) 
extracellular domain of each receptor, linked to a hydrophobic 
transmembrane domain. The intracellular portion of each receptor 
contains a juxta-membrane domain, a kinase insert domain, an ATP 
binding domain, a phosphotransferase domain and a C-terminal 
domain. The VEGFR1 and 2 cononical signalling pathways comprise of 
the PLCγ, PI3K and MAPK pathways, allowing these receptors to 
influence cell survival (yellow), cell migration (blue), cell proliferation 
(green) and vessel permeability and vasodilatation (clear). Adapted 
from information in Olsson et al., 2006; Stuttfeld and Ballmer-Hofer, 
2009; Brozzo et al., 2012; Bretz et al., 2013; Domigan et al., 2014;. 
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VEGF-A is able to bind to NPs (expressed on tumour cells and 
ECs), VEGFR1, a 180 kDa protein also referred to as Flt1, 
(expressed on monocytes and vascular ECs) and VEGFR2 
(expressed on vascular ECs) (Zachary and Gliki, 2001). 
VEGF-B and PIGF are able to bind NP as well as VEGFR1. 
Lastly, VEGF-C and VEGF-D both bind to VEGFR3 (a 195 kDa 
protein also referred to Flt4) found on lymphatic ECs (Zachary 
and Gliki, 2001).  
The extent of production and secretion of VEGF is determined 
by the extracellular environment, in particular the availability 
of oxygen (Kaur et al., 2005). When oxygen is freely available, 
factor inhibiting hypoxia inducible factors (FIH) and prolyl 
hydroxylase domain proteins (PHDs) (Maxwell et al., 2001) 
degrade cytoplasmic hypoxia inducible factors (HIF) such as 
HIF-1α (Ahn et al., 2014) reducing the ability of HIF to 
transcribe the vegf gene.  
However under hypoxic conditions, FIHs and PHDs are 
inhibited. This allows HIF-1α to translocate to the nucleus, 
whereupon it is able to increase both VEGF production and 
secretion, through its action as a transcription factor 
(Semenza et al., 1997; Ferrara, 2001). This action also 
positively feeds-back to further up-regulate HIF expression 
levels (Blancher et al., 2001).  
VEGF-A is currently the most studied VEGF variant (Goel and 
Mercurio, 2013). The VEGF-A gene is alternatively spliced to 
give multiple VEGF-A isoforms with differing bioavailability’s 
(Woolard et al., 2009). These isoforms include VEGF121, 
VEGF145, VEGF148, VEGF165, VEGF183, VEGF189 and VEGF206 
(Koch et al., 2011). Each isoform differs in its specificity for 
VEGFR2, as well as HSG and NP binding (Pan et al., 2007; 
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Koch et al., 2011). VEGF-A isoforms fall into two major 
groups: VEGFxxx and VEGFxxxb, with xxx symbolising amino 
acid number. VEGFxxx and VEGFxxxb isoforms differ primarily as 
a consequence of alternative splicing within exon 8 (Bates., 
2013). This leads to the terminal 6 amino acids, and therefore 
tertiary structure of VEGFxxx and VEGFxxxb isoforms to differ, 
for example cysteine-160 in VEGF165 is changed to a serine in 
VEGF165b (Woolard., 2009). This alters the tertiary structure of 
VEGF165b, in comparison to VEGF165, by removing a disulphide 
bond formed between cysteine-160 and cysteine-146 in the 
VEGF165 isoform (Woolard et al., 2009). There are also a 
number of charged amino acids (such as arginine) in the 
C-terminus of VEGF165, which are supplemented by neutral 
amino acids, such as lysine in VEGF165b, further varying each 
isoform’s tertiary structure. Although these structural changes 
do not greatly affect the affinity of VEGF165b for VEGFR2 in 
comparison to VEGF165 (Kawamura et al., 2008), they are 
thought to reduce VEGF165b efficacy at the VEGFR2 receptor by 
reducing the probability of receptor transphosphorylation 
(Kawamura et al., 2008). This reduces the probability and 
amplification of receptor-mediated downstream signalling. It 
has also been shown that VEGF165b is unable to bind to the 
VEGFR2 co-receptor, NP1 which acts to enhance the cell 
migratory and cell proliferative signalling of VEGFR1 and 
VEGFR2 (Kawasaki et al., 1999; Chaudhary et al., 2014; 
Zachary, 2014). The reduced efficacy of VEGF165b at VEGFR2 
and reduced affinity for NP1, in comparison to VEGF165, has led 
to VEGF165b being referred to as ‘anti-angiogenic’ due to its 
weak agonist action and its ability to competitively inhibit the 
receptor binding of more efficacious VEGFs such as VEGF165a 
(Woolard et al., 2004; Kawamura et al., 2008; Carter et al., 
2015). VEGF165b comprises around 50% of the VEGF165 
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isoforms found in tissues such as the lung, kidney, bladder and 
colon (Cheung et al., 1998). However, in relatively angiogenic 
tissues, such as the placenta, VEGF165b expression is low 
(Bates et al., 2006). It has also been noted that tumours that 
express abnormally high amounts of VEGF165b grow more 
slowly in comparison to those expressing high amount of 
VEGF165, further suporting the hypothesis that VEGF165b is a 
weaker promoter of angiogenesis (Pritchard-Jones et al., 
2007). The presence of VEGF165b has also been shown to 
reduce the potency of Avastin (bevacizumab) (Varey et al., 
2008). This is thought to be due to VEGF165b competitively 
binding to Avastin leaving VEGF165 able to activate 
VEGFR2-mediated angiogenesis. As VEGF165b has been shown 
to be overexpressed in various tumours (Rennel et al., 2008), 
understanding the effect of VEGF165b on RTKI action is 
important for future drug development and has potential 
clinical applications regarding treatment choice.  
Binding of VEGF-C and VEGF-D to VEGFR3 leads to the 
activation of the Phosphatidylinositide 3-kinase (PI3K) and 
mitogen activated protein kinase (MAPK) pathways (Salameh 
et al., 2005). This is important for lympho-EC survival and 
proliferation. VEGFR3 signalling has also been shown to have a 
role in cardiovascular development with vegfr3 -/- mice dying 
at embryonic day 9.5 due to impaired cardiovascular and 
vessel development (Dumont et al., 1998). However, VEGFR3 
signalling has not been shown to be integral to adult vascular 
development, and therefore will not be discussed further. 
VEGFR1, VEGFR2 and the co-receptor NP1 are known to 
facilitate a number of processes in the vasculature, including 
EC survival, vessel sprouting and vasodilatation (Olsson et al., 
2006). The activation of VEGFR2, via VEGF-A isoforms, has the 
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most prominent promotional effect on these processes (Koch 
et al., 2011). NP1 is able to bind VEGF-A, VEGF-B and PIGF. 
This interaction allows it to form an oligomeric complex with 
VEGFR1 or VEGFR2 and enhance the resultant cell migration 
and proliferation (Kawasaki et al., 1999; Parker et al., 2012).  
VEGFR1 binds to its ligand via extracellular Ig domains 1-3 
(Nieminen et al., 2014). This interaction induces receptor 
dimerisation and trans-phosphorylation of intracellular tyrosine 
residues, subsequently leading to activation of phospholipase 
C (PLC) and MAPK signalling cascades (Sawano et al., 1997) 
increasing cell migration, proliferation and vascular 
permeability (Ito et al., 1998). Although it is clear that 
VEGFR1 causes downstream signalling when activated, the 
current level of involvement of VEGFR1 in EC proliferation, 
migration and vascular permeability is debated in the 
literature. It has been shown in vitro that VEGFR1 is not 
essential for these processes to occur (Gille et al., 2001). 
However, contrary to this, phosphorylation of VEGFR1 tyrosine 
residue 1213 has been shown to cause sustained activation of 
angiogenesis through its interaction with the p85 subunit of 
PI3K, leading to the induction of the PI3K pathway (Cai et al., 
2003). Although the full role of VEGFR1 remains to be 
determined, its presence has been shown to be important in 
development, with the vegfr1 -/- knockout being lethal in mice 
at embryonic day 8.5 (Fong et al., 1999). Interestingly, 
deletion of the tyrosine kinase domain of VEGFR1 in mice 
leads to normal development (Hiratsuka et al., 1998). This has 
led to the theory that sVEGFR1 and VEGFR1 may act as 
anti-angiogenic decoy receptors, by sequestering VEGF and 
therefore reducing the extent of the angiogenic response 
(Carmeliet et al., 2001; Murakami et al., 2006).  
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Like VEGFR1, VEGFR2 knockout mice also experience 
embryonic lethality at embryonic day 8.5-9 (Shalaby et al., 
1995). This, and the embryonic lethality of vegfa -/- (lethal at 
embryonic day 9.5-10.5) and vegfa+/- (lethal at embryonic 
day 11-12) in mice, highlights the importance of the 
VEGF-A/VEGFR2 signalling pathway in EC survival, 
proliferation and angiogenesis (Ferrara et al., 1996; Carmeliet 
et al., 1996). VEGF-A or C-terminal truncated forms of VEGF-C 
and VEGF-D bind to the Ig 2 and 3 domains of VEGFR2. This 
leads to activation, dimerization and trans-phosphorylation of 
the receptor (Dougher-Vermazen et al., 1994), allowing 
VEGFR2 to activate various pathways, including the PLCγ, 
MAPK, focal adhesion kinase (FAK), PI3K and phospholipase A2 
(PLA2) pathways (Figure 1.1). These interactions lead to 
VEGF-A/VEGFR2- induced proliferation, migration, cell 
survival, cell permeability and angiogenesis, as well as 
vasodilatation though the production of nitric oxide (NO) and 
prostaglandin (PGI2), two potent vasodilatory factors (Horii et 
al., 1978; Kitsukawa et al., 1995; Bauer and Sotnikova, 
2010). NP1/VEGFR2 oligomeric complex signalling has been 
shown to increase cell migration, cell survival, permeability 
and angiogenesis, compared to that of VEGFR2 alone (Pan et 
al., 2007; Jia et al., 2010). The involvement of NP1 in VEGF 
signalling is important in the regulation of vascular 
development and tone, with np1 -/- being lethal in mice at 
embryonic day 12.5, due to reduced vasculature and irregular 
neuronal patterning (Kawasaki et al., 1999). Overexpression 
of NP1 leads to constitutive vessel dilatation and heart 
malformation (Kitsukawa et al., 1995). Due to VEGFR2 
signalling having the most influence over angiogenesis and cell 
survival, this receptor along with its ligand VEGF-A, have been 
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targeted pharmacologically in diseases where angiogenic 
regulation is abnormal, e.g. cancer. 
In addition to its role in angiogenesis (discussed in Section 
1.3.1.1), VEGF/VEGFR2 also promotes vascular permeability 
(Senger et al., 1986). Although it is not fully understood how 
VEGF increases vascular permeability, its strong affiliation with 
the production of vesicular-vacuolar organelles is thought to 
be integral (Feng et al., 1996). Vesicular-vacuolar organelles 
are able to form channels through the EC by fusing with each 
other, therefore facilitating the diffusion of molecules (Feng et 
al., 1996). Murohara et al. (1998) demonstrated that NO and 
PGI2 have been linked to the formation of vesicular-vacuolar 
organelles, showing that VEGF induced permeability was 
substantially reduced in the presence of Nω-Nitro-L-arginine 
methyl ester (L-NAME; eNOS inhibitor) and indomethacin 
(cyclooxygenase inhibitor) in vitro (Murohara et al., 1998). 
VEGF not only contributes to the progression of cancer through 
stimulating angiogenesis and increasing vascular permeability, 
but has also been linked to tumour initiation and tumour 
survival (Goel and Mercurio, 2013). Autocrine VEGF signalling 
has been observed in multiple tumour types (Bachelder et al., 
2001; Hamerlik et al., 2012), and has been suggested as a 
characteristic of aggressive cancer types (Mak et al., 2010; 
Cao et al., 2012). It is thought that the ability of the tumour 
cell to signal independently through VEGF-A, in an autocrine 
manner, helps to increase its survival. The inhibition of 
VEGF-A has been shown to reduce tumour cell growth and 
survival (Lee et al., 2012). The presence of VEGF in 
micro-dissected tumours and its role in cell de-differentiation 
have garnered interest in the function of VEGF in tumour 
initiation (Senger and Van De Water, 2000; Bates et al., 2003; 
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Mak et al., 2010). How cells increase their expression of 
VEGF-A and VEGFRs in order to promote a tumour phenotype 
is currently unknown. However, it is thought that 
environmental hypoxia may be an important driver. The 
sustained activation of HIF-1α, the hypoxic-inducible 
transcription factor for VEGF-A, in certain tumour types goes 
someway to supporting this hypothesis (Mimeault and Batra, 
2013). Finally, the presence of VEGFRs on T-cells (Hansen et 
al., 2012) and macrophages (Galdiero et al., 2013) has been 
associated with the progression of tumour growth. It has been 
hypothesised that VEGF, secreted by macrophages located in 
the hypoxic tumour environment, may act to further 
contribute to tumour growth by increasing tumour cell survival 
and angiogenesis (Goel and Mercurio, 2013). 
The high expression of VEGF-A in certain tumour types, e.g. 
breast and colorectal cancer, has also been associated with 
increased tumour aggressiveness, poorer responses to 
chemotherapy and increased mortality rates (Toi et al., 2001; 
Foekens et al., 2001; Cao et al., 2012). Due to this, 
chemotherapies have been designed to target the 
VEGF-A/VEGFR2 pathway, with some also targeting 
VEGF-A/VEGFR1 and VEGFR3 signalling in order to reduce 
tumour cell survival and tumour angiogenesis.  
1.3 VEGF in Angiogenesis 
Since the initial demonstration of the importance of the 
vasculature in the development of solid tumours (Folkman, 
1971), the wider understanding of angiogenic processes in 
health and disease has quickly developed and is now 
recognised as the process of vessel sprouting and extension 
from the pre-existing vasculature (Carmeliet and Jain, 2011). 
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In order for this to occur, Phalanx cells, an EC phenotype 
located on the luminal side of the vessel, act to monitor 
oxygen levels (De Bock et al., 2009). When hypoxic conditions 
are detected, HIF-1α translocates to the nucleus (Maxwell et 
al., 2001) and promotes the transcription of pro-angiogenic 
signalling molecules such as VEGF (Semenza et al., 1997; 
Ferrara, 2001). This action also positively feeds back to 
up-regulate HIFs, which are able to independently activate the 
PI3K and PLCγ pathways, further compounding the 
pro-angiogenic signal (Blancher et al., 2001).  
VEGF causes ECs to release matrix metalloproteases (MMPs). 
MMPs degrade the vascular basement membrane (Ohuchi et 
al., 1997) allowing the ECs to migrate to the outer layers of 
the vessel, as well as cause the release of basement 
membrane-sequestered VEGF that further promotes the 
angiogenic process (Lee et al., 2005).  
In order for the vessel to branch, the now motile ECs begin to 
segregate themselves phenotypically into either tip or stalk 
cells (Eilken and Adams, 2010). Tip cells, characterised by 
their motility and expansive filopodia, lead the branching 
process, whereas stalk cells, typically characterised by their 
high proliferation rate, fewer filopodia in comparison to tip 
cells and excretion of basement membrane proteins, follow the 
tip cell toward the concentrated end of the VEGF gradient and 
help to form the vessel lumen (Gerhardt et al., 2003). The 
identity of the cell as either a tip or stalk cell is versatile and 
changes throughout the branching process according to the 
expression of notch (Hellstrom et al., 2007); a single pass 
transmembrane receptor which is involved in the control of cell 
differentiation and cell fate. The VEGF/VEGFR-2 signalling 
pathway is able to stimulate tip cell induction, by increasing 
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production of the notch receptor ligand: delta like ligand-4 
(Dll4) (Gerhardt et al., 2003). Dll4 binds to notch on 
neighbouring cells and reduces the likelihood of them 
becoming tip cells by decreasing expression levels of VEGFR2, 
VEGFR3 and NP1, while increasing the expression level of 
VEGFR1. Once a new vessel has branched, the vessel lumen is 
formed (Bentley et al., 2009; Potente et al., 2011).  
Currently, it is thought that vessel lumen formation occurs via 
the ‘cord-hollowing’ process; a mechanism by which the ECs 
orientate themselves into an apical/basal polarity, with 
expression of negatively charged CD34-sialomucins (CD34) on 
the apical (luminal) membrane (Strilic et al., 2009) (Figure 
1.2). The negative charge leads to membrane repulsion and 
the opening of a gap between the ECs. CD34 then interacts 
with cytosolic F-actin via moesin. This interaction allows for 
cytoskeletal retraction, lumen formation and blood flow (Strilic 
et al., 2009). Perfusion of the vessel increases local oxygen 
and nutrient concentrations leading to remodelling of the 
lumen and vessel maturation (Nicoli et al., 2010).  
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Figure 1.2 Illustration of vessel lumen formation. ECs create 
VE-cadherin expressing junctions with each other while forming the 
protruding vascular stalk. This interaction causes EC polarisation 
where ECs express negatively charged CD34-sialomucins on their 
apical membrane. CD34-sialomucin recruits F-actin via binding to 
moesin, this and the negative charge of CD34-sialomucins, lead to 
apical-membrane retraction and lumen formation. Figure adapted 
from Strillic et al., 2009.  
 
The stimulation of vessel growth surrounding and within a 
tumour increases the likelihood of tumour metastasis, as 
tumour cells are able to disseminate through intravasation 
(Wyckoff et al., 2000). Once this occurs, the cell is transported 
via the vasculature to a distant organ/site. The tumour cell is 
able to extravasate into the surrounding tissue and new 
tumour formation occurs. As tumour cells must adapt to be 
able to survive within the circulating blood, these 
micro-metastases tend to create more malignant tumour types 
(Chambers et al., 2002). 
There are several different mechanisms by which a tumour 
mass can initiate angiogenesis. Amongst the most well-known 
is constitutive up-regulation of the production and secretion of 
pro-angiogenic factors, such as VEGF (Hanahan and Weinberg, 
2000; Hanahan and Weinberg, 2011). However, the 
pathological vessels created by this process are disorganised 
in structure and placement, as well as leaky and tortuous due 
to weak intercellular connections (Ehling and Mazzone, 2016). 
This increases the likelihood of tumour metastasis and 
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decreases vessel perfusion, thereby reducing the ability of the 
vessel to deliver oxygen, nutrients and chemotherapeutic 
agents. These pathological vessels are also less able to 
remove waste, causing the tumour microenvironment to 
become toxic. This is thought to promote the selection of more 
malignant tumour cell phenotypes and to maintain the 
constitutive up-regulation of pro-angiogenic factors (Potente et 
al., 2011). 
As well as tumour cells being able to cause vessel sprouting 
and extension, other mechanisms by which tumour cells 
access the vascular system have been noted. The most 
prominent of these are the induction of intussusceptive 
angiogenesis, allowing directed vessel growth through 
endothelial and mural cell reorganisation (Djonov et al., 
2003); co-option, where cancerous cells grow directly around 
vessels; and vascular mimicry, where tumour cells line the 
internal and external vessel walls. Finally some ‘stem cell-like’ 
cancer cells are able to differentiate into an EC phenotype 
which incorporates into the vessel wall in a process known as 
postnatal vasculogenesis (Carmeliet and Jain, 2011). Tumour 
cells are also able to aid vessel repair by recruiting endothelial 
progenitor cells, which strengthen and repair the vascular wall, 
ensuring blood flow to the tumour (Wang et al., 2010). 
Through the above mechanisms, neoplastic tumour cells are 
able to access oxygen and nutrients via the pre-existing 
vascular system. Therefore, the pharmacological targeting of 
signalling molecules that allow tumour cells to promote 
angiogenesis, or maintain vessel structure and permeability is 
seen as a key treatment strategy in cancer. Amongst the 
pro-angiogenic factors produced, VEGF is one of the principal 
mediators of angiogenic progression and maintenance, EC 
35 
 
survival and vessel permeability and has hence become the 
main target of anti-angiogenic treatments. 
1.3.1 Anti-VEGF Treatments in Cancer 
Pharmaceutical companies have harnessed a variety of 
techniques to neutralise the action of VEGFs. Currently there 
are a range of compounds which inhibit VEGF-A, VEGFR1, 
VEGFR2 and/or VEGFR3 and have been approved for use in 
the treatment of cancer, or are currently undergoing clinical 
trials (Arjaans et al., 2016; Bible and Ryder, 2016).  
Of the current therapeutic strategies which target VEGF 
signalling, the first to be clinically approved was the 
monoclonal humanised VEGF antibody, bevacizumab 
(AvastinTM). Bevacizumab is approved as a treatment in 
advanced metastatic cancers such as colorectal and 
non-squamous, non-small cell lung cancer. It acts by binding 
free VEGF, reducing its availability to bind to VEGFR2 and 
therefore its ability to subsequently promote angiogenesis 
(Bagri et al., 2010). Ranibizumab is another 
immuno-pharmacological agent (humanised antibody Fab 
fragment) that binds to VEGF and is FDA approved for use in 
the treatment of age-related macular degeneration (Lowe et 
al., 2007).  
Another strategy pharmaceutical companies have adopted to 
target VEGF signalling involves decoy receptors, such as 
Aflibercept. Aflibercept was approved for use in colorectal 
cancer in 2012 (Sharma et al., 2013) and works by binding to 
extracellular VEGF, again reducing circulating VEGF levels and 
inhibiting receptor downstream signalling. Aflibercept is a 
soluble humanised immunoglobin antibody constant region 
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fused to the extracellular Ig 1-3 domains of VEGFR1 
(Gomez-Manzano et al., 2008). This allows Aflibercept to bind 
to and inhibit the actions of VEGF-A, VEGF-B and PDGF.  
A further pharmacological strategy clinically approved for the 
inhibition of VEGF signalling is the use of RTKIs (Table 1.1). 
There are three classes of RKTIs. Class I RKTIs are able to 
bind to the active conformation of the receptor, competitively 
antagonising ATP binding at various intracellular kinase groups 
(Gotink and Verheul, 2010). Examples of this group include 
vandetanib, cediranib and pazopanib (Hennequin et al., 2002; 
Wedge et al., 2002; Knowles et al., 2006; Gotink and Verheul, 
2010; Davis et al., 2011; Blanc et al., 2013). Class II RTKIs, 
such as sorafenib (Zhang et al., 2009), bind to the non-active 
conformation of the receptor, at the hydrophobic pocket of the 
activation loop, and antagonise receptor activation by 
sterically blocking ATP binding. Finally, class III RTKIs work by 
covalently binding to sulphur-rich cysteine residues within the 
intracellular region of the receptor, regardless of receptor 
conformation. This action blocks ATP binding, reducing the 
ability of the receptor to enter its active conformational state. 
One example of a class III RKTI is neratinib (Gotink and 
Verheul, 2010; Davis et al., 2011). 
Unlike immunological compounds, RTKIs are multi-targeted 
(Table 1.1) (Belcik et al., 2012). The multi-targeted aspect of 
these compounds makes them a popular therapeutic tool, as 
the ability for the tumour to act independently of multiple 
signalling pathways is less likely.  
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RTKI Targets Indications Adverse effects Reference 
Vandetanib VEGFR2,3, 
EGFR, 
RET 
Medullary thyroid 
cancer 
Phase III: Non-small cell lung 
cancer 
Hypertension, 
haemorrhage, 
QT prolongation, diarrhoea, 
rash 
(Wedge et al., 2002) 
Pazopanib VEGFR1,2,3, 
PDGFR, c-kit 
Renal cell carcinoma, advanced 
tissue sarcoma 
 
Hypertension, diarrhoea, 
fatigue, weight loss 
(Bible et al., 2012) 
Sorafenib VEGFR2,3, 
PDGFR,Flt-3, 
c-kit 
Advanced renal cell 
carcinoma, hepatocellular 
carcinoma 
Hypertension, cardiac 
ischemia, diarrhoea, 
dermatological effects, 
(Eskens and Verweij, 
2006; Widakowich et 
al., 2007) 
Cediranib VEGFR1,2,3, 
PDGFR, 
FGFR1 
Phase III: Ovarian cancer 
Phase III: Cervical cancer 
Hypertension, diarrhoea, 
nausea 
(Mulders et al., 2012; 
Schmidt, 2015; 
Minguet et al., 2015; 
Ruscito et al., 2016) 
Table 1.1 Summary of four VEGFR RTKIs; their targets, indications and adverse effects. 
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All treatments which block VEGF have been shown to have 
VEGF-related side effects. These include rash, proteinuria, 
cardiomyopathy, haemorrhage, wound complications and 
hypertension amongst other effects (Eskens and Verweij, 
2006; Widakowich et al., 2007; Chen and Cleck, 2009; Hall et 
al., 2013; Le et al., 2014). These side effects are thought to 
be related to the inhibition of VEGF, as VEGF-specific 
compounds such as bevacizumab display these alone, whereas 
compounds that are multi-targeted to VEGF and other 
signalling molecules show these toxicities as well as other 
adverse effects, such as weight loss and nausea (Table 1.1). 
In order to improve cancer treatment and therefore prognosis 
and outcome, it is important to investigate why 
anti-angiogenic treatments display particular side effects and 
how these can be reduced. 
1.3.1.1  Vandetanib 
Vandetanib (otherwise known as ZD6474 or ZactimaTM, 
produced by AstraZeneca) is a Class I VEGFR2, VEGFR3, 
epidermal growth factor receptor (EGFR), rearranged during 
transfection (RET) kinase specific RTKI which is FDA approved 
for use in the treatment of medullary thyroid cancer. It is also 
known to inhibit many other kinases (Table 1.2); however, the 
significance of this on its anti-tumorigenic action and adverse 
effect profile has not been analysed.  
Vandetanib is able to cross the cell membrane and bind to the 
intracellular portion of the active conformation of the VEGFR2 
receptor, inhibiting ATP binding, receptor phosphorylation and 
consequent downstream signalling (Figure 1.3). Its action on 
VEGFR2, VEGFR3 and EGFR leads to a reduction in MAPK, PI3K 
and PLCγ pathway activation, subsequently reducing cell 
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growth, proliferation and survival (Thornton et al., 2012). 
Vandetanib has been shown to reduce tumour angiogenesis 
via inhibition of VEGFR2; and tumour cell survival, growth and 
morphogenesis due to its inhibition of EGFR (Grandis and Sok, 
2004; Thornton et al., 2012). Interestingly, the 
overexpression of EGFR has been shown in multiple cancer 
types including breast, lung and prostate (Klijn et al., 1992; 
Visakorpi et al., 1992; Fujino et al., 1996). Therefore, 
vandetanib demonstrates dual action through its 
multi-targeted design; able to inhibit blood supply and 
metastasis through its inhibition of VEGFRs, while reducing 
tumour cell growth and survival via EGFR inhibition. The 
anti-tumour effects of EGFR inhibition have also been observed 
with EGFR-specific inhibitors, such as erlotinib, a RKTI which is 
FDA approved for the treatment of non-small cell lung cancer 
(Smith, 2005). Finally, vandetanib inhibits RET, a tyrosine 
kinase receptor whose activation via glial cell line derived 
neurotrophic factor (GDNF) increases neuronal cell survival. It 
has been shown that the development of medullary thyroid 
cancer is strongly associated with gain of function mutations in 
RET (Vidal et al., 2005; Knowles et al., 2006). It is thought 
that the multi-targeted action of vandetanib reduces the 
likelihood of tumour cells to develop ‘by-pass’ mechanisms 
through progressive mutations, therefore reducing the ability 
of the tumour to become resistant to treatment. 
Vandetanib binds to VEGFR2 with a half maximal inhibitory 
concentration (IC50) of 0.38 μM, to VEGFR3 with an IC50 of 
0.26 μM and to EGFR with an IC50 of 0.043 μM (IC50 gained 
from purified Glutathione S-transferase (GST) or histidine 
(His) tagged proteins assays; (Davis et al., 2011)) (Table 1.2). 
However, its potency at tyrosine kinases can vary, with 
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inhibition of RET being reduced in cases where particular point 
mutations in the kinase insert domain are present, e.g. valine 
804 (Carlomagno et al., 2004).  
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Kinase Vandetanib (μM IC50) Pazopanib (μM IC50) 
VEGFR1 0.15 (His tagged) 0.01 
VEGFR2 0.38 (His tagged) 0.03 
VEGFR3 0.26 (His tagged) 0.047 
AKT3 >100 >20 
EGFR 0.043 >20 
EPHB4 0.32 >20 
FAK >100 0.8 
FGFR1 0.58 0.14 
FGFR3 0.75 0.13 
FGFR4 5.8 0.8 
IGFR1 >100 8 
GSK3β >100 3.4 
ITK 26 0.43 
JNK3 >100 4.06 
LCK 0.37 0.41 
PDGFRα 1.1 0.071 
PDGFRβ 5.3 0.084 
PKCβ1 >100 >20 
PKCβ2 >100 >20 
SRC 0.42 (His tagged) 3.1 
TIE2 0.52 (His tagged) 4.5 
Side effects Vandetanib pazopanib 
Percentage of patient 
populations with 
hypertension 
32-33% 33%-40% 
Table 1.2 Summary of the IC50 (μM) values of vandetanib and 
pazopanib against various kinases, and the percentage of their patient 
population who develop hypertension, respectively (Hamberg et al., 
2010; Wells et al., 2012; Bible et al., 2014). IC50s for vandetanib were 
gained from a cell based assay where all kinases were expressed as 
human recombinant GST-fusion proteins or as His tagged proteins 
(labelled in table) (Leigh Verbois, 2011). Pazopanib IC50s were gained 
using recombinantly expressed catalytic domains of the kinases 
stated above (Kumar et al., 2007).  
 
Following oral administration in humans (300 mgday-1), 
vandetanib reaches its peak plasma volume concentration 
between 4-7.5 h depending on the dose given (50-600 mg) 
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with a plasma half-life of approximately 19 days. Vandetanib 
metabolism occurs primarily via cytochrome-P4503A4 (Ton et 
al., 2013), leading to the potential for drug-drug interaction 
with concomitantly prescribed compounds such as methadone 
and cisapride. The major metabolite of vandetanib, 
N-desmethyl-vandetanib, which circulates at 11% of 
vandetanib’s total plasma concentration in humans, is 
produced via cytochrome-P4503A4 oxidation (Leigh Verbois, 
2011; Kandel and Lampe, 2014). It also has a large volume of 
distribution (2680 l) and a low clearance from the body (8.47 
lh-1) (Holden et al., 2005), signifying its presence in the body 
long after dosing. Vandetanib was approved for the treatment 
of medullary thyroid cancer in April 2011 (Chau and Haddad, 
2013). 
In humans, vandetanib has been shown to cause various 
documented side effects including nausea, rash, ECG 
prolongation, vomiting, anorexia, diarrhoea and hypertension. 
Hypertension is a common side effect among the patient 
population with 33% of those taking vandetanib developing 
graded hypertension and 9% of those developing grade 
3+ hypertension (Wells et al., 2012). 
1.3.1.2  Pazopanib 
Pazopanib, like vandetanib, is a multi-targeted RTKI approved 
for the treatment of advanced stage renal cell carcinoma and 
soft tissue sarcoma (Cella et al., 2016) Developed by Glaxo 
Smith Kline and commercially known as Votrient, pazopanib is 
a synthetic class I RTKI small molecule inhibitor of VEGFR1, 
VEGFR2, VEGFR3, PDGFRα, PDGFRβ and c-kit (Figure 1.3). By 
inhibiting all 3 forms of VEGFR, pazopanib is able to reduce 
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cell growth, cell proliferation, angiogenesis and vascular 
permeability (Verbois et al., 2008; Thornton et al., 2012).  
 
Figure 1.3 Diagrammatical representation of class I RTKI mechanism 
of action. Class I RTKIs competitively bind to the ATP binding site on 
the intracellular part of its target receptor antagonising receptor 
activation and signalling. Adapted from Gotink and Verheul, 2010 
 
Pazopanib’s inhibition of PDGFRα and PDGFRβ has been shown 
to reduce tumour angiogenesis and metastasis through 
reducing PDGFRα and PDGFRβ associated MAPK, PI3K and 
PLCγ pathway activation. In particular the reduction of PDGF 
signalling has been shown to reduce pericyte recruitment 
during angiogenesis, therefore reducing vessel stability 
(Heldin, 2013).  
c-kit, also known as the stem cell factor receptor, has been 
shown to play a role in cell survival and proliferation. Its 
constituent activation has been noted in multiple malignancies 
such as gastrointestinal stroma and melanoma. The inhibition 
of c-kit is thought to reduce cell survival and proliferation, 
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therefore, reducing tumour size (Verbois et al., 2008; Stankov 
et al., 2013). It was shown that tumours implanted into 
CB-17 SCID mice reduced in size by 90%, 77%, and 99% at 
doses of 10, 30, and 100 mgkg-1, respectively (Verbois et al., 
2008). Pazopanib has varying affinity for the VEGFR receptors 
(IC50 values of 10, 30 and 47 nM, for the human VEGFR1, 
VEGFR2 and VEGFR3 receptors respectively) and has similar 
potencies at PDGFR-α (IC50=71 nM), PDGFR-β (IC50=84 nM) 
and c-Kit (IC50 =74 nM) (Kumar et al., 2007; Verbois et al., 
2008; Bible et al., 2012). 
Following oral administration in humans, pazopanib 
(800 mgday-1) reaches its peak plasma volume concentration 
between 2.0 to 4.0 h with a mean plasma half-life of 30.9 h. 
Pazopanib is primarily metabolised by CYP3A4, and has been 
shown to be metabolised by breast cancer resistant protein 
and multi drug resistance protein 1 in vitro, indicating the 
possibility for tumour resistance to develop against pazopanib 
(Justice and Robertson, 2008; Weiss et al., 2014; Cella and 
Beaumont, 2016). 
Pazopanib has been shown to have multiple side effects in 
humans, with the most common being hair discolouration; 
thought to be linked to its action on c-kit, hepatic toxicity, 
hyperkalaemia, anorexia, vomiting, rash and hypertension. 
Hypertension occurs in 40% of the patient population, with 3% 
of those developing grade 3+ hypertension (Hamberg et al., 
2010). In a phase I study completed by GSK, where a custom 
measure of hypertension was used (patient populations who 
demonstrated >15 mmHg rise in mean arterial blood pressure 
on three separate occasions or whose anti-hypertensive 
medication had to be adjusted due to an increase in the 
severity of their hypertension (given when blood pressure 
45 
 
reached 160/100 mmHg on three separate occasions over 2 
weeks)), found that 63% of the patient population taking 
pazopanib developed hypertension, with 23% of those having 
grade 3+ hypertension. In this study, the majority of the 
patient population developed hypertension within the first 4 
weeks of treatment (Hamberg et al., 2010), prompting the 
FDA to insist on blood pressure monitoring during treatment. 
These side effects may also arise from pazopanib’s inhibition 
of various other kinases. It has been shown, that like 
vandetanib, pazopanib also inhibits a subset of cardio-active 
kinases such as TIE2 and EGFR (Kumar et al., 2007)(Table 
1.2).  
1.3.1.3 Cediranib and Sorafenib 
Sorafenib (produced by Bayer) and otherwise known as 
Nevaxar or BAY 43-9006, is a class II RTKI that inhibits 
VEGFR2, VEGFR3, PDGFR, C-Raf, B-Raf, Flt-3 and c-kit among 
other tyrosine kinases (Davis et al., 2011; Hasskarl, 2014). It 
has been FDA approved for the treatment of advanced renal 
cell carcinoma and hepatocellular carcinoma (Eskens and 
Verweij, 2006; Widakowich et al., 2007). Sorafenib has been 
shown to reduce tumour angiogenesis and tumour size. This 
action is thought to be due to its inhibition of VEGFR2 and 
PDGFR (Heldin, 2013; Mahalingam et al., 2014). In clinical 
trials where sorafenib was given orally at 400 mg twice daily it 
was shown to have a half-life of approximately 36 h with a 
peak plasma concentration after 3 h (Hasskarl, 2014). The 
side effect profile of sorafenib includes multiple cardiotoxic 
effects such as hypertension, haemorrhage, QT prolongation 
and cardiac ischemia as well as off target side effects such as 
diarrhoea and rash (Hasskarl, 2014). 
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Cediranib (produced by AstraZeneca and planned to be 
marketed under the name Recentin), is currently undergoing 
Phase III trials for ovarian cancer (Robinson et al., 2010; 
Mulders et al., 2012; Schmidt, 2015; Ruscito et al., 2016). It 
has been shown to act as a class I inhibitor (Figure 1.3) of 
VEGFR1, VEGFR2, VEGFR3, PDGFR and FGFR1 (Wedge et al., 
2005; Mulders et al., 2012; Minguet et al., 2015; Ruscito et 
al., 2016). Cediranib has been shown to lead to a reduction in 
tumour angiogenesis and tumour growth (Mulders et al., 
2012). In humans dosed orally, cediranib displays a half-life of 
22 h and maximal plasma concentration at 3 h (Ruscito et al., 
2016).However it also produces hypertension, nausea, fatigue 
and diarrhoea in the patient populations taking it (Ruscito et 
al., 2016).  
1.3.2 Cardiovascular Consequences of RTKIs 
VEGF is a key mediator of pathophysiological as well as 
physiological angiogenesis (Liang et al., 2014; Shibuya, 2014). 
Therefore the inhibition of VEGF-VEGFR signalling not only 
reduces pathophysiological vessel growth but also leads to 
multiple cardiovascular-related adverse events (Hong et al., 
2015). VEGF inhibitors have been shown to increase a patient 
population’s likelihood of developing venous or arterial 
thrombo-embolisms (Eschenhagen et al., 2011), proteinuria, 
delayed wound healing (Veronese et al., 2006), reversible 
posterior leukoencephalopathy syndrome (Govindarajan et al., 
2006), neutropenia, thrombocytopenia, haemorrhage (Hapani 
et al., 2010) and hypertension (Hong et al., 2015; Abi Aad et 
al., 2015; Souza et al., 2015).  
The above side effects are serious for the patient’s quality of 
life and chances of survival. They also have an impact on the 
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possible treatment regimens prescribed. For example, a 
patient taking a VEGF RTKI is unable to undergo surgery as 
the risks of haemorrhage and delayed wound healing are too 
great. In patient populations with metastatic colorectal cancer, 
who had discontinued the anti-VEGF therapy bevacizumab for 
60 days prior to surgery, 13% of patient populations 
experience grade 3 or 4 surgical complications, including 
haemorrhage, bowel perforation and delayed or abnormal 
wound healing (Scappaticci et al., 2005). This study 
demonstrates the need to think carefully about the side effect 
profile of compounds when embarking on surgical intervention 
or when changing treatment regimens.  
The occurrence of hypertension in anti-VEGF treatments has 
been commented on as a possible biomarker for drug efficacy, 
as patients who respond positively to anti-VEGF treatment also 
develop hypertension (Scartozzi et al., 2009; Kieran et al., 
2012; Hong et al., 2015). The percentage of patients who 
develop hypertension has been suggested to positively 
correlate with the specificity of an RTKI to VEGFRs (Sleijfer et 
al., 2009; Mourad and Levy, 2011).  
It has been shown that approximately 23 to 90% of the 
anti-VEGF treatment population develop hypertension during 
treatment (Bible et al., 2014; Hong et al., 2014; Abi Aad et 
al., 2015; Granito et al., 2016). In light of this, many 
researchers have postulated reasons as to why reduced VEGF 
levels are linked to the development of hypertension. 
However, these hypotheses should be looked upon cautiously 
(discussed further in Section 1.5).Methodological flaws in 
blood pressure measurement, for example long time lags 
between blood pressure measurements (blood pressure is 
usually measured once every 15 or 21 days, clinically), may 
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lead to an underestimation of the number of patient 
populations who develop elevated blood pressure (Mir et al., 
2009). A study in which patient populations receiving sunitinib 
had their blood pressure measured weekly, found that 100% 
of the treatment cohort developed hypertension (Azizi et al., 
2008). An increase in the cohort of pazopanib patients who 
developed hypertension was also seen in phase I trials when 
GSK changed their definition of hypertension (study described 
previously) (Hamberg et al., 2010). This result was mirrored in 
a phase II trial involving the treatment of soft tissue sarcomas 
with pazopanib, where almost all of the patient population 
treated with pazopanib developed some degree of 
hypertension (Sleijfer et al., 2009).  
Therefore, the connection between the level of hypertension 
development within anti-VEGF treatment groups and the 
anti-VEGF drug efficacy needs to be further explored. 
1.4  The Pathophysiology of Hypertension 
In order to understand how anti-VEGF/VEGFR treatments may 
cause hypertension, it is important to understand how 
hypertension can occur in the absence of pharmacological 
intervention.  
Hypertension refers to an arterial blood pressure above 
140 mmHg/90 mmHg (classed as grade I mild hypertension 
(McCormack et al., 2012)). The maintenance of a steady blood 
pressure is important for the function and health of the 
cardiovascular system as well as the body as a whole. The 
incidence of hypertension increases the risk of developing 
renal disease, stroke, heart failure and cardiac infarction 
(Cutler, 1996). 
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Blood pressure is controlled by the heart and blood vessels. 
The heart acts to pump blood around the body, providing a 
pressure gradient to ensure blood flow, while the vessels allow 
for transportation of blood and act to maintain or change 
pressure through providing resistance (Katz, 2002).  
Since vessel length doesn’t change in the adult and under 
normal conditions blood viscosity remains relatively constant, 
resistance is largely determined by the radius of blood vessels 
and is mainly dependent on vessel tone. Vessel tone is 
controlled on 3 major levels: (1) the nervous system, 
(Chapleau et al., 1991; Estanol et al., 2011) (2) the endocrine 
system (Ponchon and Elghozi, 1996) and (3) local autocrine 
and paracrine signalling (Furchgott and Zawadzki, 1980). 
1.4.1 Nervous Control of Vessel Tone 
Immediate/ short term changes in blood pressure are detected 
by baroreceptors located in the aortic arch and the carotid 
sinuses (Chapleau et al., 1991; Estanol et al., 2011). An 
increase in blood pressure leads to vessel wall stretching and 
an increase in baroreceptor signalling (Estanol et al., 2011). 
This primarily leads to the release of noradrenaline from 
sympathetic nerves innervating the vessel adventitia. 
Noradrenaline binds to and activates α and β adrenoceptors 
that can produce a change in vessel diameter (Joyner and 
Casey, 2014). The effect of noradrenaline on vascular tone 
depends on the type and subtype of adrenoceptor expressed 
(Joyner and Casey, 2014). Activation of α1-adrenoceptors 
leads to contraction of the vessel wall, whereas activation of 
β2-adrenoceptors leads to relaxation of the vessel wall and a 
reduction in heart rate. This allows the body, in a fight or flight 
situation, to reduce blood flow to organs such as the gut, 
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which are not necessary in crisis, and increase blood flow to 
necessary organs, for example the skeletal muscles and heart 
through vascular bed specific variation of the adrenoceptor 
subtype (Hauzer et al., 2014). Compounds that inhibit 
α1-adrenoceptors, such as Doxazosin, and compounds that 
inhibit β2-adrenoceptors, such as propranolol, are used to treat 
hypertension (Levy, 1989). 
1.4.2 The Renin- Angiotensin-Aldosterone System 
and its Effect on Vessel Tone 
Endocrinological control of vascular tone is dominated by the 
renin-angiotensin-aldosterone system (Ponchon and Elghozi, 
1996). The renin-angiotensin-aldosterone system is activated 
by the detection of low blood volume by baroreceptors in the 
kidney. This causes the release of renin from the 
juxta-glomerular cells of the kidney and in turn aldosterone 
release from the adrenal gland (Persson et al., 2004). When 
renin enters the circulation it cleaves the plasma protein 
angiotensinogen into angiotensin I. Angiotensin I is further 
cleaved into angiotensin II by angiotensin converting enzyme, 
located in the lungs and vascular endothelium. Angiotensin II 
is a very potent vasoconstrictor. This action is achieved 
through its interaction with angiotensin II receptor I receptors 
on smooth muscle cells and sympathetic nerve endings. 
Angiotensin II and aldosterone have both been shown to have 
an anti-natriuretic effect, increasing blood volume (Lamas and 
Rodriguez-Puyol, 2012). Compounds such as losartan, a 
selective, competitive angiotensin II receptor 1 type 1 
antagonist (Mavromoustakos et al., 2001) and Ramipril, a 
angiotensin converting enzyme inhibitor (Yasky et al., 1996), 
can be used to inhibit the vasoconstrictive actions of the 
renin-angiotensin-aldosterone system, therefore reducing 
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blood pressure. Thiazide diuretics, such as chlorthalidone, and 
aldosterone antagonists, such as spironolactone, can also be 
used to treat sodium dependent hypertension as they inhibit 
the reabsorption of sodium and chloride from the distal 
convoluted tubules of the kidney, reducing blood volume 
(Blowey, 2016). 
1.4.3 Vascular Control of Vessel Tone 
Furchgott and Zawadzki (Furchgott and Zawadzki, 1980) 
showed that the removal of ECs from the vessel lumen 
removed the ability of the vessel to dilate in response to 
acetylcholine (ACh), demonstrating the importance of 
endothelial signalling in the control of vessel tone. As well as 
responding to endocrine and neural signalling molecules 
mentioned previously, ECs are able to release their own 
vasoactive compounds such as nitric oxide (NO) (Moncada and 
Higgs, 2006), VEGF (see Section 1.1.1) and prostacyclin 
(PGI2) in response to various signals such as shear stress, ACh 
and bradykinin (Cahill and Redmond, 2016). 
Prostacyclin production is a calcium dependent process 
involving the oxidation and peroxidation of arachidonic acid via 
the PLA2- COX signalling pathway (Nakayama, 2006). Once 
released by the EC it is able to signal via IP receptors to 
reduce platelet activation, cause vasodilatation and reduce 
smooth muscle cell remodelling (Stitham et al., 2007) via the 
IP3 and PKCγ signalling pathways (Mitchell et al., 2008). Its 
vasodilatory actions have been harnessed in the treatment of 
pulmonary hypertension with the use of synthetic analogues 
like iloprost (Fallah, 2015).  
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NO, made from the enzymatic conversion of arginine by 
endothelial nitric oxide synthase (eNOS) diffuses into the 
smooth muscle cell cytosol where it induces a vasodilatory 
effect (Gelinas et al., 2002). This occurs through its interaction 
with soluble guanylate cyclase (sGC), which in turn produces 
cyclic guanosine monophosphate (cGMP). cGMP has been 
linked with the opening of Kir K+ channels leading to 
membrane hyperpolarisation and vascular smooth muscle cell 
relaxation (Levick et al., 2010). It has also been associated 
with the activation of protein kinase G (PKG), which 
phosphorylates myosin light chain phosphatase. PKG 
activation leads to the reduction of intracellular calcium 
concentrations through phosphorylation of the 
sarco-endoplasmic reticulum calcium channel (SERCA) and the 
plasma membrane calcium channel (PMCA). Overall these 
actions lead to smooth muscle cell relaxation and 
vasodilatation (Horowitz et al., 1997; Hood et al., 1998). NO 
has also been shown to be important for the kidney’s 
tubule-glomerular feedback. When NO levels are reduced, the 
kidney retains excess sodium and therefore fluid, leading to 
hypertension through increased blood volume (Zou and 
Cowley, 1999). Nitric oxide can be given to relieve angina and 
causes a reduction in blood pressure (Abrams, 1996). 
Finally, calcium channel blockers, like amlodipine, are also 
used in the treatment of hypertension (Mason et al., 2003). 
They act by inhibiting calcium influx into smooth muscle cells, 
therefore reducing the ability of the smooth muscle cell to 
constrict, leading to vasodilatation (Mason et al., 2003). 
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1.5 Current Theories on RTKI-Mediated Hypertension 
The reason why anti-VEGF therapies cause hypertension is 
unknown. Currently it is thought that it may be due to a 
reduction in NO/PGI2 and/or a reduction in vessel number or 
number of functioning vessels (vascular rarefaction (Hayman 
et al., 2012)). It is presently believed that a reduction in VEGF 
leads to the down regulation of eNOS. Under normal 
physiological conditions, VEGF is able to stimulate eNOS to 
produce NO via the PI3K, MAPK and PLCγ pathways (Gelinas 
et al., 2002) (Figure 1.1). When VEGF action is blocked, eNOS 
is down-regulated and the vessel constitutively constricts 
leading to hypertension. Within the microcirculation this leads 
to rarefaction, reducing the density of the microvascular 
network and therefore increasing blood pressure (Feihl et al., 
2006). Rarefaction can be classed as either functional, where 
there is a high density of unperfused micro vessels, or as 
structural, where there is a reduction in the density of the 
microvasculature. Both forms of rarefaction lead to an increase 
in blood pressure (Feihl et al., 2006). It has been shown that 
anti-VEGF therapies, such as bevacizumab, cause rarefaction 
and that this positively correlates to the severity of the 
hypertension developed (Mourad et al., 2008). However, 
whether rarefaction leads to hypertension or hypertension 
leads to rarefaction remains unclear.  
VEGF RTKI-mediated hypertension has been shown to be 
resistant to pharmacological intervention with angiotensin 
converting enzyme inhibitors, calcium channel blockers, beta 
blockers and thiazide diuretics (Rini et al., 2011; Kruzliak et 
al., 2013). The lack of treatment available for VEGF 
RTKI-mediated hypertension further increases the need to 
understand its aetiology.  
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1.6 Aims and Hypothesis 
Through characterising the cardiovascular action of RTKIs in 
vivo and their pharmacology at VEGFR2 in vitro, the 
detrimental cardiovascular effects of these compounds and the 
possible mechanisms of action by which VEGF is important for 
vascular tone will be explored. With this in mind, the aims of 
the present investigations were: 
a) To determine the pharmacological characteristics of a 
panel of receptor tyrosine kinase inhibitors (RTKIs) 
(cediranib, sorafenib, pazopanib and vandetanib) in a 
whole cell system using VEGF-stimulated nuclear factor 
of activated T-cell (NFAT) signalling in HEK-293 cells 
expressing the human VEGFR2 and an NFAT reporter 
gene linked to firefly luciferase. The actions of the above 
RTKIs were also explored in the presence of two VEGF-A 
isoforms, VEGF165a and VEGF165b. 
Null hypotheses: 
1. There will be no difference in IC50 between 
cediranib, sorafenib, pazopanib and vandetanib in 
the presence VEGF165a or VEGF165b. 
2. There will be no difference in agonist action (eg, 
EC50 or EMAX values) between VEGF165a and 
VEGF165b.  
b) To assess the effect of various concentrations of 
vandetanib and pazopanib on heart rate, mean arterial 
blood pressure, hindquarter, renal and mesenteric 
vascular conductances in male Sprague Dawley rats. 
Null hypotheses: 
1. There will be no vandetanib or pazopanib mediated 
effect on heart rate, mean arterial blood pressure, 
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hindquarter, renal and mesenteric vascular 
conductances in male Sprague Dawley rats. 
2. There will be no vandetanib mediated effect on 
vessel structure or number. 
3. There will be no difference in heart rate, mean 
arterial blood pressure, hindquarter, renal and 
mesenteric vascular conductances in male Sprague 
Dawley rats given vandetanib or pazopanib. 
c) To investigate the chronic effects of vandetanib and 
pazopanib on heart rate and blood pressure in male 
Sprague Dawley rats. 
Null hypothesis: 
1. There will be no chronic effects of vandetanib and 
pazopanib on heart rate and blood pressure in 
male Sprague Dawley rats. 
d) To assess the action of vandetanib and pazopanib on 
isolated pressurised mesenteric arterioles, and to 
elucidate the effect of vandetanib on VEGF and ACh-
mediated vessel dilatation. 
Null hypotheses: 
1. There will be no vandetanib or pazopanib mediated 
effects on isolated pressurised mesenteric 
arterioles. 
2. Vandetanib or pazopanib will not effect VEGF or 
ACh-mediated vessel dilatation.  
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Chapter 2 : General 
Methods  
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2.1 NFAT-Luciferase Gene Reporter Assay  
In order to look at the downstream signalling of VEGFR2 in a 
whole cell system, the NFAT reporter gene was used. NFAT 
leads to the transcription of target genes which contribute to 
cell growth and proliferation (Bretz et al., 2013). The 
activation, dimerisation and transphosphorylation of VEGFR2 
leads to the downstream activation of calcineurin and in turn 
the dephosphorylation and translocation of NFAT into the 
nucleus (Figure 2.1) (Armesilla et al., 1999). NFAT, once in 
the nucleus, forms a transcription complex with Fos and Jun 
(Hogan et al., 2003) allowing it to bind to DNA and transcribe 
various gene products, in the VEGFR2 NFAT cells used here 
(Section 2.1.1), this includes the reporter gene product: firefly 
luciferase (Figure 2.1). By measuring the amount of 
luminescence emitted from the mono-oxygenation of 
5’fluroluciferin by firefly luciferase (photinus pyralis), the 
extent of VEGFR2 activation and signalling via the 
calcium-calcineurin pathway in VEGFR2 NFAT cells can be 
quantified.  
Luciferase is an enzyme capable of catalysing the 
mono-oxygenation of 5’fluroluciferin, causing it to produce 
yellow/green light (550-570 nm) (Figure 2.1). The ONE-Glo™ 
Luciferase Assay System (Promega ONE-Glo™ Luciferase 
Assay System Literature # TM292) can be used to measure 
NFAT linked firefly luciferase reporter gene expression in 
mammalian cells.  
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Figure 2.1. Schematic Representation of the NFAT Luciferase Assay. 
The activation of VEGFR2 by VEGF causes the receptor to dimerise 
and phosphorylate specific intracellular tyrosine kinases. This in turn 
leads to the activation of calcineurin, which dephosphorylates NFAT, 
leading to the transcription of firefly luciferase though the PLCy 
pathway. The addition of 5’fluroluciferin allows for the linear 
measurement of firefly luciferase production and in turn NFAT 
activation through the measurement of oxyfluoroluciferin using a 
microplate luminescence counter (Perkin Elmer Topcount). Chemical 
reaction taken from Promega ONE-Glo™ Luciferase Assay System 
Literature # TM292. 
2.1.1 Cell Culture 
HEK 293 cells, from the human embryonic kidney, are 
commonly used as an in vitro model due to their amenable 
transfection rate and reliable growth rate in the cell culture 
enviroment. This allows them to be used in experiments where 
the activity of an induced component is of interest (Thomas 
and Smart, 2005). As HEK 293 cells do not natively express 
VEGFR1, VEGFR2 or VEGFR3, unlike more physiologically 
relevant endothelial cell models, they provide the opportunity 
to study the effects of mutli-targetted RKTIs on VEGFR2-NFAT 
signalling without interference from native receptor-NFAT 
signalling that may also be activated by VEGF165a or VEGF165b; 
the chosen agonists in these experiment.  
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HEK 293 cells were first isolated in 1977 by Graham et al., 
who transformed them into an immortal cell line by 
transfecting chromosome 19 with human adenovirus type 5 
(Ad5) DNA (Graham et al., 1977). The HEK 293 cells used 
here have been further modified with an NFAT-RE-luc2P 
vector, which leads to the transcription of firefly luciferase 
when the NFAT response element (NFAT-RE) is activated. They 
have also been transfected with a KDR-5K vector which causes 
the HEK 293 cell to transcribe and translate human VEGFR2.  
All sterile procedures were performed in the Cell Signalling 
Research Group Cell Culture Facility. Dulbecco’s Modified 
Eagle’s Media (DMEM) and Dulbecco’s phosphate buffered 
saline (PBS) were purchased from Sigma, while heat-treated 
foetal calf serum (FCS) came from PAA labs. Adherent human 
embryonic kidney 293 cells (HEK 293) stably transfected with 
an NFAT-RE-luc2P vector (Promega pGL4.30, E8481) and 
KDR-5K vector were provided by Promega Corporation 
(Madison, USA) and are referred to as VEGFR2 NFAT cells 
hereafter.  
Cells were maintained in DMEM supplemented with 10% FCS 
and 0.5% G418 (Life Technologies) (subsequently referred to 
as growth media) in humidified conditions at 37°C/ 5% CO2 + 
95% air. All sterile cell culture techniques were performed in a 
class 2 laminar flow cell culture hood with pre-warmed liquids 
so as not to cause excessive shock to the cells. 
2.1.2 Cell Passage  
Cells were generally maintained in T75 flasks containing 20 ml 
growth media and grown to between 80-90% confluency 
before passaging. In order to passage the cells, media was 
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removed and they were washed with 5 ml PBS. One ml 
trypsin-Ethylenediaminetetraacetic acid (EDTA)(0.5% and 
0.2%, respectively) was added to the cells in order to 
hydrolyse membrane bound adhesion proteins (via trypsin), 
and to chelate Ca2+ ions, reducing cell clumping by reducing 
cadherin binding (via ETDA), allowing the cells to enter 
suspension. Once cells began to detach from the flask, 9 ml of 
growth media was added. The cell suspension was transferred 
into a 25 ml universal tube and centrifuged at 1000 rpm for 
5 min and the supernatant was discarded. This was done to 
remove any cell debris and trypsin-ETDA solution. The pellet 
was suspended in 10 ml of media. This was divided into new 
flasks containing 20 ml growth media. Cells were routinely 
passaged at ratios of 1:5 and 1:10 in order to keep the 
passage number below 15 post-purchase. 
2.1.3 Long Term Storage 
For long-term storage, cells were suspended (Section 2.1.2) in 
sterile (filtered with a 0.2 μm syringe filter) FCS with 10% 
(v/v) DMSO in order to reduce ice crystal formation during 
freezing. 500 μl of cell suspension was aliquoted into cryogenic 
tubes, which were placed into an isopropanol-filled container. 
This allowed for controlled cell freezing at a rate of 1°C per 
min in a -80°C freezer. After 24 h the aliquots were 
transferred to liquid nitrogen storage until use.  
Cells were thawed rapidly before use, through the addition of 
500 μl warmed growth media. Once thawed, the cells were 
immediately transferred to a T75 flask containing 20 ml 
pre-warmed growth media. After 24 h the media in the flask 
was replaced with fresh media in order to remove DMSO and 
cell debris. This increased the likelihood of cells growing 
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healthily. Finally, cells were passaged a minimum of once 
before experimental use. 
2.2 NFAT-Luciferase Assay 
VEGFR-NFAT cells, used in this assay, artificially expressed 
firefly luciferase downstream of the NFAT promoter. 
Physiologically, NFAT leads to the transcription of target genes 
which contribute to cell growth and proliferation (Hogan et al., 
2003, Armesilla et al., 1999). However, in the VEGFR2 NFAT 
cells, NFAT activation also leads to the transcription of firefly 
luciferase. At the end of the experimental procedure, addition 
of the ONE-Glo assay reagent, lyses the cell membrane. The 
ONE-Glo assay reagent also contains the firefly luciferase 
substrate, 5-fluoroluciferin. Firefly luciferase catalyses the 
mono-oxygenation of 5-fluoroluciferin to oxyfluroluciferin 
(Figure 2.1). This reaction produces energy in the form of 
luminescence that can be measured via a luminescence 
counter, allowing the extent of VEGFR2-mediated activation of 
NFAT signalling to be quantified.  
Reporter gene systems have previously been used as an 
alternative to biochemical assays, and allow for compound 
efficacy at specific receptors to be measured. Unlike other 
assays, reporter gene assays do not involve radiation, have 
been shown to be highly sensitive and are relatively cheap due 
to their ability to be used in 96 well and 384 well plate 
systems, reducing the requirement for expensive reagents 
(Hill et al., 2001). The NFAT-luciferase reporter gene assay is 
also very sensitive because the signal measured is at the 
terminal portion of the signalling pathway, allowing for 
maximal amplification (Hill et al., 2001).  
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2.2.1 Experimental Method Protocol 1: The 
‘non-confluent monolayer’ Method 
Reagents received in the Promega ONE-Glo™ kit were 
prepared according to the manufacturer’s instructions, 
aliquoted and stored at -20°C. Reagents were used within one 
freeze thaw cycle to reduce any freeze-thaw initiated 
breakdown of reagent components. Cells were suspended in 
10 ml media and counted using a haemocytometer. Cells were 
then suspended in DMEM and seeded at a density of 30000 
cells per well in white 96 well plates with clear flat bases 
(Greiner Bio-one, Stonehouse, UK). Prior to cell seeding, wells 
were coated with 5 mgml-1 poly-D-lysine (Sigma) for a 
minimum of 30 min to enhance cell adherence. The plates 
were then washed with media, to remove any residual 
unbound poly-D-lysine before the cells were added. 
After 24 h, media was replaced with FCS free media. This was 
done to reduce FCS interference within the measured 
pathway. FCS, and growth factors contained within FCS, have 
been shown to activate multiple signalling pathways within the 
cell (Even et al., 2006). ‘Serum-starving’ helps to reduce this 
effect and produce a more specific readout (Hill et al., 2001). 
After 24 h the FCS free media was removed and replaced with 
DMEM containing 0.1% bovine albumin serum (BSA). VEGF 
was incubated with the cells at 37°C/ 5% CO2 for 5 h. After 
the 5 h incubation, the experimental media was removed from 
the wells and 50 μl of DMEM and 50 μl ONE-Glo™ Luciferase 
Assay reagent was added to the wells. A white plastic cover 
was placed over the bottom of the plate to ensure no signal 
was lost, and luminescence was measured using a microplate 
scintillation and luminescence counter (TopCount NXT 
Packard) set to read at 19.1 °C (the one-Glo™ Luciferase 
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Assay reagent is temperature sensitive and is more stable at 
lower temperatures (Promega ONE-Glo™ Luciferase Assay 
System Literature TM292)) with a 5 min delay, to allow for the 
biochemical reaction to take place and for background 
luminescence absorbed by the plate from indoor fluorescent 
lighting to fade, before reading relative luminescence units. An 
average of the counts per second, taken over 3 seconds, was 
used in all experimental analyses. Each individual experiment 
was performed in triplicate or quadruplicate and repeated a 
minimum of 4 times. 
2.2.2 Experimental Method Protocol 2: The 
‘suspension’ Method 
Cells were seeded in a T75 at 5x106 using DMEM + 10% FCS 
and incubated at 37°C/ 5% CO2 for 3 days (until the media 
turned yellow and the flask was 100% confluent). As DMEM 
contains a phenol red pH indicator, colour change from red to 
yellow indicates a more acidic pH, inferring high cell 
confluence. On the 4th day, cells were washed with 5 ml PBS 
and detached using 3 ml Versene (0.02% EDTA in PBS: as 
versene contains only a chelating agent, it is used as a gentle 
method of lifting cells from a surface into suspension (Chen et 
al., 2015)). Once cells had detached, 6 ml of DMEM + 0.1% 
BSA was added. Cells were centrifuged at 1000 rpm for 5 min, 
counted using a haemocytometer and suspended in 
DMEM + 0.1% BSA. They were subsequently seeded at a 
density of 40000 cells per well in white sided, clear 
flat-bottomed, 96 well plates which had been coated with 
poly-D-lysine. Cells were incubated for 1 h at 37°C/ 5% CO2 to 
allow them to settle within the wells. Cells were then 
incubated with set concentrations of RTKI (10x final 
concentration) at 37°C/ 5% CO2 for 1 h prior to the addition of 
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VEGF. VEGF was incubated with the cells at 37°C/ 5% CO2 for 
5 h. After the 5 h incubation, the experimental media was 
removed from the wells and 50 μl of DMEM and 50 μl 
ONE-Glo™ Luciferase Assay reagent was added to the wells. A 
white plastic cover was placed over the bottom of the plate 
and luminescence was measured using a microplate 
scintillation and luminescence counter (TopCount NXT 
Packard). Each individual experiment was performed with 
triplicate or quadruplicate replicates and the experiment was 
repeated a minimum of 4 times.  
2.2.3 Data Analysis 
All data were fitted using non-linear regression in GraphPad 
Prism 6 (San Diego, CA). VEGF165 and VEGF165b concentration 
response curves were fitted to the following equation: 
 
Where [A] is the concentration of VEGF and EC50 is the molar 
concentration of agonist required to generate 50% of the 
maximal response. Emax was defined as the maximal response 
of an agonist. In experiments where a VEGF 
concentration-response curve in the presence of RTKI was 
generated, data were also fitted to the above equation, where 
either the EC50 or Emax were shared between curves.  
Inhibition curves obtained with RTKIs in the presence of a 
fixed concentration of VEGF165 or VEGF165b were fitted to the 
following equation:  
65 
 
 
Where IC50 is the molar concentration of RTKI required to 
inhibit 50% of the response to VEGF and [I] is the 
concentration of RTKI.  
All data have been presented as mean ± SEM. Statistical 
significance was determined by Student’s unpaired t-test or by 
a one or two-way ANOVA with Dunnett’s post-hoc analysis, 
where appropriate. P<0.05 was considered statistically 
significant.  
2.3 Telemetry 
The use of radio-telemetry was first published in the early 
1990’s by Brockway et al (Brockway et al., 1991), who 
demonstrated that it was possible to accurately measure mean 
arterial blood pressure (± 5 mmHg) and heart rate chronically 
(>1 month) while not interfering with the conscious, 
unrestrained experimental rat, thereby reducing external 
stressor effects (Brockway et al., 1991; Guiol et al., 1992; 
Kramer et al., 1993). This is particularly relevant to studies 
directed at the cardiovascular system, where small 
interferences with an animal can have a detrimental effect on 
the experimental readouts (Lamprecht et al., 1973; Gartner et 
al., 1980; Kramer and Kinter, 2003). More recent advances in 
radio-telemetric methodologies have further increased the 
accuracy of blood pressure measurements to ± 3 mmHg (DSI, 
2013) (Table 2.1). 
For the studies described herein, the implanted radio 
telemetric device was placed in the intra-peritoneal cavity of 
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each rat. It consisted of a battery, a strain-gauge sensor and 
an electronic module, which was able to process information 
from the strain-gauge sensor and transmit this information to 
a receiver plate (RPC-1) (Figure 2.2) (Guiol et al., 1992). 
Protruding from the radio telemetric device was one positive 
and one negative ECG lead, as well as a catheter (outer 
diameter 0.7 mm) (Guiol et al., 1992) which was positioned in 
the abdominal aorta. The catheter tip contained an 
anti-thrombogenic film and gel membrane, ensuring catheter 
patency throughout the experiment (Brockway et al., 1991).  
Data recorded by the implanted radio-telemetric device were 
sent to the receiver plate via AM radio waves (DSI, 2013). 
Each receiver plate was programmed to receive data from one 
corresponding transmitter. All receiver plates used in an 
experiment electronically relayed data collected by their 
registered radio-telemetric device to a data exchange matrix 
(DSI, 2013) (Figure 2.2). The data exchange matrix then 
consolidated the information from multiple receiver plates 
before electronically sending it to a PC installed with 
DataSciences Dataquest A.R.T™ software (Guiol et al., 1992; 
DSI, 2013). Finally, an ambient pressure reference module 
(Figure 2.2), which was able to measure atmospheric 
pressure, relayed the atmospheric pressure to the Dataquest 
A.R.T™ software (DSI, 2013). This allowed the software to 
subtract atmospheric pressure from the pressure detected by 
the radio-telemetric device and convert it into mmHg, as well 
as display, plot and store all data collected (Guiol et al., 1992; 
DSI, 2013) (Figure 2.2).  
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Figure 2.2 Illustration of the DSI radio-telemetric experimental set up. The DSI radio-telemetric telemetry device 
was implanted into the rat, which was then housed in a cage placed on top of a receiver plate. This received 
information from the radio-telemetric device and relayed it to the data exchange matrix, and finally to a computer 
for observation and analysis. 
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2.3.1 Telemetry Variables 
Heart rate was derived from electrocardiogram (ECG) 
measurements, taken via two ECG leads positioned at the rat’s 
lower sternum and manubrium (Kramer et al., 1993). 
Dataquest A.R.T™ software isolated the R wave from each 
QRS complex. The time between each ECG R wave, also 
known as the inter-beat interval (s) was calculated. With this 
information heart rate (beats per minute, BPM) was derived 
(heart rate=60/inter-beat interval (s)) (DSI, 2013). 
The radio telemetric device also measured mean arterial blood 
pressure via an intra-arterial catheter positioned in the 
abdominal aorta. Pressure values received from the implanted 
telemetry device were averaged over 50 sub-segments of each 
pressure segment length (one pressure segment was defined 
as one systolic and two diastolic values) to give a mean 
arterial blood pressure value (mmHg) (DSI, 2013). 
2.3.2 Surgical Procedures 
2.3.2.1 Animals 
Male Sprague-Dawley rats (Charles River, Margate, UK), 
weighing between 200-300 g, were used for all telemetry 
studies. This outbred strain was chosen due to their genetic 
heterogeneity and calm nature (Ghirardi et al., 1995; Rex et 
al., 2007). Animals were housed in temperature (21-23°C) 
and light (12 h light/dark cycles from 6 am/6 pm) controlled 
conditions. All animals had free access to food and water and 
were allowed to acclimatise to the housing conditions for 
≥10 days before any surgery was performed. Animals were 
housed in pairs prior to telemetry device implantation. They 
were then singly housed overnight after telemetry device 
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implantation, and subsequently pair housed for the remainder 
of the experiment. Pair housing was maintained to ensure 
effects from long term isolation, such as increased locomotor 
activity, anxiety and aggression were mitigated (Arakawa, 
2005). This was not only important for animal welfare but also 
experimental results (Malkesman et al., 2006). All in vivo 
experimentation was approved by the Animal Welfare and 
Ethical Review Body (University of Nottingham) and performed 
in keeping with the Scientific Procedures Animals Act (1986), 
under U.K Home Office approved Project Licence (40/3466) 
and Personal License authority. 
2.3.2.2 Implantation of Telemetry Devices 
Animals were initially anaesthetised with fentanyl citrate, 
(300 µgkg-1, Jansen-Cilac Ltd, opioid agonist) mixed with 
medetomidine (Domitor, 300 µgkg-1, Pfizer, α2-adrenergic 
agonist), i.p (supplemented with 0.5 ml fentanyl citrate 
50 µgml-1 and 1 mgml-1 medetomidine to maintain anaesthetic 
depth throughout the surgery) (Flecknell, 2010). Once animals 
were fully anaesthetised (no flinch response after firmly 
pinching the hind-paw), their weight was recorded and their 
abdominal midline, and neck were shaved. The shaved areas, 
paws and tail were cleaned with chlorohexidine gluconate 
(0.5% w/v in 70% v/v IMS, Adams Healthcare) and the animal 
was wrapped in a clear surgical drape (cling film, Glad, USA) 
before being placed on a heated surgical table, set at 37°C, in 
the dorsal recumbent position. From this point onwards 
surgery was completed under aseptic conditions, which were 
approved and monitored by the Home Office. 
The telemetry device DSI C50-PXT was used in the vandetanib 
studies and DSI HD-S11 in the pazopanib studies (Table 2.1). 
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Both implants were activated using a magnet and their activity 
was checked using an AM radio receiver, prior to implantation. 
A 4-5 inch midline abdominal incision was made along the 
linea alba. The contents of the abdomen were wrapped in 
sterile, saline-saturated tissue and pushed to one side, 
exposing the vasculature underneath. The distal abdominal 
aorta was identified and cleared of adipose and connective 
tissue using blunt dissection techniques. This reduced surgical 
trauma, helping to ensure blood flow post-catheterisation 
(Huetteman and Bogie, 2009). The vessel was occluded 
superiorly and an incision made using a 21 gauge needle bent 
90° at the bevelled end. The gel filled catheter of the 
telemetry device was inserted into the distal abdominal aorta 
(approximately 1 cm below the renal artery) and the vessel 
closed using Vet Bond (3M) and cellulose patching (DSI) 
(Huetteman and Bogie, 2009). The vessel was then released, 
to ensure blood flow returned through the artery and no blood 
leaked from the incision. The content of the abdomen was 
then carefully replaced. A pouch was made on the underside of 
the xiphisternum using blunt dissection and the tip of the 
positive ECG lead was stripped of insulation and secured into a 
loop before being attached into the pouch using suture (3/0) 
(Huetteman and Bogie, 2009). A 1 cm incision was made on 
the anterior of the neck and the negative ECG lead was 
tunnelled subcutaneously from the abdomen to the opening in 
the neck (Deveney et al., 1998). The tip of the ECG lead was 
stripped of insulation and secured into a loop at the 
manubrium with suture (3/0) (Sgoifo et al., 1996). The body 
of the telemetry device was attached to the body wall via 
suture (4/0) and the abdomen and neck were then closed and 
all wounds were dusted with surgical wound powder. The 
animal was given 5 ml saline, 0.02 mgkg-1 Vetergesic 
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(Buprenorphine, Alstoe Animal Health, partial opioid agonist) 
and 1 mgkg-1 Antisedan (Atipamezole hydrochloride, Pfizer 
α2-adrenergic antagonist), i.p Vetergesic (0.02 mgkg-1) was 
given as an analgesic 4 h after surgery. Animals were then 
rehoused singularly in an individually ventilated cage over 
night before being reintroduced to their cage mate. This period 
of individual housing allowed for the rat to rest and for the 
skin and muscle incisions to begin healing. Greene et al 
demonstrated that recovery from telemetry surgery, where 
parameters such as heart rate, body temperature, mean 
arterial blood pressure and activity return to post-surgical 
readings, takes approximately 1 week (Greene et al., 2007). 
Therefore, rats were given a 10-14 day recovery period with 
free access to food and water. They were monitored daily and 
satisfactorily inspected by the Named Veterinary Surgeon 
before recording took place. 
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Table 2.1 Summary of the differences between 
the C50-PXT and HD-S11 radio-telemetric 
implants (DSI, 2013).  
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2.3.2.3 Telemetry Experimental Method 
Each telemetry device was turned on using a magnet which 
was run down the flank of the animal, ensuring its close 
proximity to the telemetry device. Heart rate and mean 
arterial blood pressure were recorded every 15 min for 1 min 
for 9 days (vandetanib) or 3 days (pazopanib) before the 
compound of interest was given either i.p in vehicle 
(2% Tween, 5% propylene glycol in 0.9% saline solution) or 
vehicle was administered i.p, once every 24 h for 21 days. A 
10 day off-treatment period was observed where recordings 
took place without the animal being disturbed. At the end of 
the study the animal was terminally anesthetised with 50 
mgkg-1 pentobarbitone (Dolethal, Vetoquinol, UK), i.p.  
2.3.2.4 Statistical Analysis 
All data were expressed as mean ± SEM. Data were displayed 
parametrically to follow scientific convention, but 
non-parametric statistical analyses were used, since not all the 
data were normally distributed (Kolmogorov-Smirnoff 
normality test). A Friedman test was performed to determine if 
within group changes from baseline values were significant. 
Between-group two tailed comparisons were made using the 
Mann Whitney-U test (for 2 groups) and the Kruskal Wallis test 
(more than 2 groups) with significance being accepted at 
P‹0.05. All statistical analysis was performed using Graphpad 
prism 6.00. 
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2.4 Mesothelium Panel Staining for ECs 
To investigate the effects of vandetanib on the 
microvasculature, a pilot study was performed where 
mesothelium, from rats participating in the radio-telemetric 
vandetanib 25 mgkg-1day-1 vs vehicle study (Chapter 2, 
Section 2.3, and Chapter 4) were harvested and stained for 
ECs using the antibody Isolectin-B4 and for cell nuclei with 
Hoechst (Benest and Bates, 2009). The rat mesentery on 
average contains 30-50 mesothelium panels (Figure 2.3), with 
each panel consisting of microvessels, macrophages, 
lymphocytes, mast cells and fibroblasts (Norrby, 2006; 
Norrby, 2011). The rat mesothelium staining study was first 
introduced by Norrby in 1986 (Norrby et al., 1986) and has 
been shown to have multiple advantages. For example the 
membranes harvested are easy to isolate and dissect, 
transparent and are only a few cells thick. They are ideal for 
histological staining as the antibody is able to penetrate the 
whole tissue without the need for tissue slicing. Therefore, 
there is a reduced risk of damaging vessel structure, ensuring 
the structures seen are as close to their native state as 
possible, and that the entire vascular network can be 
visualised (Norrby et al., 1986; Norrby, 2008; Norrby, 2011). 
The transparency and thin width of these vessels makes this 
tissue attractive for use in microscopy, as the light transmitted 
from the microscope is able to penetrate through the tissue.  
The total number of junctions (indication of vessel branching), 
and total vessel length (indication of rarefaction and vessel 
destruction) were measured (Gould et al., 2011; Zudaire et 
al., 2011).  
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2.4.1 Method of Tissue Isolation 
At the end of the 25 mgkg-1day-1 i.p vandetanib telemetry 
experiment, each animal was terminally anesthetised with 50 
mgkg-1 pentobarbitone (Dolethal, Vetoquinol, UK-GABAA 
agonist) i.p, as described above (Section 2.3.2.3). A 5 cm 
abdominal midline incision was made and the mesentery 
isolated. The superior mesenteric artery was tied as a 
physiological marker to allow for subsequent tissue orientation 
and positioning. The mesentery was washed with PBS and 
fixed in 4% paraformaldehyde (pH 7.4) for 2 h at room 
temperature. Mesothelium panels (Figure 2.3) were isolated 
from the first 3rd of the mesentery (third closest to the 
superior mesenteric artery) using blunt forceps and spring 
action surgical scissors. Mesothelium panels were stored at 
4°C in 8 well plates filled with PBS, prior to staining. 
 
  
Figure 2.3 Illustration of mesothelium panel dissection. Each rat 
mesentery contains between 30-50 panels. Each panel consists of a 
mesothelium membrane containing microvessels, macrophages, 
lymphocytes and mast cells and fibroblasts (Norrby, 2006; Norrby, 
2011). This image shows an isolated rat mesentery with the intestine, 
vessels, fat and mesothelium present. White dotted lines illustrate 
where panels were taken from. 
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2.4.2 Staining Procedure 
Each panel was washed in PBX (0.5% Trition-X100 in PBS) for 
1 h at room temperature with PBX solution being removed, 
discarded and replaced every 10 min. All wash and incubation 
steps were performed on a slow moving shaker. The 
mesothelium panels were incubated in 1% BSA in PBX 
(BSA-PBX) at room temperature to reduce the likelihood of 
antibody-nonspecific binding to reactive sites such as Fc 
receptors within the tissue (Ramos-Vara, 2005). The panels 
were then incubated overnight at 4°C with 10 μgml-1 
biotinylated Isolectin GS-IB4 (from Griffonia simplicifolia 
(Molecular Probes)). Panels were subsequently washed in PBX 
for 1 h at room temperature with PBX solution being removed, 
discarded and replaced every 10 min. Panels were then 
incubated at room temperature for 2 h with 1 μgml-1 
Tetramethyl-rhodamine-isothiocyanate (TRITC)-labelled 
streptavidin (S-870 Molecular Probes) before being washed in 
PBX (0.5% Trition-X100 in PBS) for 1 h at room temperature 
with the PBX solution being changed every 10 min. Finally, 
panels were incubated with Hoechst (2 μgml-1 diluted in 
BSA-PBX), to label cell nuclei, before being placed onto 
3-Aminopropyltriethoxysilane (APES) coated microscopy 
slides. APES coating was used to positively charge the slide 
and therefore reduce sample movement (Maddox and Jenkins, 
1987). A coverslip (32 mm x 0.17 mm) was placed over the 
tissue sample and secured in place with DABCO Fluorescence 
Mounting Medium (200 mg DABCO 
(1-4-Diazabicyclo-2-2-2-octane), 14 ml PBS, 86 ml Glycerol), 
which has been shown to reduce fluorescence signal fading 
(Valnes and Brandtzaeg, 1985). 
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2.4.3 Analysis 
16 bit images were taken on a Zeiss Axio observer Z1 using a 
Hamamatsu Orca flash 4 C11440 HD camera and an 
EC-Plan-neofluar 10x/-0.3 ph1 objective. Images were 
analysed using ImageJ and AngioTool 0.6b (Zudaire et al., 
2011). AngioTool 0.6b uses a subset of algorithms to map 
vessels within an image and calculate total vessel length and 
total number of vessel junctions. All analysis was blinded. Data 
were analysed using Microsoft Excel 2010 and GraphPad Prism 
6.0. Statistical significance was determined using an unpaired 
one tailed Mann Whitney-U test (P<0.05). 
2.4.3.1 AngioTool 0.6b 
AngioTool was used to gain a quantitative, non-subjective 
analysis of total vessel length and total number of branch 
points. AngioTool 0.6b is an open source analysis program 
written using Java script. It is compatible with the open source 
software ImageJ. The images analysed were converted into 16 
bit grey scale using ImageJ and then uploaded to the 
AngioTool software. AngioTool analyses the image using a 
multiscale hessian-based enhancement filter (Zudaire et al., 
2011), allowing the program to distinguish linear structures 
from background (Sato et al., 1998). Once the vessels are 
detected within the image, the software maps a skeleton onto 
the image (Chapter 4) (Arganda-Carreras et al., 2010) and 
calculates user set parameters, such as total vessel length and 
total junction number (junction defined as a vessel branch 
point) (Zudaire et al., 2011). The mapped skeleton layed over 
the original image allows the user to ensure that all vessel 
structures have been detected. If this is not the case the user 
can adjust pre-set parameters, which allow gaps in the 
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mapped skeleton to be filled or for background noise to be 
removed (Zudaire et al., 2011). The ‘mapped’ image is saved 
along with the values for the measured parameters into an 
excel file. 
2.5 The Measurement of Regional Haemodynamics in 
Conscious Rats 
In order to measure the effect of RTKIs on regional 
haemodynamics in the rat, blood flow velocities were 
measured using the Doppler principle (Section 2.5.1). Small 
(1-2 mm in diameter) ultrasonic pulsed Doppler flow probes 
were implanted around vessels of interest (the mesenteric 
artery, renal artery and abdominal aorta), and the Doppler 
shift (difference in frequency transmitted and frequency 
received), was measured, allowing blood flow velocity to be 
subsequently derived (Hartley and Cole, 1974). This is 
described in detail below. Alongside pulsed Doppler flow probe 
implantation, an intra-arterial (i.a) catheter was implanted 
10-14 days later to measure blood pressure and heart rate 
simultaneously. Intra-venous (i.v) and intra-peritoneal (i.p) 
catheters were also implanted to allow for drug administration. 
This method facilitated the measurement of regional 
haemodynamic changes in conscious, freely-moving animals 
for up to 4 days. Drugs were administered via intravascular 
catheters, allowing animals to remain undisturbed in their 
individual cages. The following sections will describe the 
theory behind the ultrasonic pulsed Doppler technique and 
describe the methodology used. 
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2.5.1 The Pulsed Doppler Method 
The pulsed Doppler method was first developed by Hartley et 
al. (1974) for use in dogs (Hartley and Cole, 1974). By using a 
single piezoelectric crystal, capable of emitting and receiving 
sound waves, Hartley et al were able to greatly reduce the size 
of the probes needed in comparison to methods like the 
continuous wave Doppler technique, which needs both 
emitting and receiving ultrasonic crystals. The first description 
of the use of Hartley et al’s pulsed Doppler flowmetry 
technique in rats was by Haywood et al in 1981 (Haywood et 
al., 1981). This technique was improved further by Gardiner et 
al (Gardiner et al., 1990), who adapted the system to reduce 
‘aliasing’ at high velocities (Section 2.6.3). 
Doppler shift is measured via a small (1 mm) ultrasonic 
piezoelectric crystal embedded in a probe and held at a 45° 
angle to the specified vessel. When connected to a flowmeter, 
the piezoelectric crystal emits a short burst of ultrasonic 
energy at 20 MHz. When this comes into contact with a 
moving object, for example an erythrocyte, the ultrasonic 
energy is reflected back toward the crystal face. The energy 
reflected back is time-delayed and at a slightly different 
frequency compared to the energy emitted, and the shift in 
frequency (Doppler shift) is directly related to the velocity of 
the moving target (Hartley and Cole, 1974). The frequency at 
which the ultrasound is emitted (20 MHz) is higher than that 
used in systems such as the continuous wave Doppler system. 
This is advantageous as it produces a higher energy scatter 
allowing for a small crystal face to be used, as the energy 
returned is higher (Hartley and Cole, 1974). The time delay 
seen between the emission and detection of the ultrasonic 
signal is directly proportional to the distance between the 
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moving erythrocytes and the face of the crystal. The system 
used in these studies allows for the Doppler shift to be 
measured at various points across the lumen diameter 
(between 1-10 mm) by adjusting the time delay of the crystal 
(range setting). In order to make the most reliable 
measurements, the ultrasonic energy is pulsed to the middle 
of the vessel where there is maximal laminar flow. In practice, 
this is done by slowly adjusting the range of the probe until 
the largest signal is found. 
By using the Doppler equation:  
 
Where Δ𝑓= Doppler shift, 𝑓o= transmitted frequency in Hz, 
v=velocity of fluid, C=velocity of sound in the fluid, Ө=angle 
between the flow axis and acoustic axis (the angle of the 
crystal in relation to the blood vessel), the difference between 
the frequency emitted and the frequency returned can be 
calculated. 
In the days (prior to catheter implantation) following 
implantation of the pulsed Doppler flow probe, fibrous tissue 
grows to encapsulate the vessel and probe. The fibrous 
capsule acts to keep Ө and the diameter of the vessel directly 
beneath the probe constant. As 𝑓o (20 MHz), C (velocity of 
sound in fluid) and Ө (about 45o) remain constant, Δ𝑓 is 
linearly related to the velocity of fluid, in this case blood flow 
velocity. As the diameter of the vessel directly under the cuff 
also remains constant, blood flow velocity is directly 
proportional to blood flow. This assumption was investigated 
by Haywood, who measured blood flow simultaneously using 
81 
 
the pulsed Doppler flowmeter method and the electromagnetic 
flowmeter method, Haywood showed measured changes in 
blood flow were directly proportional to changes in flow 
velocity across a range of pharmacologically-induced 
vasoconstriction and vasodilatation (Haywood et al., 1981). 
The measurement of Doppler shift in conjunction with mean 
arterial blood pressure (measured via an i.a catheter attached 
to a pressure transducer) allows for vascular conductance 
(vascular conductance=mean Doppler shift/mean arterial 
blood pressure) (Gardiner et al., 1990) to be calculated. 
2.5.2 Construction of Doppler Flow Probes 
Pulsed Doppler flow probes were assembled using a method 
similar to that described by Haywood (Haywood et al., 1981). 
Piezoelectric crystals with attached wires were obtained from 
Crystal Biotech Inc (USA) and tested for their ability to send 
and receive ultrasonic signals. This was done by attaching the 
piezoelectric crystal to a flowmeter and dipping it in and out of 
distilled water; if the crystal was working, sound was produced 
through the flowmeter. Once this had been confirmed, the 
crystal was inserted in to a 3-4 mm length of medical grade 
silicone tubing (Figure 2.4). One side of the tubing was cut at 
a 45° angle, allowing the piezoelectric crystal to sit at a 45° 
angle to the vessel when it was implanted. The wires of the 
crystal were then pulled through the other side of the tubing, 
ensuring the face of the crystal was positioned toward the 
angled side of the tubing. The crystal was held in place with a 
small amount of dental wax until it was ready to be 
permanently fixed. On the opposite side of the tubing (where 
the wires protrude) a piece of polystyrene was attached as an 
acoustic baffle, ensuring the ultrasound was projected forward 
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(Figure 2.4). The probe was then left to set for 24 h (Gardiner 
et al., 1990).  
In order to form a cuff, which was later used to attach the 
crystal to the vessel, the piezoelectric crystal + acoustic baffle 
was mounted onto a needle by melting the dental wax on the 
crystal (Figure 2.4). A silastic cuff was then built up around 
the subunit and the needle. The probe was left overnight, 
allowing the silastic gel to set (Figure 2.4). Finally, the silastic 
cuff was cut along the underside of the needle, releasing the 
probe from the needle and forming two flaps, which 
subsequently had sutures (6/0 ophthalmic silk) sewn into 
them to provide ties; this later allowed for the probe to be 
secured around the vessel (Figure 2.4, Figure 2.5.a.).
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Figure 2.4 Labelled image of the pulsed Doppler probe construction process. 
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2.6 Surgical Procedures 
2.6.1 Animals 
Male Sprague-Dawley rats (Charles River, Margate, UK) 
weighing between 300-500 g were used for all pulsed Doppler 
flowmetry studies. Animals were housed in temperature 
(21-23°C) and light (12 h light/ dark cycles from 6 am/ 6 pm) 
controlled conditions. All animals had free access to food and 
water and were allowed to acclimatise to the housing 
conditions for ≥10 days before any surgery was performed. 
Animals were housed in pairs prior to Doppler flow probe 
implantation. They were then singularly housed overnight after 
pulsed Doppler flow probe implantation, pair housed again 
before catheterisation and single housed post-catheterisation 
surgery. All in vivo experimentation was approved by the 
Animal Welfare and Ethical Review Body (University of 
Nottingham), and performed in keeping with the Animals 
(Scientific Procedures) Act (1986), under UK Home Office 
approved Project Licence (40/3466) and Personal License 
authority. 
2.6.2 Implantation of Doppler Flow Probes 
Animals were initially anaesthetised with fentanyl citrate, 
(300 µgkg-1, Jansen-Cilac Ltd, opioid agonist) mixed with 
medetomidine (Domitor, 300 µgkg-1, Pfizer, α2-adrenergic 
agonist), i.p (supplemented with 0.5 ml fentanyl citrate 
50 µgml-1 and 1 mgml-1 medetomidine to maintain anaesthetic 
depth throughout the surgery, as required) (Flecknell, 2010). 
Once animals were fully anaesthetised (assessed by firmly 
pinching the hind-paw), weight was recorded and the 
abdominal midline, posterior of the neck and left flank above 
the hind limb were shaved. The shaved areas, paws and tail 
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were cleaned with chlorohexidine gluconate (0.5% w/v in 70% 
v/v IMS, Adams Healthcare) and the animal was wrapped in a 
clear surgical drape (cling film, Glad, USA) before being placed 
on a heated surgical table, set at 37°C, in the dorsal 
recumbent position.  
A 4-5 inch midline abdominal incision was made along the 
linea alba. The contents of the abdomen were wrapped in 
sterile, saline-saturated tissue and pushed to one side, 
exposing the vasculature underneath. Vessels of interest (left 
renal artery, superior mesenteric artery and the distal 
abdominal aorta) (Figure 2.5) were identified using a 
microscope. These vessels were cleared of adipose and 
connective tissue using blunt dissection techniques. An 
appropriate sized probe, with a lumen equivalent to the 
vessels diameter (renal/ mesenteric artery approximately 
1 mm, aortic artery approximately 1.7 mm), was selected for 
each vessel and coupling gel (ultrasound gel, Henleys Medical, 
UK) was added to the centre of the probe, onto the face of the 
crystal. Each probe was then connected to a Doppler 
flowmeter and checked for acceptable signal detection. 
Providing the signal was of good quality, the probe was then 
sutured around the vessel (Haywood et al., 1981; Gardiner et 
al., 1990). 
Probe wires were secured to the left abdominal wall with 
2-0 vicryl suture (Ethicon, UK) and tunnelled via the left flank 
to the posterior of the neck, where signals were re-verified 
using the Doppler flowmeter. Wire ends were secured with 
suture and sterile tape to the nape of the neck (approximately 
0.3 cm of wire/ tape was left exposed). The abdominal 
contents were carefully repositioned and the muscle wall 
sutured using 2-0 vicryl (Ethicon, UK). Excess wire was coiled 
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and anchored subcutaneously at the left flank. Finally, the 
abdominal skin layer was sutured using 4-0 vicryl 
(Ethicon, UK) and surgical wound powder (Battle, Hayward 
and Bower Ltd, UK) was dusted over all the wounds to reduce 
the likelihood of infection and promote wound healing. Animals 
were given 0.05 ml Amoxycare LA (150 mgml-1 (15% w/v) 
ampicillin trihydrate, Animalcare, UK) intra-muscularly and 
5 ml warmed saline i.p to aid post-surgical hydration and to 
ensure the abdominal cavity and its contents were moist, 
reducing the risk of post-surgical trauma (suggested best 
practice by the named veterinary surgeon). Anaesthetic was 
reversed using 0.02 mgkg-1 Vetergesic (buprenorphine, Alstoe 
Animal Health, UK, partial opioid agonist) and 1 mgkg-1 
Antisedan (atipamezole hydrochloride, Pfizer α2-adrenergic 
antagonist). Animals were housed singly in cages positioned 
over heating pads for the first 6 h post-surgery, during this 
time their welfare was checked every 15 min and 0.02 mgkg-1 
Vetergesic was given 4 h after surgery as an analgesic top-up. 
Animals were then housed singularly in an individually 
ventilated cage over night before being reintroduced to their 
cage mate. This period of individual housing allowed for the rat 
to rest and for the skin and muscle incisions to begin to heal. 
Rats were allowed free access to food and water during their 
10-14 day recovery period, and were monitored daily and 
satisfactorily inspected by the Named Veterinary Surgeon 
before catheterisation took place. 
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Figure 2.5 Illustration of flow probe, i.v and i.a catheter placement. Doppler flow probes were tied around the 
mesenteric (a.1.), renal (a.2.) and distal aortic (a.3.) arteries. 10-14 days later, catheters were introduced into 
the right jugular vein (i.v: a.4.) and ventral caudal artery (i.a: a5.). Post-catheterisation surgery, flow probes were 
connected to a flow meter, allowing Doppler shift to be recorded (b.1., b.2, b.3. representative trace). The i.a 
catheter was connected to a pressure transducer in order to record mean arterial blood pressure (b.4). 
Representative Doppler shift and mean arterial blood pressure traces (b) were obtained from regions, as 
indicated in (a). 
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2.6.2.1 Implantation of Intra-vascular Catheters 
Venous catheters consisted of 150 cm Portex polythene tubing 
(internal diameter 0.28 mm x outer diameter 0.61 mm) and 
intra-peritoneal catheters consisted of 150 cm Portex 
polythene tubing (internal diameter 0.40 mm x outer diameter 
0.80 mm). The arterial line consisted of 6 cm Portex polythene 
tubing (internal diameter 0.28 mm x outer diameter 0.61 mm) 
heat-sealed to 85 cm Portex nylon tubing (internal diameter 
0.58 mm x outer diameter 1.02 mm). All catheters were 
packed and sterilised with ethylene oxide before surgery. Prior 
to insertion all catheters were flushed with 15 Uml-1 
heparinised saline. 
Animals were fully anaesthetised with fentanyl citrate 
(300 µgkg-1, Jansen-Cilac Ltd) mixed with medetomidine 
(Domitor, 300 µgkg-1, Pfizer) i.p, supplemented when required 
to maintain depth of anaesthesia. Depth of anaesthesia was 
monitored using the hind-paw toe pinch method. The weight of 
the animal was recorded and the anterior of the neck 
(between the larynx and sternum) and right flank were shaved 
and cleaned with chlorohexidine gluconate (0.5% w/v in 70% 
v/v IMS, Adams Healthcare). The wire tips protruding from the 
rat’s posterior neck were freed and stripped of insulation 
allowing the signal from each probe to be verified using the 
flowmeter. The wires were then soldered into a 6-way 
miniature connector (Microtech, Boothwyn, PA, USA) (Figure 
2.6). The rat was then wrapped in a clear surgical drape 
before being placed on the surgical table in the dorsal 
recumbent position. 
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2.6.2.2 Intra-venous Catheters 
A 1 cm incision was made on the anterior of the neck. 
Connective tissue was parted using blunt dissection and the 
right jugular vein isolated and ligated posteriorly. Lidocaine 
(0.5% w/v, Antigen Pharmaceuticals) was used to relax the 
vessel and further numb the neck. Either 2 (i.p administration 
studies) or 3 (i.v administration studies) venous catheters 
were tunnelled from the nape of the neck to the exposed 
jugular vein, and then advanced (by 2 cm) into the jugular 
vein through a small incision made in the vein. Catheters were 
secured into place using suture (4-0 silk thread), flushed with 
heparinised saline (15 Uml-1) and sealed with a wire spigot 
(Figure 2.5). The incision was then sutured closed and surgical 
wound powder dusted over the wound (Haywood et al., 1981, 
Gardiner et al., 1990). 
2.6.2.3 Intra-Arterial Catheters 
A 2 cm incision was made along the ventral side of the base of 
the tail and the ventral caudal artery exposed. Lidocaine 
(0.5% w/v, Antigen Pharmaceuticals) was applied to relax the 
vessel, the vessel was occluded by lifting on a pair of forceps 
and ligated; an arterial catheter was then advanced 6 cm into 
the distal aorta and secured in place with suture (4-0 silk 
thread) (Figure 2.5). The catheter was then flushed with 
heparinised saline (15 Uml-1) and sealed with a wire spigot 
before it was tunnelled via the dorsal end of the tail superiorly 
to the nape of the neck, where the probe wires and venous 
catheters exited. The tail was sutured closed (Van Dongen, 
1990). 
90 
 
2.6.2.4 Intra-peritoneal Catheters 
An incision was made along the skin of the right flank and an 
intra-peritoneal catheter inserted though the abdominal wall 
by 4 cm. The catheter was secured to the muscle wall by 
suture (4-0 silk thread), both at the site of entry and 1-2 cm 
posterior to the incision. The catheter was tunnelled 
subcutaneously to exit at the nape of the neck, flushed with 
heparinised saline (15 Uml-1) and sealed with a spigot. The 
skin was sutured and surgical wound powder dusted over the 
incision.  
2.6.3 Doppler Experimental Set Up 
Post-surgery, the animals were transferred to a cage in the 
experimental room and fitted with a harness (Figure 2.6). The 
catheters were threaded through a hollow spring attached to a 
counter balance and a miniature 6 way plug (Figure 2.6.d.) 
and secured to the harness; any exposed wires and soldered 
joints were protected with tape (Figure 2.6.b., 2.6.c.). The 
connector was attached to an extension lead and the probe 
signals checked using a Doppler flowmeter. Anaesthesia was 
reversed using 0.02 mgkg-1 Vetergesic (buprenorphine, Alstoe 
Animal Health) and 1 mgkg-1 Antisedan (atipamezole 
hydrochloride, Pfizer). The arterial line was connected to a 
fluid-filled swivel (Gardiner et al., 1990) which in turn was 
connected to an infusion pump set to infuse heparinised saline 
(15 Uml-1) at 0.4 mlh-1 during non-experimental periods 
(Figure 2.6). Animals had free movement within the cage and 
free access to food and water. 
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Figure 2.6 Illustration of exteriorised catheters, flow probe wires, harness placement and experimental set up 
(shown when the animal was recovering from anaesthesia post-catheterisation surgery). During flow probe 
implantation and catheterisation surgery, the catheters and flow probe wires were exteriorised at the back of the 
neck and a 6 way plug soldered to the wire ends (a.). While the animal was still anesthetised a harness was 
attached (b., c.). The 6 way plug + wires were wrapped in tape, to protect the soldering joints, and secured to the 
back of the harness (b.). The catheters were fed through a steel spring for protection (d.1.). The spring was 
attached to a counter balance swivel (d.2) allowing the rat free movement within the cage. The 6 way plug was 
attached to the Doppler flow meter (d.3.) via a connector lead (d.4.). Finally the i.a catheter was attached to an 
infusion pump (d.5.) set to infuse heparinised saline (15 Uml-1) at 0.4 mlh-1 during non-experimental periods. 
During experimental periods the i.a catheter was connected to a pressure transducer (d.6.).  
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After a 24 h recovery period, experiments began and lasted 
for a total of 4 days, with recordings taken continuously for 
4.5 h per day. Baseline recordings were taken for a minimum 
of 30 min in all studies undertaken. Heart rate and blood 
pressure were continuously monitored via the i.a catheter 
connected to a pressure transducer (Gould, Eastlake, Ohio, 
USA) and a transducer amplifier (Gould, Eastlake, Ohio, 
USA) model 13–4615-50)), which interfaced with the IDEEQ 
recording system (Maastrich Instruments, The Netherlands). 
Pressure changes were detected by strain gauges, in the 
pressure transducer, as changes in resistance. The change in 
resistance was converted to a change in voltage by a 
Wheatstone bridge circuit. Calibration of the pressure 
transducer, using a sphygmomanometer, allowed changes in 
voltage to be converted into changes in mmHg by the IDEEQ 
software. 
The catheter-transducer-IDEEQ recording system was able to 
follow a fundamental frequency of approximately 40 Hz. The 
ability to measure frequencies up to the 5th harmonic of the 
heart rate means that systolic and diastolic arterial blood 
pressures can be measured faithfully i.e., not over-dampened 
or under-dampened. Over-dampening of the blood pressure 
signal was reduced by using rigid arterial catheter tubing, and 
by using a custom ‘low volume’ transducer filled with 
de-gassed water. This reduced possible air spaces and bubbles 
within the transducer. Under-dampening, which would cause 
resonance, was avoided by the use of the flexible, small bore, 
intra-vascular section of the arterial catheter (Gardiner et al., 
1990). 
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The Doppler shift was measured by connecting the flow probes 
to a Doppler flowmeter (Crystal Biotech, Holliston, MA, USA) 
and in turn to the IDEEQ recording system. The Doppler 
flowmeter used here had been modified to detect pulse 
repetition frequencies (PRF) of 125 KHz. In 1990, Gardiner et 
al. demonstrated a PRF of 62.5 KHz was insufficient to 
accurately measure changes in rat aortic Doppler shift, in the 
presence of nitroprusside and methoxamine (Gardiner et al., 
1990). This was concluded to be due to the Nyquist (sampling) 
theorem (Cho et al., 2011), which states that to accurately 
convert analogue signals to digital, the sampling frequency 
(pulse-repetition frequency (PRF)), which in this case is the 
number of times the piezoelectric crystal emits and receives a 
signal per second, must be greater than half of the maximum 
frequency, or over twice the frequency response (Stewart et 
al., 1985). When this parameter is not met, a phenomenon 
called aliasing occurs. Alias signals are signals of the same 
value on corresponding sides of the waveform, when the 
maximum frequency response is not at least twice that of the 
PRF, these alias signals overlap leading to the loss of high 
frequency components of the signal and to a distortion of the 
continuous waveform (Cho et al., 2011). 
2.6.4 Statistical Analysis 
All data were expressed as mean ± SEM. Data were displayed 
parametrically to follow scientific convention, but 
non-parametric statistical analyses were used, since not all the 
data could be considered to be normally distributed. A 
Friedman test was performed to determine if within group 
changes from baseline values were significant. Between group 
two tailed comparisons were made using Mann Whitney-U test 
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(for 2 groups) and Kruskal Wallis test (more than 2 groups) 
with significance being accepted at P‹0.05. All statistical 
analysis was performed using Biomedical version 3.4 
(Nottingham, UK). 
2.7 Isobaric Myography 
Isobaric (pressure) myography comprises of an isolated vessel 
segment being mounted and secured onto 2 glass 
micro-cannulae (Mulvany and Halpern, 1976). This allows the 
vessel to be exposed to transmural pressure and changes in 
vessel diameter (caused by vessel contraction/relaxation) to 
be measured. Unlike wire myography, which measures the 
force exerted by a vessel that is undergoing contraction 
(Mulvany and Halpern, 1977), pressure myography allows for 
changes in the diameter of the vessel to be measured. It has 
multiple advantages over wire myography including 
maintenance of the cross sectional shape of the vessel, as well 
as control over the intramural pressure within a vessel. It also 
ensures that the endothelium remains relatively untouched 
during the set-up of the experimental procedure, helping to 
reduce undue vessel trauma (Mulvany and Halpern, 1976; 
Halpern and Mulvany, 1977).  
2.7.1  Preparation of Small Mesenteric Arteries 
Male, Sprague Dawley rats, weighing between 150-200 g were 
killed by striking the cranium, followed by exsanguination. This 
technique was carried out in accordance with Schedule 1 of 
the UK, Animals Scientific Procedures Act (1986). The 
mesentery was removed and transferred to a dissection dish 
containing ice cold (0-4°C) Krebs-Henseleit physiological salt 
solution (PSS) (118 mM NaCl, 4.8 mM KCl, 1.1 mM 
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MgSO4.7H20, 25 mM NaHCO3, 1.2 mM KH2PO4, 12 mM 
Glucose, 1.25 mM CaCl2.2H20) (White et al., 2013). The PSS 
was gassed with 5% CO2 95% air prior to being used. This 
ensured the pH of the solution was 7.4 and that the solution 
was oxygenated. The mesentery was laid flat in PSS and 
pinned allowing for vessel isolation. The arteriole was 
identified by its ‘V’ shaped branching anatomy. The second 
order branch of the arteriole was carefully stripped of fat and 
connective tissue with forceps and spring action surgical 
scissors, ensuring vessel stretching and damage was kept to a 
minimum. Approximately 5-7 mm of the arteriole connected to 
a 0.5-1 mm side branch was transferred into either a living 
systems CH2 or DMT 120CP pressure myography chamber. 
Second order mesenteric arterioles (diameter 100-400 μm) 
were used as they are representative of the vessels in vascular 
beds that influence total peripheral resistance and blood 
pressure (Christensen and Mulvany, 2001).  
2.7.2 Myography System 
Due to equipment availiblity, two separate pressure 
myography systems were used to collect data, the living 
systems CH2 and DMT 120CP pressure myographs. This 
Section shall discuss how the vessel was mounted onto the 
myograph and highlight any differences between the two 
set-ups (Table 2.2).  
The myography bath contained 10 ml PSS and was perfused 
with 95% air 5% CO2 to maintain a pH of approximately 7.4. 
Temperature was maintained at 36-37°C. Both myography 
systems used self-heating baths. All tubing was filled with PSS 
solution ensuring all air bubbles were removed. This was done 
so that no air could enter the vessel when it was mounted. It 
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has been shown that perfusion of a vessel with air disrupts the 
endothelial layer affecting the ability for the endothelium to 
control vessel tone and, therefore, affecting the results gained 
(Falloon et al., 1993). The side of the vessel which had an off 
branch attached was carefully slipped onto the right hand 
micro-cannula using forceps. It was then tied in place, 
ensuring the tie was placed after the off-branch, with a single 
strand of nylon thread. A small amount of PSS solution was 
allowed to flow through the micro-cannula and vessel to 
remove any residual blood in the vessel. The other side of the 
vessel was then carefully mounted onto the left hand 
micro-cannula and tied in place. The myography bath was 
then placed onto the microscope platform (Table 2.2).  
90 mmHg was applied to the vessel and no flow of PSS was 
allowed to ensure no flow mediated vasoactivity (Ando and 
Yamamoto, 2009). Static pressure of the vessel was checked 
in the living systems CH2 system by switching the peristaltic 
pump to manual and checking for maintenance of pressure; on 
the DMT 120CP system maintenance of pressure was checked 
by comparing the pre-vessel and post-vessel pressure 
transducer readings and looking for pressure differences. One 
of the major differences between these two systems is how 
the vessel was pressurised. The Living Systems myograph 
used a pressure-servo peristaltic pump connected to a 
pressure transducer. The peristaltic pump worked by actively 
displacing fluid, therefore forcing it along the tubing. The DMT 
120CP system used a flow control system, where a mixture of 
95% air 5% CO2 was used to pressurise a bottle containing 
PSS solution, the pressure in the bottle forced the fluid out of 
the bottle, and through the vessel, at a set pressure (detected 
by pressure transducers placed before and after the vessel).  
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Intraluminal pressure was set to 90 mmHg (Fenger-Gron et 
al., 1995). Fenger et al (1995) demonstrated that in conscious 
freely moving Wistar rats, the approximate blood pressure in 
the intestine was 96 mmHg. However, as these animals had 
recently undergone surgery prior to the blood pressure 
measurement, a procedure that has been shown to raise blood 
pressure for up to 10 days (Greene et al., 2007) a pressure of 
90 mmHg was chosen to reduce the likelihood of 
over-stretching and/or damaging the vessel. 
Edge detection software (Table 2.2) was used to measure the 
distance between each of the vessel walls, giving a value for 
internal vessel diameter (μm). The edge detection software 
worked by identifying changes in brightness across an image. 
As the vessel wall is thicker and does not allow as much light 
to penetrate it, in comparison to the vessel lumen, the vessel 
lumen diameter can be easily distinguished and measured. 
Both edge detection systems allowed the user to adjust the 
edge detection in real time to ensure an accurate 
measurement was taken. The vessel was allowed to equilibrate 
to bath conditions for 30 min before the experimental 
procedure began (see Chapter 6 for further detail). 
Table 2.2 Summary of the key differences between the Living 
Systems CH2 and DMT 120CP myography systems.   
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2.7.3 Statistical Analysis 
Data collected from more than one system was not collated 
but instead has been shown and analysed independently. Data 
obtained from the DMT 120CP system were fitted using 
non-linear regression in GraphPad Prism 6 (San Diego, CA) to 
obtain EC50 values. 
 
Where [A] is the concentration of VEGF or ACh and EC50 is the 
molar concentration of agonist required to generate 50% of 
the maximal agonist response. In experiments where a 
VEGF/ ACh concentration- response curve in the presence of 
RTKI/ DMSO/ PSS control was generated, data were also fitted 
to the above equation. 
All data were expressed as mean ± SEM. A non-parametric, 
two-tailed group comparison Friedman test was performed to 
determine if any changes seen from the baseline value were 
significant. Non-parametric between group two tailed 
comparisons (Mann Whitney (for 2 groups) and Kruskal Wallis 
(more than 2 groups) were performed to look for significant 
differences between groups. An unpaired student T test was 
used to compare Emax and EC50. These were gained by 
averaging the individual experimental Emax and EC50 values 
from each experimental non-linear regression curve fit 
(Graphpad prism 6.00). Significance was accepted at P‹0.05.  
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Chapter 3 : Effects of 
Receptor Tyrosine 
Kinase Inhibitors on 
VEGF165- and 
VEGF165b-Stimulated 
NFAT-Luciferase Gene 
Transcription in 
HEK-293 Cells 
Expressing Human 
VEGFR2 
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3.1 Introduction 
This Chapter will address the in vitro action of RTKIs on 
VEGFR2-mediated responses, by quantifying their ability to 
inhibit the VEGF-VEGFR2-mediated activation of the 
PLCγ-NFAT pathway in a whole cell system. This pathway was 
chosen as it is involved in the promotion of cell growth and 
proliferation (Figure 1.1) (Armesilla et al., 1999; Hogan et al., 
2003). As these processes specifically contribute to the 
progression of angiogenesis and therefore, pathologically, the 
progression of solid tumour growth (Section 1.3), their 
inhibition by VEGF RTKIs is important for the successful 
treatment of cancer.  
The use of an in vitro whole cell system allows for the 
inhibitory actions of vandetanib, pazopanib, cediranib and 
sorafenib at VEGFR2 to be quantified. Additional understanding 
of the RTKI mechanism of action at VEGFR2 in vitro is 
important. It is currently thought that the ability of RTKIs to 
elicit an effect is dependent on their capacity to bind to 
intracellular regions of VEGFR2 (Wedge et al., 2002; 
Hennequin et al., 2002; Knowles et al., 2006; Gotink and 
Verheul, 2010; Davis et al., 2011; Blanc et al., 2013), 
therefore understanding the potency of these RTKIs when a 
cell membrane is present is important.  
Finally, a better understanding of the mechanism of 
antagonism and order of potency of cediranib, sorafenib, 
pazopanib and vandetanib, against two VEGF-A splice 
variants: VEGF165, the predominantly studied pro-angiogenic 
VEGFR2 ligand (Liang et al., 2013), and VEGF165b, a VEGF-A 
splice variant with reduced efficacy at VEGFR2 in comparison 
to VEGF165 (Woolard et al., 2009), may help to further the 
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understanding of how VEGFR inhibitors lead to varying levels 
of hypertension in vivo and in the clinic (Varey et al., 2008) 
(Section 1.1). VEGF165b has previously been shown to be over 
expressed in various tumour types (Rennel et al., 2008) and 
to affect the growth of tumours (Pritchard-Jones et al., 2007) 
(described fully in Section 1.2). It has also been shown to 
affect the potency of Avastin (Varey et al., 2008), an 
anti-angiogenic monoclonal humanised VEGF antibody. 
Therefore, a better understanding of RTKI action against 
VEGF165b is important for future drug development and has 
potential clinical applications regarding treatment choice. 
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3.2 Methods 
3.2.1 Experimental Method Protocol 1: The 
‘non-confluent monolayer’ Method 
VEGFR2 NFAT cells were detached from the T75 flask (as 
described in Section 2.1.2) and seeded at a density of 30000 
cells per well in white sided, clear flat-bottomed 96 well plates 
which had been coated with poly-D-lysine. After 24 h, media 
was replaced with FCS free media. 24 h later, the FCS free 
media was removed and replaced with DMEM + 0.1% BSA. 
10 μl DMEM + 0.1% BSA or VEGF165 diluted in DMEM + 0.1% 
BSA (100 nM–30 pM final concentration) were then added and 
the cells incubated at 37°C/ 5% CO2 for a further 5 h. After 
the 5 h incubation period, the experimental media was 
removed from the wells and 50 μl of DMEM and 50 μl 
ONE-Glo™ Luciferase Assay reagent was added to each well. A 
white plastic cover was placed over the bottom of the plate 
and luminescence was measured using a microplate 
scintillation and luminescence counter (TopCount NXT 
Packard) set to read at 19.1°C with a 5 min delay before 
reading relative luminescence units. An average of the counts 
per second, taken over 3 seconds, was used in all 
experimental analysis. Each individual experiment was 
performed in quadruplicate and repeated n number of times (n 
number per experiment specified in Section 3.3). 
3.2.2 Experimental Method Protocol 2: The 
‘suspension’ Method 
VEGFR2 NFAT cells were seeded in a T75 at 5x106 using 
DMEM + 10% FCS and incubated at 37°C/5% CO2 for 3 days 
(until the media turned yellow and the flask was 100% 
confluent). On the 4th day cells were washed with PBS and 
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detached using 3 ml Versene. Once cells had detached, 6 ml of 
DMEM + 0.1% BSA was added and the cells were counted 
using a haemocytometer. Cells were centrifuged at 1000 rpm 
for 5 min and re-suspended in DMEM + 0.1% BSA. They were 
subsequently added to the well at a density of 40000 cells per 
well in white sided, clear, flat-bottomed, 96 well plates which 
had been coated with poly-D-lysine. Cells were incubated for 
1 h at 37°C/5% CO2 and then incubated with set 
concentrations of RTKI (10 μl diluted to 10x final 
concentrations in DMEM + 0.1% BSA) at 37°C/5% CO2 for 1 h 
prior to the addition of 10 μl VEGF in DMEM + 0.1% BSA. VEGF 
was incubated with the cells at 37°C/5% CO2 for 5 h. After the 
5 h incubation, 100 μl ONE-Glo™ Luciferase Assay reagent was 
added to the wells and the plate was prepared and read as 
described in Section 3.2.1. Each individual experiment was 
performed in triplicate or quadruplicate and repeated n 
number of times (n number per experiment specified in 
Section 3.3). 
3.2.3 Data Analysis 
Data were fitted using non-linear regression (see Section 
2.2.3). All data have been presented as mean ± SEM. 
Statistical significance was determined by either Student’s 
T-test or a one or two way ANOVA with Dunnett’s post-hoc 
analysis, where appropriate. P<0.05 was considered 
statistically significant. Data were fitted using non-linear 
regression (GraphPad Prism 6.00).  
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3.3 Results 
3.3.1  Characterisation of the VEGF165-Mediated NFAT 
Luciferase Response, in the Presence and 
Absence of RTKIs 
VEGF165 produced a concentration dependent increase in 
NFAT-mediated luciferase production (Figure 3.1). Cells 
cultured using the ‘non-confluent monolayer method’ gave a 
larger SEM and a lower signal: basal noise ratio between and 
within experiments (Figure 3.1) in comparison to experiments 
performed using the ‘suspension method’ (Figure 3.1). Due to 
this, it was decided that the more cell dense, suspension cell 
culture method, where cells were not allowed to form a 
monolayer would be used throughout the remainder of the 
study (protocol 2). VEGF165 pEC50 values obtained using this 
methodology were similar to those obtained using the 
non-confluent monolayer methodology, however the 
experimental window was larger and variation within and 
between experiments was reduced (Figure 3.1, Table 3.1). 
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Figure 3.1 The effect of VEGF165 on firefly luciferase production (luminescence measured using relative luminescence units 
(RLU)) in VEGFR2 NFAT Cells. Cells were treated with VEGF165 either in suspension (a, b) or as a non-confluent monolayer 
(c, d). Graphs on the left are representative of one experiment (performed in quadruplicate), graphs on the right represent 
normalised pooled data (b n=10, d n=6), where 0% is defined as the basal luminescence count (RLU) and 100% is defined as 
the 10 nM VEGF165 positive control luminescence count (RLU). 
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Table 3.1 Comparison of the suspension or non-confluent monolayer 
cell culture methods on NFAT reporter gene responses following 
stimulation with VEGF165. VEGFR2 NFAT cells were treated with 
VEGF165 (in quadruplicate at each concentration in each experiment) 
either as suspension or as a non-confluent monolayer. Table 3.1 
shows the E
max
 (fold over basal), demonstrating the size of assay 
window for each technique, the VEGF165 pEC50 (negative log of the 
EC50 (mol/L)) and number of individual experiments performed (n) for 
each technique. Data are displayed as mean ± SEM. Students 
unpaired T test between group compairision demonstrated a 
significant difference between Emax.  
 
Using the suspension method, all four VEGF RTKIs were shown 
to inhibit VEGF165-NFAT-mediated luciferase production (Figure 
3.2, Figure 3.3). The action of these compounds was not 
increased or diminished by DMSO (vehicle), which was used at 
a comparable concentration to the highest concentration of 
experimental compound used (as seen in Figure 3.2). pIC50 
values obtained for each compound were similar to the KD 
values reported by Davis et al., (Davis et al., 2011), who used 
purified VEGFR2 kinase domains (Table 3.2) to look at RTKI 
binding. Although IC50 values are related to affinity (KD), they 
are an empirical measure which are dependent upon a number 
of different experimental factors. Perhaps most importantly, 
the IC50 of competitive compounds is directly related to the 
concentration of agonist used to stimulate the system. In 
addition, where IC50s are determined for compounds targeting 
intracellular binding sites, the membrane permeability of 
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compounds can have a significant impact on observed IC50 
values, with poorly permeable compounds having much higher 
cellular IC50s than their Kis measured against soluble purified 
catalytic domains. The observation that the cellular IC50s 
observed in this study are similar to the KD values reported for 
soluble catalytic domain (Gotink and Verheul, 2010; Davis et 
al., 2011) suggests that these compounds are not competitive 
with VEGF and also readily cross the plasma membrane to 
access the intracellular binding site.  
Sorafenib (-25.0 ± 2.6%, n=5) and vandetanib 
(-23.0 ± 3.7%, n=5) both caused a significant inhibition below 
constitutive (basal) activity (P<0.05, paired T test, Figure 3.3 
a, d). This may indicate that sorafenib and vandetanib have off 
target effects at higher concentrations. Cediranib and 
pazopanib did not show a marked inhibition below basal 
(Figure 3.3 b, c). However, when cediranib was incubated with 
unstimulated cells, an inhibition of basal readings was seen 
(Figure 3.4). This suggests that the inhibition below basal seen 
in these experiments is caused by off-target effects. 
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Figure 3.2 The effect of selected RTKIs on VEGF165 stimulated firefly luciferase production in VEGFR2 NFAT cells in suspension 
(confluent method). VEGFR2 NFAT cells were pre-treated with vandetanib (n=1) (a), pazopanib (n=1) (b), cediranib (n=1) (c) 
and sorafenib (n=1) (d) for 1 h at 37°C/ 5% CO2 before treatment with +1 nM VEGF165 for 5 h at 37°C/ 5% CO2. Data shows 1 
representative experiment. Data are displayed as mean ± SEM. Each individual experiment was performed in quadruplicate. 
Student paired T test of basal value versus RTKI highest concentration showed vandetanib and sorafenib significantly inhibited 
constitutive activity.  
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Figure 3.3 The effect of selected RTKIs on VEGF165 stimulated firefly luciferase production in VEGFR2 NFAT cells in suspension 
(confluent method). VEGFR2 NFAT cells were pre-treated with vandetanib (n=5) (a), pazopanib (n=5) (b), cediranib (n=5) (c) 
and sorafenib (n=5) (d) for 1 h at 37°C/ 5% CO2 before treatment with +1 nM VEGF165 for 5 h at 37°C/ 5% CO2. Data have 
been pooled and normalised to the corresponding basal and 1 nM VEGF165 controls. Data are displayed as mean ± SEM. Each 
individual experiment was performed in quadruplicate. Student paired T test of basal value versus RTKI highest concentration 
showed vandetanib and sorafenib significantly inhibited constitutive activity.   
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Figure 3.4. The effect of cediranib on basal NFAT-luciferase Production. VEGFR2 NFAT cells were pre-treated with cediranib for 
1 h at 37°C/ 5% CO2 before treatment with 10 μl DMEM+0.1% BSA for 5 h at 37°C/5% CO2. Data shown in panel a. is 
representative of 1 experiment, whereas data shown in panel b. shows n=5 experiments which have been pooled and 
normalised to the basal response. Each individual experiment was performed in quadruplicate. Data are displayed as 
mean ± SEM. 
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Table 3.2 RTKI pIC50 values (negative log of the IC50 (mol/L)) 
obtained from VEGF165-mediated NFAT responses versus published 
pKD values (negative log of the KD (mol/L)) from purified kinase 
domains. VEGFR2 NFAT cells were treated with each RTKI + 1 nM 
VEGF165. Data are presented as mean ± SEM of n separate 
experiments *pKD values were taken from Davis et al., 2011 (Davis 
et al., 2011). 
 
All four RTKIs inhibited VEGF165-mediated NFAT activation in a 
non-competitive manner. This was demonstrated by the 
significant reduction in VEGF165 Emax coupled with a relatively 
small shift in pEC50 with increasing concentrations of each RTKI 
(Figure 3.5, Table 3.3). Each RTKI demonstrated a significant 
decrease in Emax (P<0.05, two-way ANOVA) between 
concentrations. VEGF165 in the presence of the highest 
concentration of each RTKI showed a significant change in 
pEC50 compared to VEGF165 alone (P<0.05, two-way ANOVA). 
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Figure 3.5 The effect of varying concentrations of RTKIs on VEGF165-stimulated firefly luciferase production in VEGFR2 NFAT 
cells. VEGFR2 NFAT cells were treated with 10 nM VEGF165 and varying concentrations of vandetanib (a), pazopanib (b), 
cediranib (c) and sorafenib (d). Data have been pooled and normalised to the corresponding basal and 10 nM VEGF165 controls. 
Data displayed as mean ± SEM. Each individual experiment was performed in quadruplicate and repeated n=6 (cediranib), 5 
(pazopanib), 7 (sorafenib) and 5 (vandetanib) times separately. Between group two-way ANOVA with dunnett’s post hoc 
analysis was performed on Emax and EC50 values. 
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 Table 3.3 The effect of pre-incubation with RTKI on VEGF165-induced NFAT production. pEC50 and Emax values for VEGF165 were 
obtained in the presence of increasing concentrations of 4 RTKIs. Data shown are mean ± SEM. Each individual experiment 
was performed in quadruplicate and repeated n=6 (cediranib), 5 (pazopanib), 7 (sorafenib) and 5 (vandetanib) times 
separately. * P<0.05 compared to corresponding control in the absence of RTKI (between group two-way ANOVA with Dunnett’s 
post-hoc analysis). 
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3.3.2  Characterisation of the VEGF165b Mediated 
NFAT Luciferase Response, in the presence and 
absence of RTKIs 
In comparison to VEGF165, VEGF165b was shown to be a lower 
efficacy agonist at VEGFR2 (Figure 3.6). VEGF165b led to a 
concentration dependent NFAT-mediated luciferase production 
and had a pEC50 of 9.21 ± 0.08 (n=5). When normalised to 
the 30 nM VEGF165 response, VEGF165b had an Emax of 
62.1 ± 1.2% (n=5). As the EC50 values demonstrated by 
VEGF165 and VEGF165b were similar, the data shown here 
suggest that although the efficacy between these two 
endogenous ligands is different, their potency is not. 
As with VEGF165, the four RTKIs inhibited VEGF165b stimulation 
of the NFAT response element (Table 3.4). pIC50 values for the 
four RTKIs in respect to inhibition of VEGF165b signalling, were 
similar to those seen when using VEGF165 stimulation 
(Table 3.2, Table 3.4). 
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Figure 3.6 Characterisation of the VEGF165b-mediated NFAT luciferase response. VEGFR2 NFAT cells were treated with increasing 
concentrations of VEGF165 or VEGF165b in order to investigate isoform specific differences in NFAT production (n=5) (a). VEGFR2 
NFAT cells were also pre-treated with increasing concentrations of cediranib (1 h at 37°C/5% CO2) followed by stimulation with 
3 nM VEGF165b (5 h at 37°C/5% CO2) (n=5) (b). Data have been pooled and normalised to the corresponding basal and 30 nM 
VEGF165 controls except for the data in b that have been normalised to 3 nM VEGF165b. Data are displayed as mean ± SEM. 
Each individual experiment was performed in quadruplicate. 
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Table 3.4 Inhibition of 3 nM VEGF165b by four representative RTKIs. 
VEGFR2 NFAT cells were treated with increasing concentrations of 
each RTKI and 3 nM VEGF165b. Data were presented as mean ± SEM 
of n separate experiments. Each individual experiment was performed 
in triplicate (vandetanib and sorafenib) or quadruplicate (cediranib 
and pazopanib). Individually fitted pIC50 values were obtained from 
each individual experiment and then pooled to provide the mean ± 
SEM data provided here. 
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3.4 Discussion 
In order to investigate the potency of vandetanib, sorafenib, 
cediranib and pazopanib at VEGFR2 in living cells, an NFAT 
reporter gene assay was used (Voon et al., 2005). This also 
allowed for the quantitative analysis of RTKIs in the presence 
of VEGF165 and VEGF165b and for a comparison of VEGF165 and 
VEGF165b-mediated NFAT stimulation. 
3.4.1 Methodology 
Cells were treated either in a non-confluent monolayer (using 
protocol 1: Section 3.2.1) or in suspension (using protocol 2: 
Section 3.2.2). In experiments where cells were allowed to 
adhere to the base of the well, a large SEM and a 
low signal: basal noise ratio between and within experiments 
was seen (Figure 3.1c, d). However, when cells were grown to 
full confluence in a T75 flask and then used in suspension 
during the experimental procedure (Figure 3.1 a, b), the error 
within and between experiments was reduced. One reason for 
this difference may be the difference in cell cycle stage. Cells 
which have been cultured and maintained at 100% confluence 
(labelled here as suspension) are more likely to be in a state 
of quiescence (G0), or senescence (G1/S) where the cell is in 
a resting state and not preparing for mitosis (Patel et al., 
2005; Yoon and Seger, 2006), therefore the production and 
secretion of growth factors is reduced (Zhang et al., 2004). 
Autocrine and paracrine signalling from growth factors 
produced by cells which are growing or preparing to go 
through mitosis would lead to a high basal level of 
bioluminescence (as seen in non-confluent monolayer 
experiments, Figure 3.1 c, d).  
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3.4.2 Characterisation of the VEGF165 and VEGF165b 
Mediated NFAT Luciferase Response 
Both VEGF165 and VEGF165b were able to stimulate 
NFAT-mediated luciferase expression in a concentration 
dependent manner (Figure 3.6). Although both isoforms had 
very similar pEC50 values (VEGF165: 9.66 ± 0.05 vs 
VEGF165b: 9.21 ± 0.08), VEGF165b was a partial agonist of 
NFAT-luciferase production eliciting a maximal response that 
was 61.94% ± 2.26% (mean ± SEM) of that achieved by 
VEGF165. The reduced efficacy of VEGF165b at VEGFR2 
compared with VEGF165 had been previously reported by 
Woolard et al and others (Woolard et al., 2004; Cebe Suarez 
et al., 2006; Kawamura et al., 2008; Catena et al., 2010) and 
is thought to be caused by differences between the protein 
structure of VEGF165 and VEGF165b (Chapter 1, Section 1.2). 
Another reason for the difference in the reported efficacy of 
VEGF165b at VEGFR2 compared to VEGF165 may be due to the 
cell type tested and/or the signalling cascade measured in the 
experiment. It has previously been shown that VEGF165b is a 
lower efficacy agonist of VEGFR2-mediated MAPK 
phosphorylation in CHO cells transfected with VEGFR2 
(Woolard et al., 2004). However, VEGF165b showed greater 
efficacy at VEGFR2 compared to VEGF165 at the same signalling 
pathway in human microvascular ECs (Woolard et al., 2004). 
This difference may be due to differences in receptor 
expression, downstream transcription machinery and/or 
receptor coupling efficiency between cell phenotypes.  
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3.4.3 The Action of RTKIs on the VEGF165 and 
VEGF165b Mediated NFAT Luciferase Response 
The 4 RTKIs tested here (cediranib, vandetanib, sorafenib and 
pazopanib) demonstrated the ability to inhibit VEGFR2-NFAT 
signalling mediated by VEGF165 and VEGF165b. There was little 
difference in pIC50 values for each RTKI between the two VEGF 
isoforms. As the binding target for all of the RTKIs tested is 
different from the binding site of VEGF165 and VEGF165b 
(intracellular kinase domain of the receptor vs Ig domain 2 
and Ig domain 3 on the extracellular portion of the receptor) 
their ability to inhibit VEGFR2, regardless of ligand subtype 
(i.e. VEGF165 or VEGF165b) may be due to their allosteric action 
(Zhang et al., 2009; Dosch and Ballmer-Hofer, 2010; Gotink 
and Verheul, 2010; Leppanen et al., 2010; Davis et al., 2011). 
This result also suggests that these RTKIs have lipophilic 
properties, allowing them to diffuse through the cell 
membrane and bind to the intracellular portion of the receptor 
in a whole cell system. Their ability to readily cross the cell 
membrane is further implied by the similarity between the IC50 
values gained here and Davis’ KD values calculated from 
isolated catalytic domains (Table 3.2) (Gotink and Verheul, 
2010; Davis et al., 2011).  
Sorafenib and vandetanib both caused a significant inhibition 
(below basal) of VEGF165 NFAT-luciferase activation (P<0.05, 
paired T test; Figure 3.3.a, d). This was also seen for 
cediranib, (P<0.05, paired T test; Figure 3.6.b) with 
VEGF165b-mediated NFAT-luciferase activation. When cediranib 
was incubated with unstimulated cells it produced an inhibition 
of the basal RLU reading (Figure 3.4). Therefore, it is likely 
that RTKI inhibition below basal is due to the multi-targeted 
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nature of these RTKIs, allowing them to reduce basal NFAT 
activity via a different tyrosine kinase system.  
All of the RTKIs tested demonstrated classical non-competitive 
antagonism of VEGFR2 (a significant decrease in Emax without 
a marked change in VEGF165/VEGF165b EC50 (Figure 3.5)), an 
outcome that is likely to be due to the difference in ligand and 
drug receptor binding sites. A decrease in Emax occurs when an 
antagonist, in this case an RTKI, is able to remove a 
proportion of the signalling receptor population from the 
system, reducing the ability for the agonist (in this case VEGF) 
to produce a full response, regardless of concentration, 
resulting in the EC50 remaining relatively constant.  
3.4.4 Conclusion 
In conclusion, cediranib, sorafenib, pazopanib and vandetanib 
have been shown to non-competitively (Figure 3.5) inhibit 
VEGF165- and VEGF165b–VEGFR2 mediated activation of the 
NFAT-luciferase reporter gene, demonstrating nano-molar IC50 
values (Table 3.2, Table 3.4). Finally, both VEGF165 and 
VEGF165b were shown to stimulate VEGFR2-mediated 
NFAT-luciferase activation; however the efficacy of VEGF165b 
at VEGFR2 was lower than VEGF165 (Figure 3.6).  
Based on the data discussed in this Chapter, vandetanib and 
pazopanib, two class I RTKIs with different IC50 values were 
selected to be characterised in vivo. By being able to relate 
the inhibition of VEGFR2 by pazopanib and vandetanib in vitro 
to the hypertensive side effect profile of vandetanib and 
pazopanib in vivo, the importance of VEGF signalling in VEGF 
RTKI induced hypertension can be further explored. 
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Chapter 4 : The In Vivo 
Cardiovascular Actions 
of Vandetanib 
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4.1 Introduction 
Approximately 23%, up to as many as 90%, of the patient 
populations taking VEGF therapies develop hypertension or 
experience a worsening in their existing hypertensive condition 
(Hamberg et al., 2010; La Vine et al., 2010; Aparicio-Gallego 
et al., 2011; Bible et al., 2014). The development and 
escalation of pre-existing hypertension in these patient 
populations has been linked to multiple severe complications 
including venous or arterial thrombo-embolisms, acute heart 
failure, proteinuria, haemorrhage and reversible posterior 
leukoencephalopathy syndrome (Govindarajan et al., 2006; 
Chu et al., 2007; Pouessel and Culine, 2008; Eschenhagen 
et al., 2011). A deeper understanding of the acute and chronic 
hypertensive effects of RTKIs may help to elucidate the 
physiological sequelae responsible.  
With this in mind, the hypertensive effect of vandetanib, a 
VEGFR2, VEGFR3, EGFR and RET kinase inhibitor (see Section 
1.3.1.1) approved for the treatment of medullary thyroid 
cancer, was explored in the rat. Regular (1 min recording 
every 15 min) recordings of heart rate and mean arterial blood 
pressure were taken with the intention of exploring the long 
term effects of vandetanib (21 day treatment; 25 mgkg-1day-1 
i.p) on blood pressure and heart rate. The post-treatment 
effects of vandetanib (measured for 10 days post-treatment) 
were also analysed with the aim of investigating whether 
vandetanib-induced cardiovascular physiological changes, such 
as vessel rarefaction.  
Mesenteric mesothelium were taken from rats involved in the 
study described above and stained for ECs with the hope of 
better understanding the effects of vandetanib on vessel 
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structure over time. It is currently thought that a key 
mechanism by which VEGF RTKIs, such as vandetanib, cause 
hypertension is vascular rarefaction (Small et al., 2014). 
Vascular rarefaction is the process of vessel regression, 
reducing the density of the microvascular network and 
therefore increasing blood pressure (Feihl et al., 2006; see 
Section 1.2.5). Rarefaction has previously been described in in 
vivo models of hypertension, within multiple tissue types such 
as the mesentery, cremaster muscle, skin and brain showing 
these vascular changes (Triantafyllou et al., 2015). Rarefaction 
has also been implicated as a possible cause of VEGF RTKI 
induced hypertension, with Steeghs et al demonstrating a 
reduction in capillary density in humans during a phase I trial 
for telatanib, a VEGFR2, VEGFR3 and PDGFR-β RTKI (Steeghs 
et al., 2008; Mross et al., 2011).  
In the study presented herein, the regional haemodynamic 
effects of vandetanib on heart rate, mean arterial blood 
pressure and mesenteric, renal and hindquarter vascular 
conductances over a period of 4 days were also investigated. 
Although it is widely known that VEGF RTKIs cause 
hypertension in humans (Lankhorst et al., 2015; Abi Aad et 
al., 2015; Kruzliak et al., 2014), there has been little or no 
investigation into the regional haemodynamic effects of these 
compounds in either animal models or human subjects. 
Understanding how vandetanib affects blood flow to specific 
vascular beds may help to elucidate some of the physiological 
processes responsible for the wide range of side effects caused 
by vandetanib.   
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4.2 Methodology  
4.2.1 Time Course of the Effects of Vandetanib on 
Cardiovascular Variables, Measured By 
Radio-Telemetry  
Rats were implanted with radio-telemetry devices as described 
in Chapter 2.4. Ten days post-surgical implantation of the 
radio-telemetry device, mean arterial blood pressure and heart 
rate were monitored and recorded for 1 min, every 15 min, for 
9 days. Rats were randomly assigned to be administered 
0.5 ml of either 25 mgkg-1day-1 vandetanib i.p (Sequoia 
research products, SRP0098v), diluted in vehicle (2% Tween, 
5% propylene glycol in 0.9% saline solution) (n=7) or vehicle 
(n=5) for 21 days. A post-treatment monitoring period of 10 
days was observed (Figure 4.1).  
 
Figure 4.1 Schematic diagram of the vandetanib 
25 mgkg-1day-1 i.p radio-telemetric experimental timeline. 
4.2.1.1 Statistical Analysis 
All data have been expressed as mean ± SEM with significance 
being accepted at P‹0.05. A Kolmogorov-Smirnoff test was 
performed to test for normality. This test showed data was not 
normally distributed. A non-parametric, two-tailed within 
group comparison (Friedman’s test) was performed to 
determine if any changes seen from the baseline value were 
significant. A non-parametric between group two tailed 
comparison (Mann Whitney-U test) was performed to analyse 
whether differences between test groups were significant. This 
was done using Graphpad prism 6.00.  
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4.2.2  The Action of Vandetanib on Mesenteric Vessel 
Structure Following In Vivo Dosing For 21 Days 
and a Post-Treatment Period of 10 Days 
On the final day of the telemetric study, as described in 
Section 2.3, rats were killed with 50 mgkg-1 pentobarbitone i.p 
and the mesentery was removed (as detailed in Section 2.4). 
The mesentery was washed with PBS and fixed in 4% 
paraformaldehyde (pH 7.4) before 4 mesenteric membranous 
panels were isolated, washed in PBX (0.5% Triton-X100 in PBS 
for 1 h) and incubated in 1% BSA-PBX for 1 h. Mesenteric 
panels were then incubated over night at 4°C with 10 μgml-1 
biotinylated Isolectin GS-IB4 (from Griffonia simplicifolia; 
Molecular Probes), washed with PBX for 1 h and incubated 
with 1 μgml-1 TRITC-labelled streptavidin (S-870 Molecular 
Probes) for 2 h to stain ECs. Mesenteric panels were washed 
with PBX for 1 h and then incubated with Hoechst (2 μgml -1 
diluted in BSA-PBX 30 min), to stain for cell nuclei, before 
being mounted onto APES coated microscopy slides with 
fluorescence mounting media.  
4.2.2.1 Data Analysis 
Images (16 bit) were taken on a Zeiss Axio observer Z1 using 
a Hamamatsu Orca flash 4 C11440 HD camera and an EC-Plan 
neofluor 10x/-0.3 ph1 objective. Images were analysed using 
Angiotool 0.6b (Zudaire et al., 2011). All analysis was blinded. 
Data were collated and plotted to show mean ± SEM using 
Microsoft Excel 2010 and GraphPad Prism 6.00. Statistical 
significance was determined using an unpaired one tailed 
Mann Whitney-U test (P<0.05). 
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4.2.3 Regional Haemodynamic Effects of Vandetanib 
Measured by Pulsed Doppler Flowmetry (i.v)  
Rats were implanted with miniature pulsed Doppler flow 
probes and intra-vascular catheters as described in Section 
2.6. Starting 24 h after catheter surgery, animals were 
randomly assigned to be administered with a 0.4 ml priming 
bolus dose of vandetanib (Sequoia research products, 
SRP0098v) at 12.5 mgkg-1h-1 (n=6), 25 mgkg-1h-1 (n=6) or 
vehicle (2% Tween 80, 5% propylene glycol in 0.9% saline) 
(n=6) i.v infused over 6 min once every 24 h. 0.4 ml of 
vandetanib or vehicle was then immediately infused over 45 
min at a concentration of 12.5 mgkg-1h-1. Cardiovascular 
variables were recorded continuously for 4.5 h per day over a 
4-day period (Figure 4.2).  
 
Figure 4.2 Schematic diagram of the vandetanib i.v Pulsed 
Doppler Flowmetry experimental timeline. 
4.2.4 Regional Haemodynamic Effects of Vandetanib 
Measured by Pulsed Doppler Flowmetry (i.p) 
Rats were implanted with miniature pulsed Doppler flow 
probes and intra-vascular catheters as described in Section 
2.6. Starting 24 h after catheter surgery, animals were 
randomly assigned to be administered with a 0.5 ml bolus 
dose of vandetanib (Sequoia research products, SRP0098v) at 
12.5 mgkg-1day-1 (n=8), 25 mgkg-1day-1 (n=8), 
50 mgkg-1day-1 (n=8) or vehicle (n=8) (2% Tween 80, 
5% propylene glycol in 0.9% saline), i.p once every 24 h. 
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Cardiovascular variables were recorded continuously for 4.5 h 
per day over a 4-day period (Figure 4.3). 
 
 
Figure 4.3 Schematic diagram of the vandetanib i.p Pulsed 
Doppler Flowmetry experimental timeline. 
 
4.2.4.1 Statistical Analysis 
All data have been expressed as mean ± SEM with significance 
being accepted at P‹0.05. A Kolmogorov-Smirnoff test was 
performed to test for normality. This test showed data was not 
normally distributed. A non-parametric, two-tailed within 
group analysis (Friedman’s test) was performed to determine 
if changes seen from baseline values were significant. 
Non-parametric between group two tailed comparisons (Mann 
Whitney (for 2 groups) and Kruskal Wallis (more than 2 
groups) were performed to test for significant differences 
between groups. All statistical analyses were performed using 
Biomedical version 3.4 (Nottingham, UK). 
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4.3 Results 
4.3.1 Time Course of Effects of Vandetanib on 
Cardiovascular Variables Measured By 
Radio-Telemetry  
Effects of vandetanib on cardiovascular variables measured by 
radio-telemetry are shown on Figure 4.1, Figure 4.2, Figure 
4.3, Figure 4.4, Table 4.1 and Table 4.2. 
4.3.1.1 Mean Arterial Blood Pressure  
Mean arterial blood pressure remained steady throughout the 
9 day pre-treatment period in both the vandetanib and vehicle 
groups, mean arterial blood pressure did not change 
significantly throughout the study for the vehicle group (Figure 
4.4). In rats administered vandetanib (25 mgkg-1day-1) i.p, 
mean arterial blood pressure increased significantly by 
4.5 ± 0.3 mmHg (P<0.05, Friedman) during the first 24 h of 
the treatment period (Figure 4.4, Table 4.1). This pressor 
effect was maintained throughout the remainder of the dosing 
period. However, when the peak plasma concentration time 
range (4-8 h post-dosing) (Ton et al., 2013) was analysed 
(see Section 1.3.1.1 for more detail), a significant increase of 
+13.8 ± 2.6 mmHg from baseline was seen on day 2 of 
treatment (Figure 4.4, Table 4.1). This finding was mirrored 
when the data were analysed in 3 h time slots (P<0.05, 
Friedman comparison against mean daytime (06:00-18:00) 
baseline data) (Figure 4.4). The rise in mean arterial blood 
pressure (mmHg) was significantly different from the vehicle 
group (P<0.05, Mann Whitney; Figure 4.1) and was 
maintained throughout the 21 day dosing period (P<0.05, 
Friedman; Figure 4.4, Table 4.1).  
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During the post-dosing observation period, mean arterial blood 
pressure decreased from +10.9 ± 0.4 mmHg to 
+8.4 ± 0.6 mmHg (25 mgkg-1day-1 i.p) on the 7th day after 
treatment (Figure 4.4, Table 4.1). The decrease was 
maintained for the remainder of the post dosing period 
(Figure 4.4, Table 4.1). The steady decline in mean arterial 
blood pressure over the 10 day post-dosing observation period 
can be seen in more detail in Figure 4.4d., which shows the 
final day of treatment followed by the 10 day post-treatment 
observation period analysed in 3 h time slots. At the end of 
the study (Day 10 post-treatment period), there was no 
significant difference between the vandetanib and vehicle 
groups. The vandetanib treatment group had a mean arterial 
blood pressure of +4.4 ± 0.4 mmHg, whereas the vehicle 
group had a mean arterial blood pressure of 
+2.4 ± 0.4 mmHg above baseline (Table 4.1). Of interest a 
daytime/ night-time increase and decrease in mean arterial 
blood pressure can be clearly seen in Figure 4.4c, d. This was 
further explored in Figure 4.5. 
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Figure 4.4. Mean arterial blood 
pressure of male Sprague Dawley 
rats dosed with vandetanib 25 
mgkg-1day-1 i.p (n=7) vs vehicle 
(n=5). Data displayed as mean ± 
SEM. Data were analysed and 
displayed in 24 hour bins (a), 4-8 
h after dosing (b) or in 3 h bins, 
separated into the last day prior 
to dosing and the first 4 days of 
dosing (c) or the last day of 
dosing followed by the 10 day 
post-treatment period (d). Red 
line- vandetanib 25 mgkg-1day-1 
i.p, black line- vehicle i.p 
#-P<0.05 Mann Whitney 
between group comparision 
*-P<0.05 Friedman test with data 
points compared against the 
mean of the 9 day pre-treatment 
period (a, b) or against the mean 
daytime (06:00-18:00) 
(orange*) and mean night-
time (18:00-06:00) (black*) 
values (c, d). Arrows show dosing 
times (c, d) 
131 
 
 
Table 4.1 Mean ± SEM change from baseline (defined as the mean 
value of the 9 day pre-treatment period) mean arterial blood pressure 
of male Sprague Dawley rats dosed with vandetanib 25 mgkg-1day-1 
i.p (n=7) vs vehicle (n=5). Data were analysed and displayed in 24 h 
bins (left) or 4-8 h Sections after dosing (right). Black baseline: 
average of 9 days pre-treatment period; blue text: treatment period; 
red text: post-treatment period.   
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Due to the daytime/ night-time pattern seen in the mean 
arterial blood pressure recordings (Figure 4.4d) the data were 
analysed in two 12 h slots (06:00-18:00 h or 18:00-06:00 h) 
(Figure 4.5). Changes in mean arterial blood pressure in 
response to vandetanib (25 mgkg-1day-1 i.p) or vehicle, i.p 
followed the same trend (pre-, during- and post- treatment) 
as the data presented in Figure 4.4a, b (analysed over 24 h or 
4-8 h post-dosing). The average mean arterial blood pressure 
was higher during the night-time throughout the study (Figure 
4.5). 
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Figure 4.5 Mean arterial blood pressure of male Sprague Dawley rats dosed with vandetanib 25 mgkg-1day-1 i.p (n=7) vs vehicle 
(n=5). Data displayed are mean ± SEM. Data were analysed and displayed in 12 h bins, separated into (a) daytime 
(06:00-18:00) or (b) night-time (18:00-06:00). Red line- vandetanib 25 mgkg-1day-1 i.p, black line- vehicle i.p #-P<0.05 Mann 
Whitney between group comparision *-P<0.05 Friedman test with data points compared against the mean 9 day pre-treatment 
period.  
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4.3.1.2 Heart Rate  
In the vehicle group, heart rate was significantly higher 
compared to the vandetanib group prior to vandetanib 
administration (Figure 4.6). Over the 21 day treatment period, 
and during the 10 day post-treatment period, heart rate in the 
vehicle group gradually reduced such that by the end of the 
study it was -40 ± 3 BPM lower than at the start (Table 4.2). 
The pattern of heart rate change was similar in the vandetanib 
group to that seen in the vehicle-treated group (Figure 4.6, 
Table 4.2). 
The average heart rate (throughout the study) was lower in 
the vehicle group in the 4-8 h post-dosing data analysis 
(330 ± 2 BPM) compared to the 24 h analysis (366 ± 2 BPM 
(Table 4.2)). There was a similar reduction in heart rate in the 
vandetanib group (25 mgkg-1day-1, i.p). The average heart 
rate, over the entire study, was approximately 320 ± 1 BPM 
(4-8 h post-dosing) compared to 358 ± 1 BPM (24 h analysis 
(Figure 4.6, Table 4.2)) in the vandetanib group.  
There was a significant difference between the vehicle and 
vandetanib groups (P<0.05, Mann Whitney; Figure 4.6) during 
the last day of baseline recording and the first 4 days of 
treatment, however, there was no significant difference 
between groups in the last day of treatment and 10 days 
post-treatment observation period (Mann Whitney). There 
were no significant changes in heart rate in the vehicle or 
vandetanib groups during the last 10 days of dosing (Friedman 
compared to the last 24 h of dosing) (Figure 4.6). 
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Figure 4.6 Mean heart rate of 
male Sprague Dawley rats dosed 
with vandetanib 25 mgkg-1day-1 
i.p (n=7) vs vehicle (n=5). Data 
are displayed as mean ± SEM. 
Data were analysed and 
displayed in 24 h bins (a), 4-8 h 
after dosing (b) or in 3 h bins, 
separated into the last day prior 
to dosing and the first 4 days of 
dosing (c) or the last day of 
dosing followed by a 10 day post-
treatment period (d). Red line 
shows data obtained with 
vandetanib 25 mgkg-1day-1 i.p 
Black line shows the vehicle 
control i.p #P<0.05 Mann 
Whitney between group 
comparision *-P<0.05 Friedman 
test with data points compared 
against the mean of the 9 day 
pre-treatment period (a, b) or 
against the mean daytime 
(06:00-18:00 h) (blue*) and 
mean night-time (18:00-06:00 
h) (black*) values (c, d). Arrows 
show dosing times (c, d) 
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Table 4.2 Mean ± SEM change from baseline (defined as the mean 
value of the 9 day pre-treatment period) heart rate of male Sprague 
Dawley rats dosed with vandetanib 25 mgkg-1day-1 i.p (n=7) vs 
vehicle (n=5). Data displayed are mean ± SEM. Data were analysed 
and displayed in 24 h bins (left) or 4-8 h Bins after dosing (right). 
Black baseline: average of 9 days pre-treatment period; blue text: 
treatment period; red text: post-treatment period. 
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A daytime/ night-time elevation and reduction in heart rate 
can be clearly seen in Figure 4.6c, d. Therefore data were 
analysed in as two 12 h slots (06:00-18:00 h or 18:00-16:00 
h) (Figure 4.7). Changes in heart rate in response to 
vandetanib (25 mgkg-1day-1, i.p) or vehicle i.p followed the 
same trend (pre-, during- and post-treatment) as the data 
presented in Figure 4.6a, b. (analysed over 24 h or 4-8 h 
post-treatment). However there was an average difference of 
52 BPM between the daytime (Figure 4.7.a.) and night-time 
(Figure 4.7b) data, with the night-time heart rate being higher 
throughout the study (Figure 4.7). 
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Figure 4.7 Mean heart rate of male Sprague Dawley rats dosed with vandetanib 25 mgkg-1day-1 i.p (n=7) vs vehicle i.p (n=5). 
Data displayed as Mean ± SEM. Data were analysed and displayed in 12 h bins from 06:00-18:00 h (a) or from 18:00-06:00 
h (b). Red line- vandetanib 25 mgkg-1day-1, i.p, black line- vehicle i.p #-P<0.05 Mann Whitney between group comparision 
*-P<0.05 Friedman test with data points compared against the mean of the 9 day pre-treatment period (a, b)  
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4.3.2 The Effects of Vandetanib on Mesenteric Vessel 
Structure Following In Vivo Dosing For 21 Days 
and a Post-treatment Treatment Period of 10 
Days 
In order to explore the possibility of structural vascular 
changes following treatment with vandetanib, mesenteric 
capillary beds were collected at the end of the experiment, 
stained for the presence of isolectin-B4, an EC marker, and 
evaluated for vessel length and the number of vessel 
junctions. 
Mesenteric capillary beds taken from rats treated with 
vandetanib (25 mgkg-1day-1, i.p) showed a trend towards 
reduction in total vessel length and total vessel junction 
number compared to those taken from the vehicle-treated 
group (Figure 4.8, Figure 4.9, Figure 4.10), however this trend 
was not significant (P>0.05 Student T test). A reduction in 
total vessel length and total vessel junction number is 
suggestive of vessel rarefaction (Small et al., 2014).  
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Figure 4.8 Representative images of the mesenteric vasculature of male Sprague Dawley rats treated with vandetanib 
25 mgkg-1day-1, i.p or vehicle i.p for 21 days before a 10 day post-treatment observation period. The mesentery was harvested 
and stained for cell nuclei (images in blue), and Isolectin-B4 (a marker of ECs) (images in red). Images were analysed using 
AngioTool 6.0b. AngioTool 6.0b vessel tracking overlay is shown on the right, with red lines indicating vessel structure and blue 
dots indicating vessel junctions. 
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Figure 4.9 Total mesenteric vessel length (mm) in Sprague Dawley rats treated with vandetanib 25 mgkg-1day-1 i.p or vehicle 
i.p for 21 days before a 10 day post-treatment period. The mesentery was harvested and stained for cell nuclei and Isolectin-
B4 (EC marker). 4 mesenteric panels were taken from each rat (n=3 rats for both groups). These data were pooled to give 
mean total vessel length of treated (red bar) and vehicle (black bar) groups (a). Individual rat data (mean of 4 mesenteric 
panels per animal) for treated (red bars) and vehicle (black bars) groups is shown in (b). Data displayed as mean ± SEM. 
Between group unpair Student T test showed no significant difference, P>0.05  (a). 
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Figure 4.10 Total vessel junction number in Sprague Dawleys treated with vandetanib 25 mgkg-1day-1, i.p or vehicle i.p for 21 
days before a 10 day post-treatment period. The mesentery was harvested and stained for cell nuclei and Isolectin-B4 (EC 
marker). 4 mesenteric panels were taken from each rat (n=3 rats for both groups). These data were pooled to give total vessel 
junction number mean total vessel junction number of treated (blue bar) and vehicle (black bar) groups (a). Individual rat data 
(mean of 4 mesenteric panels per animal) for treated (blue bars) and vehicle (black bars) groups are shown in (b). Data shown 
as mean ± SEM. Between group unpair Student T test showed no significant difference, P>0.05 (a). 
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4.3.3 Regional Haemodynamic Effects of Vandetanib 
Measured by Pulsed Doppler Flowmetry (i.v)  
The cardiovascular effects of vandetanib (12.5 mgkg-1day-1 or 
25 mgkg-1day-1) or vehicle administered i.v are shown in 
Figure 4.11 and Table 4.3. 
Prior to administration of vandetanib on day 1 of the 
experiment, there were no significant differences between any 
of the experimental groups (Table 4.3).  
In rats given vehicle, there were no significant changes in 
heart rate and small rise in blood pressure compared to 
baseline (P<0.05, Friedman) at 24-28 h, followed by a 
decrease from 48 h onwards with the exception of the 51 h 
and 72 h time points, compared to baseline (Figure 4.11). 
Renal vascular conductance showed small decreases towards 
the end of the study compared to baseline (P<0.05, Friedman) 
at 51, 52, 75 and 76 h. There was no significant change in 
mesenteric vascular conductance compared to baseline. 
Hindquarters vascular conductance showed a reduction at 
24-28 h (P<0.05, Friedman) and then increased at 48-52 h 
(P<0.05, Friedman) compared to baseline (Figure 4.11). 
In rats administered 12.5 mgkg-1day-1 vandetanib i.v, there 
were no significant changes in heart rate, mean arterial blood 
pressure or hindquarters vascular conductance compared to 
baseline (Figure 4.11). However, there was a gradual reduction 
in renal vascular conductance, compared to baseline, which 
was significant from 48 h onwards (Figure 4.11). Mesenteric 
vascular conductance showed an early, transient fall at 1-4 h 
(P<0.05, Friedman) and then a later, more persistent, 
significant decrease from 48 h onwards, with the exception of 
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the 72 h time point in comparison to baseline (P<0.05, 
Friedman).  
The heart rate, mean arterial blood pressure, and the 3 
vascular conductance measurements for 12.5 mgkg-1day-1 
vandetanib i.v group were not significantly different (P>0.05, 
Mann Whitney) from the corresponding vehicle i.v 
measurements (Figure 4.11). 
In rats given 25 mgkg-1day-1 vandetanib i.v, there was a 
gradual, modest decrease in heart rate at 50 h, 52 h and 76 h 
(P<0.05, Friedman; Figure 4.11b.) compared to baseline. 
Mean arterial blood pressure significantly increased at 25-28 h 
and 49 h, 50 h, 51 h, 73 h and 74 h compared to baseline 
(P<0.05, Friedman; Figure 4.11). No significant changes in 
renal vascular conductance were seen throughout the study 
(Figure 4.11), but there were significant decreases in 
mesenteric vascular conductance and hindquarters vascular 
conductance compared to baseline (P<0.05, Friedman; Figure 
4.11). The heart rate, mean arterial blood pressure, and the 3 
vascular conductance measurements for 25 mgkg-1day-1 
vandetanib i.v group were not significantly different (P>0.05, 
Mann Whitney) from the corresponding vehicle i.v 
measurements (Figure 4.11). 
The 25 mgkg-1day-1 vandetanib i.v and 12.5 mgkg-1day-1 
vandetanib i.v were not significantly different in any of the 
cardiovascular variables measured (P<0.05, Mann Whitney) 
(Figure 4.11). 
 
145 
 
 
Figure 4.11 Regional haemodynamic effects of vandetanib in conscious male Sprague-Dawley rats following i.v administration 
of vandetanib at 12.5 mgkg-1day-1 (a, n=6), 25 mgkg-1day-1 (b, n=6) or vehicle (a, b, n=6). Data shown (mean ± SEM) illustrate 
mean arterial blood pressure, heart rate and regional changes in vascular conductance over the entire study period (4 days). 
Open circle- vandetanib 12.5 mgkg-1day-1 i.v (a.) or vandetanib 25 mgkg-1day-1 i.v (b.), closed circle- vehicle i.v (a., b.). 
#-p<0.05 Mann Whitney between group comparision*-p<0.05 Friedman test with data points compared against baseline 
(defined as 0 h on day 1 (before treatment took place). Δ-change from baseline. 
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Table 4.3 Resting (day 1 at least 30 min prior to drug administration) cardiovascular variables prior to the administration of 
vandetanib or vehicle i.v (n=6). Representative measurements were taken in the 30 min prior to i.v administration. Data 
displayed as mean ± SEM. HR: heart rate, MAP: mean arterial blood pressure, DS: Doppler shift, VC: vascular conductance. 
Mann Whitney between group comparision showed no significant differences between resting varibles, P>0.05. 
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4.3.4 Regional Haemodynamic Effects of Vandetanib 
Measured by Pulsed Doppler Flowmetry (i.p)  
Cardiovascular effects of vehicle or vandetanib administered 
i.p are shown in Figure 4.12, Figure 4.13, Figure 4.14, Table 
4.4 and Table 4.5.  
Prior to administration of vandetanib on day 1 of the 
experiment, there were no significant differences between any 
of the experimental groups (Table 4.4).  
In rats given vehicle i.p, there was a significant decreases in 
heart rate (P<0.05, Friedman; Figure 4.9) and a significant 
increases in mean arterial blood pressure at sporadic time 
points throughout the study, compared to baseline (P<0.05, 
Friedman; Figure 4.12). There were no significant changes in 
renal and mesenteric vascular conductance compared to 
baseline (Figure 4.12). Hindquarters vascular conductance was 
significantly reduced during day 2, 3 and 4 of the study 
compared to baseline (P<0.05, Friedman; Figure 4.12). 
In rats given vandetanib (12.5 mgkg-1 day-1) i.p there was a 
sporadic but significant change from baseline in heart rate 
(P<0.05, Friedman). There was also a significant pressor effect 
relative to baseline (P<0.05, Friedman) throughout day 2, 3 
and 4 of the study (Figure 4.12). Renal vascular conductance 
significantly decreased (P<0.05, Friedman) from 26 h onwards 
compared to baseline (Figure 4.12). Mesenteric vascular 
conductance significantly decreased (P<0.05, Friedman) 
during the 24-76 h time points (excluding the 48 and 72 h 
time points) of the study compared to baseline (Figure 4.12). 
Hindquarters vascular conductance significantly decreased 
(P<0.05, Friedman) in comparison to baseline 2 h after the 
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first dose of vandetanib was administered. This decrease was 
maintained from 4 h until the end of the study (Figure 4.12). 
Mean arterial blood pressure and hindquarters vascular 
conductance for the vandetanib (12.5 mgkg-1 day-1) i.p group 
were significantly different from the vehicle i.p group (P<0.05, 
Mann Whitney; Figure 4.12, Table 4.5). 
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Figure 4.12 Regional haemodynamic effects of vandetanib in 
conscious male Sprague Dawley rats following i.p administration of 
vandetanib 12.5 mgkg-1day-1 (n=8) or vehicle i.p (n=8). Data shown 
(mean ± SEM) illustrate mean arterial blood pressure, heart rate and 
regional changes in vascular conductance over the entire study period 
(4 days). Open circles show data obtained with vandetanib 12.5 
mgkg-1day-1 i.p and closed circles show the corresponding vehicle 
control i.p #p<0.05 Mann Whitney between group compairision 
*p<0.05 Friedman test with data points compared against baseline 
(defined as 0 h on day 1 (before treatment was initiated). Δ-change 
from baseline measurements. 
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In rats given vandetanib (25 mgkg-1day-1) i.p there was a 
significant decrease in heart rate during day 2 and during the 
last 2 h of days 3 and 4 compared to baseline (P<0.05, 
Friedman). Mean arterial blood pressure increased (P<0.05, 
Friedman) throughout day 2, 3 and 4 of the study compared to 
baseline (Figure 4.13). Renal vascular conductance was 
significantly decreased (P<0.05, Friedman) 25 h after dosing. 
This reduction was relatively consistent throughout the study 
(Figure 4.13). Mesenteric vascular conductance significantly 
decreased in comparison to baseline (P<0.05, Friedman) 24 h 
after the first dose, and similarly to the renal effects, this 
reduction was maintained until the end of the study period 
(Figure 4.13). Hindquarters vascular conductance significantly 
decreased (P<0.05, Friedman) in comparison to baseline at 24 
h after the first dose of vandetanib (25 mgkg-1day-1) i.p was 
administered. This decrease was maintained until the end of 
the study (Figure 4.13). 
Mean arterial blood pressure, mesenteric and hindquarters 
vascular conductance for the Vandetanib (25 mgkg-1 day-1) i.p 
group were significantly different from the vehicle i.p group 
(P<0.05 Mann Whitney; Figure 4.13, Table 4.5). 
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Figure 4.13 Regional haemodynamic effects of vandetanib in 
conscious male Sprague Dawley rats following i.p administration of 
vandetanib 25 mgkg-1day-1 (n=8) or vehicle i.p (n=8). Data shown 
(mean ± SEM) illustrate mean arterial blood pressure, heart rate and 
regional changes in vascular conductance over the entire study period 
(4 days). Open circle- vandetanib 25 mgkg-1day-1 i.p, closed 
circle- vehicle i.p #-p<0.05 Mann Whitney between group 
comparision *-p<0.05 Friedman test with data points compared 
against baseline (defined as 0 h on day 1 i.e. before treatment took 
place). Δ-change from baseline measurement 
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In rats given vandetanib (50 mgkg-1day-1) i.p a significant 
decrease in heart rate (P<0.05, Friedman) from 1 h-76 h 
(excluding the 4 h time point) was seen in comparison to 
baseline (Figure 4.14). The highest dose of vandetanib caused 
a significant pressor effect compared to baseline (P<0.05, 
Friedman), which was apparent 1 h after drug administration. 
Mean arterial blood pressure was consistently higher than the 
baseline on days 2, 3 and 4 (Figure 4.14). Although there was 
little effect in the renal vascular bed at earlier time points, 
renal vascular conductance was significantly decreased 
(P<0.05, Friedman) during day 4 in comparison to baseline 
(Figure 4.14). In contrast, mesenteric vascular conductance 
was significantly decreased 1 h after vandetanib 
administration and this vasoconstriction was sustained for the 
remainder of the study (P<0.05, Friedman; Figure 4.14). 
Likewise, hindquarters vascular conductance significantly 
decreased (P<0.05, Friedman) 1 h after the first dose of 
vandetanib in comparison to baseline (Figure 4.14). This 
decrease was also maintained until the end of the study, 
although there were some fluctuations throughout the study 
period (Figure 4.14). 
The mean arterial blood pressure for the vandetanib 
(50 mgkg-1day-1) i.p group was significantly different from the 
vehicle i.p group (P<0.05, Mann Whitney; Figure 4.14, Table 
4.5). No other measured variables were significantly different 
between groups. 
There were no significant differences between all measured 
variables in the 12.5 mgkg-1day-1, 25 mgkg-1day-1 and 
50 mgkg-1day-1 groups (P<0.05, Kruskal Wallis).
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Figure 4.14 Regional haemodynamic effects of vandetanib in 
conscious male Sprague-Dawley rats following i.p administration of 
vandetanib 50 mgkg-1day-1 (n=8) or vehicle (n=8). Data shown 
(mean ± SEM) illustrate mean arterial blood pressure, heart rate and 
regional changes in vascular conductance over the entire study period 
(4 days). Open circle- vandetanib 50 mgkg-1day-1 i.p, closed 
circle- vehicle i.p #-p<0.05 Mann Whitney between group 
comparision*-p<0.05 Friedman test with data points compared 
against baseline (defined as 0 h on day 1 (before treatment took 
place). Δ-change from baseline measurement. 
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Table 4.4 Resting (day 1 at least 30 min prior to drug administration) cardiovascular variables prior to the administration of 
stated compound i.p (n=8). Representative measurements were taken 30 min prior to i.p administration. Data represented as 
mean ± SEM. HR: heart rate, MAP: mean arterial blood pressure, DS: Doppler shift, VC: vascular conductance. Mann Whitney 
between group comparision showed no significant differences between resting varibles, P>0.05.  
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Table 4.5 Summary of the regional haemodynamic effects of 12.5 mgkg-1day-1 vandetanib i.p (n=8), 25 mgkg-1day-1 vandetanib 
i.p (n=8) and 50 mgkg-1day-1 vandetanib i.p (n=8) over the entire study period (4 days). Arrows represent significant direction 
of change compared to vehicle group (n=8) (P<0.05, Mann Whitney).Dashes represent no significant change in comparison to 
vehicle (p>0.05 Mann Whitney). Δ-change in HR (heart rate), MAP (mean arterial blood pressure), renal, mesenteric and 
hindquarters DS (Doppler shift) and renal, mesenteric and hindquarters VC (vascular conductance). 
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4.4 Discussion 
A greater understanding of how VEGF RTKIs cause 
hypertension is needed. Through examining the actions of 
vandetanib on cardiovascular variables such as heart rate and 
blood pressure, the cardiovascular side effect profile of 
vandetanib can be further elucidated. The data discussed in 
this Chapter demonstrate that vandetanib has a hypertensive 
and vasoconstrictive action in the rat.  
4.4.1 Methodology 
To examine the acute actions of vandetanib on heart rate, 
blood pressure and vascular conductance in the rat, 
vandetanib was first administered i.v. This decision was made 
based on previous experience with other RTKIs in this model 
(Woolard et al.; unpublished observations). The method of i.v 
administration allows vandetanib to enter the blood plasma 
instantly and avoid first pass metabolism. However, 
preliminary data (Figure 4.11) showed only very small 
increases in blood pressure vs vehicle. The hypertensive action 
of vandetanib has previously been reported to be a 
substantially larger than this (Janse, 2005; Gu et al., 2009; 
Blasi et al., 2012). This observation, coupled with the lack of 
immediate effect on blood pressure one would expect to see 
with i.v administration and the difficulties experienced in 
maintaining vandetanib in solution; made it clear that either 
an alternative route of administration or an alternative vehicle 
should be considered. The vehicle used in this study was a 
combination of previously published vandetanib vehicles 
(Advani et al., 2007; Tai et al., 2010; Wibom et al., 2010). It 
was observed that vandetanib, although unable to solubilise 
fully in 0.4 ml vehicle (volumes used for i.v administration), it 
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was able to solubilise in a larger volume of vehicle. This lead 
to the conclusion that the vandetanib concentrations 
administered (12.5 mgkg-1, 25 mgkg-1) were higher than the 
limit of solubility for our chosen vehicle. A lack of full 
compound solubility could lead to a reduction in drug exposure 
and therefore a reduction in the vandetanib-mediated effects 
seen. As vandetanib is given orally in humans, it was decided 
that i.p delivery would more closely mimic the route of 
administration in humans (Turner et al., 2011). Logistically, 
changing the route of delivery to i.p allowed for a larger 
catheter to be implanted (see Section 2.6.2.4) and for 
vandetanib to be delivered in a larger volume of vehicle. i.v 
administration limits the volume that can be administered, as 
an increase in blood volume leads to a direct increase in blood 
pressure; this is not an issue with i.p delivery.  
4.4.2 Mean Arterial Blood Pressure 
In the telemetry study, vandetanib caused a significant 
increase in blood pressure within the first 24 h after the initial 
dose. This increase was sustained throughout the dosing 
period and for 7 days post-dosing, before decreasing to 
between +5.0 mmHg ± 0.5 mmHg and +4.4 mmHg ± 
0.5 mmHg on day 7-10 post-dosing (Figure 4.4, Figure 4.5, 
Table 4.1). The hypertensive effect of vandetanib was shown 
to be time dependent (Figure 4.4) with mean arterial blood 
pressure being significantly higher 4-8 h after dosing 
compared to the mean 12 h (daytime) blood pressure 
(P<0.05, Mann Whitney). This result indicates that vandetanib 
may reach its peak plasma volume concentration within 4-8 h 
of i.p administration. This conclusion is supported by 
vandetanib’s FDA report which states that absorption typically 
took between 2-8 h in rats and dogs (Thornton et al., 2012).  
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In the haemodynamic studies, a significant pressor effect was 
observed in all vandetanib (i.p) treatment groups within 24 h 
of dosing, compared to baseline. All concentrations of 
vandetanib showed a significant increase in blood pressure 
compared to the vehicle group (Figure 4.12, Figure 4.13 and 
Figure 4.14). However, there was no significant difference in 
mean arterial blood pressure between dose groups. The lack of 
dose-dependent response implies the maximum hypertensive 
effect of vandetanib has been reached with these doses. The 
ability for VEGF RTKIs, including vandetanib, to cause 
hypertension has been well documented (Gu et al., 2009; 
Kappers et al., 2010; Leigh Verbois, 2011; Blasi et al., 2012; 
Grabowski et al., 2012). 
The reason as to why VEGF RTKIs cause hypertension is not 
fully understood. Currently it is thought that their action on 
VEGFR2 signalling activity is key as the VEGFR2 signalling 
pathway is involved in vascular growth and maintenance. A 
study by Mayer et al confirmed that vandetanib led to 
hypertension in humans within a 6 week treatment period 
(Mayer et al., 2011). Mayer hypothesised that this action may 
be due to antagonism of VEGF NO-dependant vasodilatation 
and subsequently demonstrated the capacity of vandetanib to 
reduce resting brachial arterial diameter, increase vascular 
resistance and decrease systemic nitrate concentrations 
(Mayer et al., 2011). VEGF-antagonism related hypertension 
has also been shown to not be related to the renin-angiotensin 
and sympathetic systems, further supporting hypertension in 
patient populations taking VEGF RTKIs as being primarily 
caused by vessel dysregulation (Veronese et al., 2006).  
Vascular rarefaction, which has been shown to occur in mice 
within 7 days of administration of AG-013736, a small 
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molecule inhibitor of VEGF/PDGF (Kamba and McDonald, 
2007), has also been implicated as a cause of VEGF-RTKI 
induced hypertension. It has been shown that when vessels 
close down, for example due to pro-constrictive signalling or 
vessel damage, autonomic rarefaction can occur (Greene et 
al., 1981). A reduction in vessel number and/or functioning 
vessels may go some way to explaining the prolonged 
hypertensive effect of vandetanib post-treatment regimen 
(Figure 4.4). Vessel regrowth, a process which would increase 
vessel surface area and therefore decrease blood pressure can 
take between 5-10 days to occur (in vitro) (Davis et al., 2000, 
di Blasio et al., 2015), and requires VEGF (Cai et al., 2003).  
However, in the preliminary staining study of mesenteric 
panels taken from rats treated with 25 mgkg-1day-1 (Figure 
4.8, Figure 4.9, Figure 4.10), vandetanib showed no significant 
signs of rarefaction in comparison to the vehicle group. 
However, the 25 mgkg-1day-1 vandetanib group mesenteric 
staining showed a trend toward reduced total vessel length 
and total vessel junction number in the vandetanib group, 
compared to vehicle, which could indicate a reduction in vessel 
density and an increased degree of spacing between vessels. 
As animals in this study had a 10 day ‘recovery’ period before 
tissue was harvested, it is possible that during vandetanib 
treatment rarefaction may occur, although it is not permanent 
once vandetanib is removed. This theory is supported by the 
gradual trend of reduction in blood pressure when vandetanib 
treatment was removed. It would be interesting to perform 
this study on animals at different lengths of treatment period, 
for example 4 days, 10 days and 21 days to test this 
hypothesis. Whether sustained hypertension is a production of 
reduced VEGF-dependant vasodilatation, vascular rarefaction 
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or a combination of both is unknown and needs further 
investigation. 
The most commonly seen hypertensive reaction in humans 
taking vandetanib is grade 2 hypertension (160-169 systolic 
over 100-109 mmHg diastolic; Qi et al., 2012). Given the 
variation in age and the possible pre-existing cardiovascular 
pathophysiology’s within the human patient population taking 
vandetanib, it is difficult to know the average increase in blood 
pressure seen due to vandetanib, rather than other variables. 
It is therefore difficult to compare the average increase in 
mean arterial blood pressure seen in the rat to the human. 
These results suggest more extensive human studies are 
needed to look at the off- as well as on-treatment 
development and progression of hypertension while taking 
vandetanib. 
4.4.3 Vascular Conductance 
Vandetanib (i.v or i.p) had no significant effect on the renal 
vascular bed in comparison the vehicle (Table 4.5). However, 
mesenteric (25 mgkg-1day-1 i.p) and hindquarter (12.5 
mgkg-1day-1 and 25 mgkg-1day-1 i.p) vascular conductances 
were significantly reduced, in comparison to vehicle (Figure 
4.12, Figure 4.13, Figure 4.14). There were no significant 
differences between the renal, mesenteric and hindquarter 
vascular conductances in the 12.5 mgkg-1day-1 and 
25 mgkg-1day-1 groups i.v. These results suggest that 
vandetanib (i.p) has a vascular bed-specific vasoconstrictive 
effect in the hindquarters and mesenteric vascular beds at 
various doses. The 50 mgkg-1day-1 i.p group showed no 
significant differences compared to vehicle in any of the 
vascular beds studied. The variation between doses implies 
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that the vasoconstrictive effect of vandetanib is dose 
dependent and therefore may be due to inhibition of multiple 
receptors. 
A reduction in vascular conductance is indicative of a reduction 
in vessel diameter and an increased resistance to blood flow. 
Vandetanib induced-vasoconstriction has been previously 
reported in resting brachial arteries in humans (Mayer et al., 
2011) and implies that vessel function and signalling may be 
altered by vandetanib. Whether sustained hypertension is a 
product of reduced VEGF-dependant vasodilation or due to off-
target, i.e inhibition of other vasoactive receptor tyrosine 
kinases, effects needs further investigation. 
4.4.4 Heart Rate  
Vandetanib produced a significant decrease in heart rate 
throughout the telemetry study, when dosed at 25 
mgkg-1day-1 for 21 days (Figure 4.6, Figure 4.7). However, 
when the data was normalised to baseline (Table 4.2), the 
vandetanib group did not have as great a decrease in heart 
rate as the vehicle group. Vandetanib did not cause a 
significant decrease in heart rate compared to the vehicle 
group in both regional haemodynamic studies (i.p and i.v; 
Figure 4.11, Figure 4.12, Figure 4.13, Figure 4.14, Table 4.5), 
however the vandetanib 50 mgkg-1day-1 group had a 
significantly decreased heart rate in comparison to baseline, 
which looked to be time dependent, with heart rate decreasing 
throughout the day, after each dose, and then increasing at 
the beginning of the next day (prior to dosing). Overall, these 
results suggest vandetanib does not have a predominant 
bradycardic effect in the rat. 
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Vandetanib has been previously reported to induce 
bradycardia in orally dosed rats (Verbois, 2011). Although this 
is the only previously published record of vandetanib causing a 
decrease in heart rate, other VEGF-targeting RTKIs have also 
been shown to result in bradycardia, including pazopanib and 
sunitinib (Blasi et al., 2012; Heath et al., 2013). The 
bradycardic effect seen in the 50 mgkg-1day-1 haemodynamic 
study group may be a compensatory reaction to vandetanib-
induced vessel constriction. A drug-induced consistent 
increase in blood pressure would be detected by baroreceptors 
found on the aortic arch and carotid bodies. When 
baroreceptors are activated through vessel stretching, 
negative feedback on heart rate occurs through vagal 
parasympathetic action (Janse, 2005). This would lead to a 
compensatory decrease in heart rate, and in turn blood 
pressure. However, this hypothesis needs to be explored 
further.  
4.4.5 Conclusion  
Vandetanib demonstrated a hypertensive effect when given 
chronically. It also caused vasoconstriction of the mesenteric 
and hindquarter vascular beds at 12.5 and 25 mgkg-1day-1. 
This and previously discussed data suggest that these effects 
may be due to antagonism of VEGFR2, which initially leads to 
inhibition of NO-dependent vasodilatation and subsequently 
endothelial dysfunction. This action would chronically manifest 
in vivo as a reduction in vessel conductance, seen in the 
regional haemodynamic studies in this Chapter, and an 
increase in blood pressure, which in turn may lead to a 
compensatory bradycardic effect (as seen with 50 mgkg-1day-1 
vandetanib). The preliminary mesenteric vascular staining 
results also suggest that vandetanib, when given over a 3 
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week period, may cause a reduction in vessel number. This 
rarefractive response to vandetanib would further promote 
hypertension in the rat (Triantafyllou et al., 2015). The 
constrictive effect of vandetanib in regionally specific vascular 
beds is a novel finding. However, whether the cardiovascular 
profile found here is unique to vandetanib is unknown. In 
order to gain a better understanding of VEGF RTKI 
cardiovascular profiles, it is important to be able to compare 
compounds. In order to look for similarities and differences 
between VEGF RTKIs, and therefore gain a better 
understanding of RTKI cardiovascular profiles, the next 
Chapter (Chapter 5) will study pazopanib, a class I VEGF RTKI 
with a greater potency at VEGFR2 than vandetanib (Chapter 3, 
(Davis et al., 2011; Carter et al., 2015)).
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Chapter 5 : The In Vivo 
Cardiovascular Actions 
of Pazopanib 
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5.1 Introduction 
To determine whether mean arterial blood pressure, heart rate 
and vascular conductance in the renal, mesenteric and 
hindquarters vascular beds differ between RTKIs of the same 
class (Gotink and Verheul, 2010), but with differing potencies 
at VEGFR2 (Davis et al., 2011; Carter et al., 2015), pazopanib 
was studied in the rat as a comparison to vandetanib (Chapter 
4). Pazopanib, like vandetanib, is a Class I RKTI. However, 
pazopanib demonstrates greater potency at VEGFR2 (Chapter 
3) and a higher incidence and severity of hypertension in the 
human pazopanib-patient population has been reported (see 
Section 1.3.1.2, Table 1.2) (Hamberg et al., 2010; Wells et 
al., 2012; Bible et al., 2014). 
In order to compare the action of vandetanib with pazopanib; 
chronic, regular recordings of heart rate and blood pressure 
were analysed in order to explore the long-term effects of 
pazopanib on blood pressure and heart rate. The 
post-treatment effects of pazopanib were also analysed to 
assess pazopanib-induced cardiovascular changes, such as 
vessel rarefaction, which may lead to a sustained hypertensive 
response after pazopanib treatment was stopped.  
Moreover, the regional haemodynamic effects of pazopanib on 
blood pressure, heart rate and the vascular conductance of the 
mesenteric, renal and hindquarter vascular beds over a period 
of 4 days were also investigated.  
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5.2 Methodology  
5.2.1 Time Course of Effects of Pazopanib on 
Cardiovascular Variables Measured By 
Radio-Telemetry  
Rats were implanted with radio-telemetry devices as described 
in Section 2.3. Ten days post-surgical implantation of the 
device, mean arterial blood pressure and heart rate were 
monitored and recorded for 1 min, every 15 min, for 3 days. 
Rats were randomly assigned to be given 0.5 ml of either 
pazopanib 30 mgkg-1day-1, i.p (Sequoia research products, 
SRP010772p), diluted in vehicle (2% Tween, 5% propylene 
glycol in 0.9% saline solution) (n=7) or vehicle (n=4) for 21 
days. A post-treatment monitoring period of 10 days was 
observed (Figure 5.1).  
 
Figure 5.1 Schematic diagram of the pazopanib 
30 mgkg-1day-1 i.p radio-telemetric experimental timeline. 
 
5.2.1.1 Statistical Analysis 
All data have been expressed as mean ± SEM with significance 
being accepted at P‹0.05. A Kolmogorov-Smirnoff test was 
performed to test for normality. This test showed data were 
not normally distributed. A non-parametric, two-tailed within 
group comparison (Friedman’s test) was performed to 
determine if any changes seen from the baseline value were 
significant. A non-parametric between group two-tailed 
comparison (Mann Whitney-U test) was performed to analyse 
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whether differences between test groups were significant. This 
was done using Graphpad Prism 6.00.  
5.2.2 Regional Haemodynamic Effects of Pazopanib 
Measured by Pulsed Doppler Flowmetry (i.p) 
Rats were implanted with miniature pulsed Doppler flow 
probes and intra-vascular catheters as described in Section 
2.6. 24 h after catheter surgery, animals were randomly 
assigned to be administered with a 0.5 ml bolus dose of 
pazopanib i.p (Sequoia research products, SRP010772p) at 10 
mgkg-1day-1 (n=8), 30 mgkg-1day-1 (n=8), 100 mgkg-1day-1 
(n=8) or vehicle (n=8) (2% Tween 80, 5% propylene glycol in 
0.9% saline) i.p once every 24 h. Cardiovascular variables 
were recorded continuously for 4.5 h per day over a 4 day 
experimental period (Figure 5.2). 
 
Figure 5.2 Schematic diagram of the pazopanib Pulsed Doppler 
Flowmetry experimental timeline. 
 
5.2.2.1 Statistical Analysis 
All data have been expressed as mean ± SEM with significance 
being accepted at P‹0.05. A Kolmogorov-Smirnoff test was 
performed to test for normality. This test showed data were 
not normally distributed. A non-parametric, two-tailed within 
group (Friedman’s test) was performed to determine if 
changes seen from baseline values were significant. 
Non-parametric between group two tailed comparisons (Mann 
Whitney (for 2 groups) and Kruskal Wallis (more than 2 
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groups) were performed to test for significant differences 
between groups. All statistical analyses were performed using 
Biomedical version 3.4 (Nottingham, UK). 
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5.3 Results 
5.3.1 Time Course of Effects of Pazopanib on 
Cardiovascular Variables Measured By 
Radio-Telemetry  
The effects of pazopanib on cardiovascular variables measured 
by radio-telemetry are shown in Figure 5.3, Figure 5.4, Figure 
5.5, Figure 5.6, Table 5.1 and Table 5.2.  
5.3.1.1 Mean Arterial Blood Pressure 
Mean arterial blood pressure, measured by radio-telemetry, 
remained consistent throughout the 3 day pre-treatment 
period in both the pazopanib and vehicle groups, and was 
steady thereafter in the vehicle group (Figure 5.3). In rats 
given pazopanib (30 mgkg-1day-1 i.p), mean arterial blood 
pressure increased significantly by +7.1 ± 0.5 mmHg (P<0.05, 
Friedman) during day 8 of the treatment period (Figure 5.3, 
Table 5.1). This was maintained throughout the dosing and 
post-dosing periods. The increase in mean arterial blood 
pressure (mmHg) in the pazopanib 30 mgkg-1day-1 i.p group 
was significantly different from the vehicle group (P<0.05, 
Mann Whitney; Figure 5.3). The vehicle group did not 
demonstrate a significant increase in mean arterial blood 
pressure throughout the study (Figure 5.3). 
As the vehicle group had a higher starting mean arterial blood 
pressure (Table 5.1) data have been normalised 
(value - average of 3 day pre-treatment period) (Figure 5.3b, 
Table 5.1). In order to more easily see the differences within 
and between the pazopanib 30 mgkg-1day-1 i.p and vehicle i.p 
groups, this style of analysis has been adopted throughout. 
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Figure 5.3 Mean arterial blood pressure (measured by radio-telemetry) of male Sprague Dawley rats dosed with pazopanib 30 
mgkg-1day-1 i.p (n=7) or vehicle (n=4). Data are displayed as mean ± SEM. Data were analysed and displayed in 24 h bins 
(a), or as mean change from baseline (average of 3 day pre-treatment period) in 24 h bins (b). Red line-pazopanib 30 
mgkg-1day-1 i.p and black-vehicle controls i.p #p<0.05 Mann Whitney (pazopanib vs vehicle) or *p<0.05 Friedman test with 
data points compared against the mean of the 3 day pre-treatment period. 
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Table 5.1 Mean arterial blood pressure (mmHg) and change in mean 
arterial blood pressure (Δ mmHg) from baseline (defined as the mean 
value of the 3 day pre-treatment period) of male Sprague Dawley rats 
dosed with pazopanib 30 mgkg-1day-1 i.p (n=7) or vehicle (n=4). Data 
are presented as mean ± SEM and were analysed and displayed in 24 
h bins (left) or 2-4 h bins after dosing (right). Black baseline: average 
of 3 days pre-treatment period; blue text: treatment period; red text: 
post-treatment period.   
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Due to the daytime/ night-time pattern seen in the mean 
arterial blood pressure recordings, the data were analysed in 
two 12 h slots-segments: (a) daytime (06:00-18:00 h) and 
(b) night-time (18:00-06:00 h) (Figure 5.4). Changes in mean 
arterial blood pressure in response to pazopanib 
(30 mgkg-1day-1 i.p) or vehicle followed the same trend 
(pre-, during- and post-treatment) as the data presented in 
Figure 5.3 (analysed over 24 h). However there was a 
significant mean difference of 5.3 mmHg between the daytime 
(P<0.05, Mann Whitney) and night-time data (Figure 5.4), 
with the night-time mean arterial blood pressure higher in 
comparison throughout the study (Figure 5.4). 
The peak plasma concentration time range (2-4 h 
post-treatment) (Justice and Robertson, 2008) for pazopanib 
was also analysed. Figure 5.4c shows a significant (P<0.05, 
Friedman) difference from baseline (+7.8 ± 1.1 mmHg) on 
day 5 of treatment (Figure 5.4, Table 5.1). 
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Figure 5.4 Change in mean arterial blood pressure from baseline of male Sprague Dawley rats dosed with pazopanib 30 
mgkg-1day-1 i.p (n=7) or vehicle i.p (n=4). Data are displayed as mean ± SEM. Data were analysed and displayed in 12 h bins, 
separated into daytime (06:00-18:00 h) (a), or night-time (18:00-06:00 h) (b) periods. Data collected 2-4 h after dosing are 
displayed in graph (c). Red line and symbols show data obtained following treatment with pazopanib 30 mgkg-1day-1 i.p The 
black line and symbols show the equivalent vehicle control i.p #p<0.05 Mann Whitney between group comparision *p<0.05 
Friedman test with data points compared against the mean daytime (a), night-time (b) or 2-4 h after 9 am (scheduled dosing 
time) (c) of the 3 day pre-treatment period.  
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5.3.1.1  Heart Rate  
Data have been normalised (value - average of 3 day 
pre-treatment period) (Figure 5.5, Table 5.2) to more clearly 
show the change in heart rate in comparison to baseline. 
Over the 21 day treatment period and the 10 day 
post-treatment period, heart rate in the vehicle group showed 
a greater decline than the pazopanib group, such that at the 
end of the study it was -18.5 ± 4.0 BPM lower than at the 
start (Table 5.2). A significant difference between the 
pazopanib and the vehicle groups was seen (P<0.05, Mann 
Whitney; Figure 5.5, Table 5.2) with the vehicle group 
showing a greater decrease in heart rate than pazopanib 
throughout the study.  
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Figure 5.5 Mean heart rate of male Sprague Dawley rats dosed with pazopanib 30 mgkg-1day-1 i.p (n=7) or vehicle i.p (n=4). 
Data are displayed as mean ± SEM. Data were analysed and displayed in 24 h bins (a), or as mean change from baseline 
(average of 3 day pre-treatment period) in 24 h bins (b). Red line show data obtained with pazopanib 30 mgkg-1day-1 i.p Black 
line shows the vehicle controls i.p #p<0.05 Mann Whitney test performed for pazopanib vs vehicle *p<0.05 Friedman test with 
data points compared against the mean of the 3 day pre-treatment period. 
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Table 5.2 Mean ± SEM change from baseline (defined as the mean 
value of the 3 day pre-treatment period) heart rate of male Sprague 
Dawley rats dosed with pazopanib 30 mgkg-1day-1 i.p (n=7) vs vehicle 
(n=4). Data were analysed and displayed in 24 h bins (left) or 2-4 h 
bins after dosing (right). Black baseline: average of 3 days 
pre-treatment period; blue text: treatment period; red text: 
post-treatment period. 
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A daytime/ night-time fluctuations in heart rate was clearly 
seen. Therefore data were analysed in two 12 h time periods: 
(a) daytime (06:00-18:00 h) and (b) night-time (18:00-06:00 
h) (Figure 5.6a, b). Changes in heart rate in response to 
pazopanib or vehicle i.p followed the same trend 
(pre-, during- and post-treatment) as the data presented in 
Figure 5.5a, b (analysed over 24 h). However, there was a 
significant mean difference of 50 BPM between the daytime 
(P<0.05, Mann Whitney; Figure 5.6a.) and night-time (Figure 
5.6b.) data, with the heart rate higher during the night-time 
period (Figure 5.6). 
The peak plasma concentration time range 
(2-4 h post-treatment) for pazopanib was analysed (Justice 
and Robertson, 2008). There were no significant differences 
within the pazopanib and vehicle treatment groups in 
comparison to baseline (P<0.05, Friedman). However, there 
was a significant difference between the pazopanib and vehicle 
group (P<0.05, Mann Whitney; Figure 5.6). 
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Figure 5.6 Change in heart rate from baseline of male Sprague Dawley rats dosed with pazopanib 30 mgkg-1day-1 i.p (n=7) or 
vehicle i.p (n=4). Data are displayed as mean ± SEM. Data were analysed and displayed in 12 h daytime bins (06:00-18:00 
h) (a), 12 h night-time Sections (18:00-06:00 h) (b) or to show the 2-4 h period after treatment (c.). Red line- pazopanib 30 
mgkg-1day-1 i.p, black line- vehicle i.p #p<0.05 Mann Whitney test performed for pazopanib vs vehicle groups *p<0.05 
Friedman test with data points compared against the mean daytime (a.), night-time (b.) or 2-4 h after 9 am (scheduled dosing 
time) (c.) of the 3 day pre-treatment period. 
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5.3.2 Regional Haemodynamic Effects of Pazopanib 
Measured by Pulsed Doppler Flowmetry (i.p)  
Cardiovascular effects of pazopanib or vehicle administered i.p 
are shown in Figure 5.7, Figure 5.8, Figure 5.9, Table 5.3 and 
Table 5.4.  
Prior to administration of pazopanib on day 1 of the 
experiment, there were no significant differences between any 
of the experimental groups (Table 5.3).  
In rats given vehicle i.p, heart rate significantly decreased 
compared to baseline, although not consistently, throughout 
the study (P<0.05, Friedman). Mean arterial blood pressure 
significantly decreased, at 50 and 72-76 h, in comparison to 
baseline (P<0.05, Friedman; Figure 5.7). Renal vascular 
conductance showed a continued significant decrease from 
baseline at 50-76 h (P<0.05, Friedman; Figure 5.7). 
Mesenteric vascular conductance increased significantly from 
baseline at 4 and 24 h (P<0.05, Friedman; Figure 5.7). 
Hindquarters vascular conductance was significantly reduced 
at 1 h and throughout days 2, 3 and 4 of the study (P<0.05, 
Friedman; Figure 5.7). 
In rats given pazopanib (10 mgkg-1 day-1 i.p), there was a 
significant decrease in heart rate, in comparison to baseline, at 
1 h and throughout days 2, 3 and 4 of the study (excluding 25 
and 72 h) (P<0.05, Friedman; Figure 5.7). Mean arterial blood 
pressure significantly increased, compared to baseline, 3 h 
after the initial dose, this increase was maintained and was 
significant throughout days 2 and 3 (P<0.05 Friedman; Figure 
5.7). There was no significant change in renal vascular 
conductance throughout the study (P<0.05, Friedman; Figure 
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5.7). Mesenteric vascular conductance significantly decreased, 
compared to baseline (P<0.05, Friedman) at 1 h and then 
from 25 h until the end of the study (Figure 5.7). Hindquarters 
vascular conductance significantly decreased (P<0.05, 
Friedman), in comparison to baseline, at 1, 2 and 4 h. This 
significant decrease was maintained throughout the study 
(excluding time points 75 and 76 h) (Figure 5.7).  
All measured variables of the pazopanib (10 mgkg-1 day-1) i.p 
group were not significantly different from the vehicle i.p 
group (P<0.05, Mann Whitney; Figure 5.7, Table 5.4). 
181 
 
 
Figure 5.7 Regional haemodynamic effects of pazopanib in conscious 
male Sprague-Dawley rats following i.p administration of pazopanib 
10 mgkg-1day-1 (n=8) or vehicle (n=8). Data shown (mean ± SEM) 
illustrate mean arterial blood pressure, heart rate and regional 
changes in vascular conductance over the entire study period (4 
days). Open circle- pazopanib 10 mgkg-1day-1 i.p, closed 
circle- vehicle i.p #-p<0.05 Mann Whitney pazopanib vs vehicle 
groups *-p<0.05 Friedman test with data points compared against 
baseline (defined as 0 h on day 1 (before treatment took place). 
Δ-change from baseline measurement (0 h) 
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In rats given pazopanib (30 mgkg-1 day-1 i.p) there was a 
significant decrease in heart rate during days 2, 3 and 4 
(P<0.05, Friedman Figure 5.8). Mean arterial blood pressure 
significantly increased from baseline throughout days 2, 3 and 
4 (P<0.05, Friedman Figure 5.8). There was a significant 
decrease in renal, mesenteric and hinquarters vascular 
conductance, from baseline, from 24 h onwards (P<0.05, 
Friedman; Figure 5.8).  
Mean arterial blood pressure, renal and mesenteric vascular 
conductance for the pazopanib (30 mgkg-1 day-1 i.p) group 
were significantly different from the vehicle i.p group (P<0.05, 
Mann Whitney; Figure 5.8, Table 5.4). 
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Figure 5.8 Regional haemodynamic effects of pazopanib in conscious 
male Sprague-Dawley rats following i.p administration of pazopanib 
30 mgkg-1day-1 (n=8) or vehicle (n=8). Data shown (mean ± SEM) 
illustrate mean arterial blood pressure, heart rate and regional 
changes in vascular conductance over the entire study period (4 
days). Open circle show data obtained with pazopanib 30 mgkg-1day-1 
i.p Closed circle show the corresponding vehicle controls i.p #p<0.05 
Mann Whitney test between pazopanib vs vehicle groups *-p<0.05 
Friedman test with data points compared against baseline (defined as 
0 h on day 1 (before treatment took place). Δ-change from baseline. 
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In rats given pazopanib (100 mgkg-1day-1 i.p) there were 
significant decreases in heart rate compared to baseline, 
sporadically throughout the study (P<0.05, Friedman; Figure 
5.9). Mean arterial blood pressure significantly increased, in 
comparison to baseline, throughout days 2, 3 and 4 (P<0.05, 
Friedman; Figure 5.9). There was a significant decrease in 
renal vascular conductance, compared to baseline, primarily 
during day 4 of the study (P<0.05, Friedman; Figure 5.9). 
Mesenteric vascular conductance significantly decreased from 
24 h onwards, in comparison to baseline (P<0.05, Friedman; 
Figure 5.9). Hindquarters vascular conductance significantly 
decreased (P<0.05, Friedman), in comparison to baseline, at 4 
h; this was maintained for the remainder of the study (Figure 
5.9).  
Mean arterial blood pressure, mesenteric and hindquarters 
vascular conductance for the pazopanib (100 mgkg-1 day-1 i.p) 
group were significantly different from the vehicle i.p group 
(P<0.05, Mann Whitney; Figure 5.9, Table 5.4). 
There were a no significant differences between heart rate, 
mean arterial blood pressure, mesenteric and hindquarters 
vascular conductance between the 10 mgkg-1 day-1, 30 mgkg-1 
day-1 and 100 mgkg-1 day-1 groups. However, there was a 
significant difference between the renal vascular conductance 
in the 30 mgkg-1 day-1 and 100 mgkg-1 day-1 groups (P<0.05, 
Kruskal Wallis). 
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Figure 5.9 Regional haemodynamic effects of pazopanib in conscious 
male Sprague Dawley rats following i.p administration of pazopanib 
100 mgkg-1day-1 (n=8) or vehicle (n=8). Data shown (mean ± SEM) 
illustrates mean arterial blood pressure, heart rate and regional 
changes in vascular conductance over the entire study period (4 
days). Open circle- pazopanib 100 mgkg-1day-1 i.p, closed 
circle- vehicle i.p#-p<0.05 Mann Whitney test for comparison 
between the pazopanib and vehicle groups*-p<0.05 Friedman test 
with data points compared against baseline (defined as 0 h on day 1 
(before treatment took place). Δ-change from baseline. 
 
186 
 
 
Table 5.3 Resting (day 1 at least 30 min prior to drug administration) cardiovascular variables prior to the administration of 
stated compound i.p (n=8). Representative measurements were taken 30 min prior to i.p administration. Data represented as 
mean ± SEM. HR: heart rate, MAP: mean arterial blood pressure, DS: Doppler shift, VC: vascular conductance. Mann Whitney 
between group comparision showed no significant differences between resting varibles, P>0.05. 
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Table 5.4 Summary of the regional haemodynamic effects of 10 mgkg-1day-1 pazopanib i.p (n=8), 30 mgkg-1day-1 pazopanib 
i.p (n=8) and 100 mgkg-1day-1 pazopanib i.p (n=8) over the entire study period (4 days). Arrows represent significant direction 
of change compared to vehicle group (n=8) (P<0.05, Mann Whitney between group comparision). Δ-change in HR (heart rate), 
MAP (mean arterial blood pressure), renal, mesenteric and hindquarters DS (Doppler shift) and renal, mesenteric and 
hindquarters VC (vascular conductance). 
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5.4 Discussion 
Through examining the actions of pazopanib on cardiovascular 
variables such as heart rate and blood pressure, the 
cardiovascular side effect profile of pazopanib can be further 
elucidated. The data discussed in this Chapter demonstrate 
pazopanib has a dose dependent, time dependent 
hypertensive, vasoconstrictive action in the rat with the dosing 
schedules used here. This discussion will also compare these 
findings with those in Chapter 4: The In vivo Cardiovascular 
Actions of Vandetanib, with the purpose of highlighting 
differences and similarities between these two compounds. 
5.4.1 Methodology 
During the pazopanib (30 mgkg-1day-1) i.p telemetry 
experiment, variation between the baseline recordings of the 
pazopanib and vehicle groups made changes between and 
within the group, in non-normalised data, difficult to see 
(Figure 5.3). However, the difference between the baseline 
values of the vehicle group and pazopanib group were not 
significant (P>0.05; student T test, Figure 5.10). Variation 
between animals prior to treatment may be a consequence of 
genetic heterogeneity due to the strain of rat used (Ghirardi et 
al., 1995; Rex et al., 2007). This hypothesis is supported by 
Rex et al, who demonstrated that populations of rats from the 
same stock, but bred separately, show different behavioural 
and genetic differences (Rex et al., 2007).This study was 
performed over a 1 year period, allowing genetic variation 
between the cohorts of rats used to develop. This variation 
may lead to distortion of the power calculation, performed 
prior to performing the experiment, in order to justify the 
number of animals needed to gain statistical power. The power 
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calculation for this experiment stated that 3.29 rats were 
needed, per group, to gain statistical power to test changes in 
mean arterial blood pressure against P=0.05.  
  
190 
 
 
Figure 5.10 Mean 72 h baseline radio-telemetric recordings of mean 
arterial blood pressure of male Sprague Dawley rats prior to 
treatment with pazopanib 30 mgkg-1day-1 i.p (n=7, in red) or vehicle 
(n=4, in blue). Data are displayed as mean ± SEM. Between group 
Student T test demonstrated no significance.  
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5.4.2 Mean Arterial Blood Pressure 
In the telemetry study, when the data were analysed as 12 h 
and 24 h data bins, pazopanib caused a significant pressor 
effect 8 days after the initial dose. However, when the data 
from 2-4 h after dosing were analysed, blood pressure was 
significantly higher 5 days after the initial dose. This result 
indicates that pazopanib has a greater pressor effect 2-4 h 
after administration. Pazopanib has been shown to reach its 
peak plasma volume concentration between 2-8 h in humans 
(Justice and Robertson, 2008). As the process of an i.p 
injection can cause animal stress and therefore elevate heart 
rate and blood pressure transiently, it is important to take into 
account the effect of post-injection stress when taking 
measurements close to the injection time. However, this is 
unlikely to have affected the analysis here, as seen in Figure 
5.4, the 2-4 h post-administration data point is on average 
lower than the 3 h data point which includes the dose 
administration; implying dosing stress has not caused the 
increase in blood pressure. 
The increase in blood pressure seen throughout the pazopanib 
telemetry dosing period was maintained throughout the 10 
day no-treatment period, unlike vandetanib (Section 4.3.1). 
This difference between the two compounds is of particular 
interest as pazopanib is reported to have a shorter plasma 
half-life (vandetanib: 19 days vs pazopanib: 30.9 h see 
Sections 1.3.1.1 and 1.3.1.2). Therefore the results gained 
here suggest that pazopanib may lead to less severe but also 
less-reversible hypertension, in comparison to vandetanib. 
One explanation for this disparity could be a difference in the 
kinetic profile of pazopanib in comparison to vandetanib. Slow 
dissociation of drug from its target can lead to a disconnect 
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between the drugs pharmacokinetic profile and 
pharmacodynamic effects, with measured efficacy significantly 
outlasting detectable plasma concentrations of drug 
(Vauquelin and Charlton, 2010). 
In the haemodynamic studies a significant rise in blood 
pressure was observed in all pazopanib (i.p) treatment groups 
within 24 h of dosing, compared to baseline. The 30 and 100 
mgkg-1 day-1 pazopanib groups showed a significant elevation 
in mean arterial blood pressure compared to the vehicle group 
(Figure 5.8 and Figure 5.9). The pressor effect of pazopanib 
appears to be dose dependent, with the increase in blood 
pressure correlating to the increase in dose (Figure 5.7, Figure 
5.8 and Figure 5.9). This was not seen with the vandetanib 
(Chapter 4). 
Previous studies have shown that the ED50 for pazopanib is 
29.4 mgkg-1day-1 when given twice daily, orally (Justice and 
Robertson, 2008) in comparison to 25 mgkg-1day-1 for 
vandetanib (Ciardiello et al., 2003) in mice i.p. Therefore 
assuming that the ED50 in rat is the same as mouse and that 
the difference between a dose of 29.4 mgkg-1day-1 and 30 
mgkg-1day-1 is negligible, it is possible to directly compare the 
effect of pazopanib and vandetanib at these doses. In the 
telemetry studies, vandetanib caused a significantly greater 
increase in daily (24 h) mean arterial blood pressure than 
pazopanib (P<0.05, Mann Whitney U). However, the difference 
between vandetanib-induced and pazopanib-induced 
hypertension in the haemodynamic study (over 4 days) was 
not significantly different.  
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The reasons why VEGF RTKIs may cause an increase in blood 
pressure have been previous discussed in Sections 1.5 and 
4.4.2. 
5.4.3 Vascular Conductance 
Renal and mesenteric vascular conductances were significantly 
lower, in comparision to vehicle, in the 30 mgkg-1day-1 
pazopanib treatment group, and mesenteric and hindquarter 
vascular conductances were significantly reduced, in 
comparison to vehicle, in the 100 mgkg-1day-1 i.p group 
(Figure 5.8, Figure 5.9). There was a significant difference in 
renal vascular conductance between the 30 mgkg-1day-1 and 
100 mgkg-1day-1 i.p groups, however there was no significant 
difference in regional vascular conductances between the 
vandetanib 25 mgkg-1day-1 i.p and the pazopanib 30 mgkg-1 
day-1 i.p groups. 
The implications of reduced vascular conductance have 
previously been discussed in Section 4.4.3. 
5.4.4 Heart Rate 
Throughout the telemetry study, no significant differences in 
heart rate from baseline were seen, and the heart rate in the 
pazopanib group was significantly higher than that of the 
vehicle group (Figure 5.5, Figure 5.6, Table 5.2). Pazopanib 
did not produce a significant decrease in heart rate, compared 
to vehicle, in the i.p regional haemodynamic study. However it 
did cause sustained significant decreases in heart rate 
compared to baseline in the 10 and 30 mgkg-1day-1 groups 
(Figure 5.7, Figure 5.8). These results suggest pazopanib does 
not have a prominent bradycardic effect. 
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However, in a published randomised, double blind placebo 
controlled study in humans, it was shown that pazopanib was 
able to induce concentration dependent bradycardia which 
occurred by day 9 of the study (Heath et al., 2013). 
Heart rate for vandetanib 25 mgkg-1 day-1 i.p and pazopanib 30 
mgkg-1 day-1 i.p were not significantly different in either the 
haemodynamic or telemetry studies. Whether or not VEGF 
RTKIs cause bradycardia has not been well documented. Along 
with the above mentioned human study using pazopanib and 
the previously discussed published evidence of 
vandetanib-induced bradycardia (Section 4.4.4), sunitinib, a 
VEGF RTKI, has also been reported to cause a decrease in 
heart rate in telemetered rats, while not affecting cardiac 
structure or function (Blasi et al., 2012). The reasons why 
RTKIs may lead to bradycardia have been previously discussed 
in Section 4.4.4. 
5.4.5 Conclusion 
The data shown here demonstrates that pazopanib causes 
hypertension and dose dependent constriction of the renal, 
mesenteric and hindquarter vascular beds (Figure 5.7, Figure 
5.8, Figure 5.9). Of particular interest is the prolonged 
hypertension seen post-treatment with pazopanib. This finding 
is novel and suggests pazopanib is either able to cause 
more-permanent physiological changes within the rat’s 
cardiovascular system or that it has a different kinetics profile 
in comparison to vandetanib (Chapter 4). Although vandetanib 
and pazopanib commonly inhibit VEGFR2, their IC50 at VEGFR2 
vary from 6.72 ± 0.03 to 8.25 ± 0.03, respectively (Chapter 
3; Carter et al., 2015). Potency at VEGFR2 seems to be 
directly comparable to the percentage of patients who develop 
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hypertension, with the more potent compounds such as 
pazopanib, having a wider spread hypertensive effect in the 
populous taking them (Hamberg et al., 2010; Wells et al., 
2012; Bible et al., 2014). However, in the rat, vandetanib was 
shown to cause a numerically greater and more transient 
increase in mean arterial blood pressure, in comparison to 
pazopanib, highlighting the need for further research into RTKI 
pharmacodynamic and pharmacokinetic profiles. 
As the in vivo data collected here and in Chapter 4, along with 
the literature discussed (Section 1.2.5) suggest that the 
hypertensive side effect profile of VEGF RTKIs may be, in part, 
linked to endothelial dysfunction and changes in vessel tone, 
Chapter 6 will primarily focus on the effect of vandetanib on 
vessel tone. 
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Chapter 6 : The Actions of 
Vandetanib, Pazopanib, 
hVEGF165 and 
Acetylcholine on Vessel 
Diameter   
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6.1 Introduction 
Current literature (Fan et al., 2014; Kruzliak et al., 2014; 
Lankhorst et al., 2014; Abi Aad et al., 2015; Lankhorst et al., 
2015) and the data discussed so far suggest that the 
hypertensive side effect profile of VEGF RTKIs may be linked 
to endothelial dysfunction and vessel tone. Therefore this 
Chapter focuses on the actions of vandetanib and pazopanib 
on vessel tone. It will also explore the effect of vandetanib on 
VEGF165 and ACh-mediated vasodilatation. 
It has previously been shown that haemodynamic force is a 
key stimulus for the production of vasoactive and vasodilatory, 
substances, such as NO, by ECs (Rubanyi et al., 1986). 
Haemodynamic force, created by the flow of blood, can be 
characterised into two major types; shear stress and cyclic 
circumferential stretch (Yamamoto and Ando, 2015; 
Gutterman et al., 2016). Increases in force cause activation of 
calvolae-situated mechanosensory complexes consisting of 
stretch activated (SA) channels, integrin proteins and platelet 
EC adhesion molecule-1 (PECAM) and VEGFR2 (Chatterjee and 
Fisher, 2014b), leading to the production of vasoactive 
signalling molecules, such as NO and PGI2, as well as 
anti-thrombogenic mediators e.g. thrombomodulin and HSG 
(Ando and Yamamoto, 2009; Conway and Schwartz, 2012). 
Therefore, understanding the action of vandetanib and 
pazopanib on vessel tone, in pressurised vessels, may help to 
elucidate whether vandetanib and pazopanib-mediated 
hypertension is due to the inhibition of constitutive vasoactive 
substances. 
Secondly, the inhibition of VEGF-mediated dilatation by 
vandetanib was explored. VEGF is a potent mediator of 
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vasodilatation (Section 1.2), and its inhibition by RTKIs is 
believed to be the most likely cause of hypertension in the 
patient populations taking VEGF targeted anti-angiogenic 
treatments (Kruzliak et al., 2014; Lankhorst et al., 2014; 
Small et al., 2014; Lankhorst et al., 2015). Although the 
above hypothesis is widely accepted, the actions of RTKIs on 
vessel tone in the presence of VEGF have not previously been 
explored. 
Finally, due to the results obtained in Chapter 3, which 
demonstrate vandetanib is able to inhibit basal measurements 
of NFAT-mediated luciferase production (Section 3.4.3) and 
because of the reported multi-targeted nature of VEGF RTKIs 
(Section 1.3.1), the effects of vandetanib on ACh-mediated 
vasodilatation was explored. ACh is a neurotransmitter able to 
cause vasodilatation through activating the muscarinic (M3) 
ACh receptor (mAChR) on vascular ECs (Kruse et al., 2012). 
This leads to vasodilatation through the production of NO and 
PGI2 (Durand and Gutterman, 2013), because ACh-meditated 
dilatation has been shown to use the same vasodilatory 
signalling molecules as VEGF (NO and PGI2) but does not do 
this through activation of a receptor tyrosine kinase, knowing 
if vandetanib is able to inhibit ACh-mediated dilatation is 
indicative of whether vandetanib is able to potently inhibit the 
intracellular signalling kinases responsible for the production of 
NO and PGI2. 
By understanding the action of vandetanib and pazopanib, 2 
VEGF RTKIs and the action of vandetanib on VEGF and ACh-
mediated dilatation, on vessel tone in the presence of cyclic 
circumferential stretch, the role of these vasoactive 
substances in VEGF RTKI-induced hypertension can be further 
elucidated.  
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6.2 Methodology 
6.2.1 Living Systems Pressure Myography 
Rats were killed using stunning and cervical dislocation in 
accordance with Schedule 1 of the UK, Animals Scientific 
Procedures Act (1986). Second order mesenteric vessels were 
harvested, cleaned of connective tissue and mounted on the 
pressure myograph (Living Sytems pressure myograph, 
Section 2.7). The myography bath contained 10 ml PSS 
(118 mM NaCl, 4.8 mM KCl, 1.1 mM MgSO4.7H20, 25 mM 
NaHCO3, 1.2 mM KH2PO4, 12 mM Glucose, 1.25 mM 
CaCl2.2H20) and was perfused with 95% air/ 5% CO2 to 
maintain a pH of approximately 7.4. Temperature was 
maintained at 36-37°C. Intraluminal pressure was set to 90 
mmHg and the vessel was allowed to equilibrate to these 
conditions for 30 min (Figure 6.1). 
After 30 min, PEG vehicle (2% Tween, 5% poly ethylene glycol 
in 0.9% saline solution) (final concentrations of 0.001%-10%), 
vandetanib (stock: 10-2 M diluted in DMSO, then further 
diluted in PSS to give final concentrations of 10-10 M-10-5 M), 
pazopanib (stock: 10-2 M diluted in DMSO, then further diluted 
in PSS to give final concentrations of 10-10 M-10-5 M) or DMSO 
(equivalent volumes of DMSO to those found in the vandetanib 
and pazopanib final solutions, diluted in PSS) were added 
cumulatively to the bath to generate a concentration response 
curve. Each concentration was added for 10 min. Vessels were 
dilated using 10-5 M ACh (final concentration) at the end of the 
experiment to check for endothelial function. If there was no 
response the experiment was discounted from the analysis. 
Vessels were imaged using an inverted microscope attached to 
a camera, and the internal diameter was measured using a 
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dimension analyser (Living Systems Instrumentation), linked 
to a MacLab data acquisition system. 
6.2.2 DMT 120CP myography 
Rats were killed using stunning and cervical dislocation in 
accordance with Schedule 1 of the UK, Animals Scientific 
Procedures Act (1986). Second order mesenteric vessels were 
harvested, cleaned of connective tissue and mounted on the 
pressure myography (DMT 120CP, Section 2.7). The 
myography bath contained 10 ml PSS and was perfused with 
95% air/ 5% CO2 to maintain a pH of approximately 7.4. 
Temperature was maintained at 36-37°C. PSS contained 
0.01% BSA if hVEGF165 was used in the study, this was done 
to ensure the hVEGF165 did not adhere to surfaces within the 
bath. Intraluminal pressure was set to 90 mmHg and the 
vessel was allowed to equilibrate to these conditions for 
30 min (Figure 6.1). After 30 min vessels were constricted by 
40-60% of the initial diameter using 10-7 M U46619 
(9,11-dideoxy-9α,11α-methanoepoxy prostaglandin F2α), this 
response was allowed to stabilise for 30 min before 
compounds: vandetanib (stock: 10-2 M diluted in DMSO, then 
further diluted in PSS to give final concentrations of 
10-10 M-10-5 M), DMSO (equivalent volumes of DMSO to those 
found in the vandetanib final solutions, diluted in PSS), ACh 
(diluted in PSS, final concentration range from 10-10 M-10-5 M) 
or hVEGF165 (stock concentration: 10-6 M, stock diluted in PBS 
+ 0.1% BSA final concentration range, diluted in PSS + 0.1% 
BSA, between 10-14 M-10-9 M) were added cumulatively to the 
bath to generate a concentration response curve (Figure 6.1). 
Each concentration was added and incubated with the vessel 
for 5 min (time taken to see full response). Vessels were 
dilated using 10-5 M ACh (final concentration) at the end of the 
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experiment to check for endothelial function. If there was no 
response the experiment was discounted from the analysis. 
Vessels were imaged using an inverted microscope attached to 
a camera, and the internal diameter was measured using a 
dimension analyser (DMT) linked to a computer with DMT 
MyoView II software (Figure 6.1).  
6.2.3 Statistical Analysis 
Data obtained from the DMT 120CP system were fitted using 
non-linear regression (3-parameter) in GraphPad Prism 6 
(San Diego, CA) to obtain EC50 values (Section 2.8.3). All data 
have been expressed as mean ± SEM with significance being 
accepted at P‹0.05. A non-parametric, two-tailed group 
comparison (Friedman) was performed to determine if any 
changes seen from the baseline value were significant. 
Non-parametric between group two-tailed comparisons (Mann 
Whitney U test for 2 groups and Kruskal Wallis for more than 2 
groups) were performed to look for significant differences 
between groups. An unpaired Student’s T test was used to 
compare Emax and pEC50 values which had been gained by 
averaging the individual n values from each experimental 
non-linear regression curve fit. This was done using Graphpad 
prism 6.00.  
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Figure 6.1 Representative trace showing the experimental protocol for pre-constriction of mesenteric arterioles with U46619. 
30 min after preconstriction, vandetanib (10 μl 10-4 M, giving a final concentration of 10-7 M) was incubated with the vessel for 
10 min and a concentration response curve for ACh was generated (10-10 M-10-5 M-final concentrations). 
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6.3 Results 
6.3.1 The Effects of Vandetanib and Pazopanib on 
Pressurised Vessel Diameter 
Increasing concentrations of vandetanib, pazopanib and the 
corresponding vehicle control of DMSO caused no significant 
change in vessel diameter, compared to baseline 
measurements (P<0.05, Friedman; Figure 6.2). However, 
there was a significant difference between the vandetanib 
concentration response vs the corresponding vehicle control of 
DMSO for vandetanib and pazopanib (P<0.05, Mann Whitney; 
Figure 6.2). 
The PEG vehicle used in the in vivo studies in Chapters 4 and 
5, was also tested on pressurised mesenteric vessels, in order 
to explore whether the PEG vehicle has a constrictive effect on 
rat vessels. The PEG vehicle (2% tween80 + 5% PEG in 0.9% 
saline solution) showed no significant effect on vessel diameter 
at concentrations up to 10% vehicle (final concentration) in 
comparision to baseline (Friedman; Figure 6.2).  
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Figure 6.2 The effect of 
selected RTKIs on vessel 
diameter. Vessels were 
treated with increasing 
concentrations of vandetanib 
n=5 (a), pazopanib n=6 (b), 
equivalent DMSO vehicle 
concentrations n=4 (a, b) or 
the in vivo PEG vehicle used in 
Chapters 4 and 5 (2% 
tween80 + 5% PEG in 0.9% 
saline solution) n=7 (c). Data 
presented has been pooled 
and normalised to initial vessel 
diameter. Each point 
represents the mean ± SEM. 
#-p<0.05 Mann Whitney 
between group comparision 
*-p<0.05 Friedman test with 
data points compared initial 
vessel diameter 
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6.3.2 The Effects of Vandetanib on the Vessel 
Diameter of Pre-Constricted Pressurised 
Vessels 
Vandetanib significantly increased vessel diameter at 
concentrations between 3x10-7 M and 10-5 M in pre-constricted 
vessels in comaprison to the vessel diameter produced by 
U46619 constriction (P<0.05, Friedman; Figure 6.3). This 
increase in diameter was significantly different to the DMSO 
vehicle control (P<0.05, Mann Whitney; Figure 6.3). The 
DMSO vehicle control, at the equivilent concentration of 
vandetanib 10-5 M, caused a significant increase in vessel 
diameter (P<0.05, Friedman). 
hVEGF165 caused an increase in vessel diameter in 
pre-constricted vessels. This was significantly different, from 
baseline, at 3x10-9 M and 1x10-9 M (P<0.05, Friedman; Figure 
6.3). hVEGF165 had a pEC50 of 13.0 ± 0.5. The increase in 
diameter was significantly different from the DMSO vehicle 
control group (P<0.05, Mann Whitney; Figure 6.3). The DMSO 
concentration response data showed that DMSO caused a 
significant increase in vessel diameter at 3x10-10 M-10-9 M 
(P<0.05, Friedman).  
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Figure 6.3 The effects of vandetanib and hVEGF165 on vessel diameter after preconstriction with U46619. Vessels were 
preconstricted with U46619 (10-7 M), allowed to normalise of 30 min and then treated with increasing concentrations of 
vandetanib n=6 (a), VEGF n=5 (b) or the vehicle DMSO (n=6 (a) n=5 (b)). Data presented have been pooled and normalised 
to the vessel diameter produced by U46619 constriction. Each point represents the mean ± SEM. #-p<0.05 Mann Whitney 
between group comaprision *-p<0.05 Friedman test with data points compared against the vessel diameter produced by 
U46619 constriction. 
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6.3.3 The Effects of Vandetanib on hVEGF165 Mediated 
Vessel Dilatation 
Vandetanib significantly inhibited hVEGF165-mediated vessel 
dilatation in comparison to the DMSO control (P<0.05, Mann 
Whitney; Figure 6.4). The hVEGF165 + 10-7 M vandetanib 
concentration response curve experiment showed no 
significant change in vessel diameter throughout the 
concentration range tested (P<0.05, Friedman; Figure 6.4). 
However, hVEGF165 + DMSO control caused a significant 
increase in vessel diameter from 3x10-10 M onwards (P<0.05, 
Friedman), with an Emax of 110% ± 27% compared to the 
mean hVEGF165 +10-7 M vandetanib Emax of 37% ± 15%. The 
mean pEC50 for the hVEGF165+10-7 M vandetanib group was 
11.7 ± 0.6, compared to the mean pEC50 of 12.2 ± 0.2 for the 
hVEGF165a + DMSO, demonstrating that although vandetanib 
did not cause a significant shift in hVEGF165 pEC50 it did cause 
a reduction in the efficacy of hVEGF165. 
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Figure 6.4 The effect of vandetanib on VEGF induced vessel dilatation after preconstriction with U46619 (10-7 M) Vessels were 
preconstricted with U46619, allowed to normalise of 30 min and then treated with 10-4 M vandetanib (10-7 M final concentration) 
(n=7), or the equivalent DMSO control (n=5) for 10 min before being exposed to increasing concentration of VEGF. Data 
presented have been pooled and normalised to the vessel diameter produced by the addition of vandetanib or DMSO, after 
U46619 constriction. Each point represents the mean ± SEM from n separate experiments. #-p<0.05 Mann Whitney between 
group comparision*-p<0.05 Friedman test with data points compared against vandetanib/DMSO incubation step 
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6.3.4 The Effects of Vandetanib on ACh Mediated 
Vessel Dilatation 
ACh + 10 μl PSS elicited significant vessel dilatation between 
10-7 M-10-5 M ACh (P<0.05, Friedman; Figure 6.5). The 
ACh + DMSO control group showed a significant increase in 
vessel diameter between 10-6 M-10-5 M ACh 
(P<0.05, Friedman; Figure 6.5). The ACh + 10-7 M vandetanib 
group demonstrated a significant increase in vessel diameter 
at 10-5 M ACh (P<0.05, Friedman; Figure 6.5) The 
ACh + 10-7 M vandetanib group showed a significantly smaller 
increase in vessel diameter in comparison to ACh + 10 μl PSS 
(P<0.05, Kruskal Wallis). This difference was not seen 
between the ACh + 10-7 M vandetanib and ACh + DMSO 
control or between the ACh + DMSO control and ACh + 10 μl 
PSS group (P>0.05, Kruskal Wallis), demonstrating vandetanib 
significantly inhibits ACh-mediated dilatation. The pEC50 for 
ACh + PSS was 6.6 ± 0.2. pEC50 values for the other 
experimental groups could not be calculated due to the 
non-linear regression curve not reaching the asymptote. 
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Figure 6.5 The effect of vandetanib, DMSO and PSS on ACh induced vessel dilatation after preconstriction with U46619 (10-7 M) 
Vessels were preconstricted with U46619, allowed to normalise of 30 min and then treated with 10 μl 10-4 M vandetanib (10-7 
M final concentration) (n=7), or 10 μl of the equivalent DMSO concentration (n=5), or 10 μl PSS (n=6) for 10 min before being 
exposed to increasing concentration of ACh. Data presented has been pooled and normalised to the vessel diameter produced 
by the addition of vandetanib, DMSO or PSS after U46619 constriction. Each point represents the mean ± SEM. #-p<0.05 
Kruskal Wallis between group comparision*-p<0.05 Friedman test with data points compared against the 
PPS/ DMSO/ vandetanib incubation value after U46619 constriction. 
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6.4 Discussion  
This Chapter set out to characterise the effects of vandetanib 
and pazopanib alone, and vandetanib in combination with 
hVEGF165 or ACh on vessel tone. The effects of vandetanib in 
the presence of hVEGF165 or ACh were explored due to the 
preliminary experimental results shown in Section 4.3.2. In 
vessels not pre-constricted with U46619, vandetanib and 
pazopanib had no significant effect (Figure 6.2). However, in 
pre-constricted vessels vandetanib caused a significant 
dilatation (Figure 6.3). Vandetanib was also shown to 
significantly reduce hVEGF165 and ACh-mediated vessel 
dilatation (Figure 6.4, Figure 6.5). Here the possible reasons 
for these findings and how they relate to the current literature 
will be discussed. 
6.4.1  The Effect of Vandetanib and Pazopanib on 
Pressurised Vessel Diameter 
Vandetanib and pazopanib did not have a significant effect on 
vessel diameter in vessels which had not been pre-constricted 
with U46619 (Figure 6.2). The PEG vehicle used in Figure 6.2 
and for the in vivo experiments in Chapters 4 and 5 had no 
significant effect on vessel tone. 
The lack of effect of vandetanib and pazopanib on vessel 
diameter was somewhat unexpected as Mayer et al (2011) had 
previously reported vandetanib was able to reduce resting 
brachial arterial diameter and increase vascular resistance 
(Mayer et al., 2011).  
One explanation for the above result is that the vessels used 
in the experimental preparation were not under sufficient 
haemodynamic pressure to produce vascular cell signalling, 
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and therefore vandetanib/pazopanib targeted receptor tyrosine 
kinases were not activated. This would mean vandetanib and 
pazopanib were unable to bind to their target kinases (see 
Section 1.3.1 for explanation of class I RTKI mechanism) and 
could not elicit an effect. Haemodynamic pressure consists of 2 
factors; shear stress and cyclic circumferential stretch 
(Chatterjee and Fisher, 2014a; Yamamoto and Ando, 2015,) 
In the isobaric myography protocol used here, vessels 
experienced cyclic circumferential stretch but not shear stress, 
as no flow through the vessel was allowed. The role of shear 
stress in the absence of cyclic circumferential stretch and vice 
versa, along with how ECs differentiate these mechano-signals 
is not fully understood (Yamamoto and Ando, 2015). However, 
there is an emerging theme in the literature that suggests 
cyclic stress in the absence of shear stress is primarily linked 
to endothelial remodelling. Sipkema et al demonstrated that in 
intact vessels, cyclic stretch lead to reorganisation of the 
endothelial cytoskeleton, with actin filaments realigned toward 
the direction of the cyclic stress (Sipkema et al., 2003). Cyclic 
circumferential stretch has also been linked to the regulation 
of cell and vessel remodelling by Wang et al who showed 
human ECs exposed to cyclic stress had increased expression 
of metalloproteinases (Michel, 2003; Wang et al., 2003). The 
myography experiments discussed herein would need to be 
repeated with the addition of shear stress to test this 
hypothesis further. 
Vandetanib- and pazopanib-mediated vasodilatation would go 
relatively unseen in vessel preparations that had not been 
pre-constricted, as the vessel diameter does not have as much 
capacity to dilate. In order to test this vandetanib was added 
in a cumulative manner to vessel pre-constricted with U46619.  
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6.4.2 The Effect of Vandetanib on the Vessel 
Diameter of Pre-Constricted Pressurised 
Vessels 
Vandetanib led to a significant dilatation in vessels 
pre-constricted with U46619 (Figure 6.3). This result was 
unexpected and contradicts the current literature (Bhargava, 
2009; Kruzliak et al., 2014; Lankhorst et al., 2014; Abi Aad et 
al., 2015; Lankhorst et al., 2015).  
U46619, used to constrict the vessels, is a thromboxane A2 
(TxA2) agonist (Scornik and Toro, 1992). TxA2 production in 
the EC is initiated by shear stress, which triggers the Ca2+ 
dependent production of arachidonic acid; this is converted 
into prostaglandin H2 and subsequently to TxA2 by TxA2 
synthase (otherwise known as CYP5). TxA2 binds to 
thromboxane receptors (TP) on smooth muscle cells. TP is 
coupled to both Gq/11 and G12/13 G proteins, and therefore 
signals via the PLC and Rho kinase pathways to elicit 
contraction (Tsai and Jiang, 2006; Ellinsworth et al., 2014). 
TxA2 has been shown to reduce NO and PGI2-mediated vessel 
relaxation (Feletou et al., 2011). Vandetanib has been shown 
to bind to intracellular kinases involved in the vascular smooth 
muscle contraction mediated by TxA2, for example Davis et al 
showed that vandetanib was able to bind to MEK with a Kd of 
49 nM (Davis et al., 2011). Vandetanib has been shown to be 
able to bind to the active conformation of tyrosine kinase 
domains (Gotink and Verheul, 2010), this paired with its ability 
to cross the cell membrane (Carter et al., 2015) and reverse 
U46619-mediated constriction suggests that vandetanib may 
inhibit tyrosine kinase activity in vasoconstrictive as well as 
vasodilatory signalling pathways.  
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6.4.3 The Effects of Vandetanib on 
hVEGF165a-Mediated Vessel Dilatation 
Vandetanib was shown to non-competitively inhibit 
hVEGF165a-mediated dilatation (Figure 6.4) significantly 
reducing the maximal effect of hVEGF165a while not causing a 
significant shift in hVEGF165a pEC50 (Figure 6.4), in keeping 
with the in vitro findings in Chapter 3. The inhibition of 
VEGF-mediated dilatation in isolated vessel preparations 
supports the hypothesis that VEGF RTKIs cause 
vasoconstriction. 
hVEGF165 had a pEC50 of 13.0 ± 0.5 (Figure 6.3) in 
pre-constricted rat mesenteric arterioles. This is significantly 
different from the potency of hVEGF165a in HEK293 cells 
transfected with VEGFR2 and NFAT-RE-luc2P (Chapter 3, 
hVEGF165a pEC50=9.66 ± 0.05 p<0.05, student T test). This in 
part may be due to the use of human VEGF165, rather than the 
equivalent rat VEGF164 (Ishii et al., 2001). The protein 
sequence for rat VEGF164 has 88% homology with the human 
VEGF165a (Figure 6.6). Although this does not rule out a 
difference between the potency of the two VEGF isoforms at 
VEGFR2, it does show that these 2 isoforms are similar. 
Comparing the effect of rat VEGF164 in this experimental set up 
to human VEGF165 data shown here (Figure 6.3) would allow 
for any difference between the actions of these two isoforms 
on rat mesenteric arterioles to be further explored. 
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Figure 6.6 Protein sequence homology between human VEGF165 
(obtained from uniprot.org, UNIprotKB-P15692, 03.05.2016) and rat 
VEGF164 (obtained from uniprot.org, UNIprotKB-P16612, 
03.05.2016). Protein sequence alignment was performed using 
blast.ncbi.nlm.nih.gov/Blast 03.05.2016. 
 
The difference in the potency of VEGF in the recombinant 
VEGF-NFAT cell line vs the isolated rat mesenteric arteriole 
could also be due to the physiological and structural 
differences between tissues and cell lines. Unlike the 
recombinant cell line, the arteriole is comprised of multiple cell 
phenotypes which natively express VEGFR2 and the 
corresponding signalling proteins needed to produce a 
vasoactive response. As the vessel is intact, its ability to 
increase a vasodilatory/ vasoconstrictive response though 
electrical transduction is maintained (Segal et al., 1999). This 
process primarily occurs through gap junction signalling. Gap 
junctions are comprised of two connexons, one provided by 
each cell to form small ‘pores’ between cells in very close 
proximity. Gap junctions allow small molecules (<1000 Da) 
and electrical current to pass between cells (Salameh et al., 
2005). Propagation of electrical signals between endothelial 
and vascular smooth muscle cells leads to a fast response to 
stimuli and smooth coordinated constriction/dilatation of the 
vessel (Lehoux et al., 2006). As each cell does not have to be 
216 
 
stimulated individually, less agonist is needed reducing the 
EC50 of stimulatory molecules.  
6.4.4 The Effects of Vandetanib on ACh-Mediated 
Vessel Dilatation 
ACh causes endothelium dependent relaxation of vascular 
smooth muscle, and therefore vessel dilatation (Furchgott and 
Zawadzki, 1980). ACh binds to M3 mAChR on ECs. This in turn 
leads to the production of NO and PGI2 via the activation of 
the PLC and PI3K pathways (Socha et al., 2012; Kang, 2014). 
ACh uses the same signalling pathways as VEGFR2 to produce 
NO and PGI2. Therefore inhibition of ACh-mediated dilatation 
by VEGF RTKIs, which have not been shown it interact with 
GPCRs, such as the M3 mAChR, would demonstrate vandetanib 
is able to functionally inhibit intracellular signalling kinases 
alongside receptor tyrosine kinases. Figure 6.5 shows 
vandetanib is able to significantly inhibit ACh-mediated vessel 
dilatation. This result, and the findings from Davis et al and 
others (Kumar et al., 2007; Davis et al., 2011), which 
demonstrate RTKIs are able to bind to catalytic domains of 
intracellular kinases, as well as the data in Chapter 3, which 
shows vandetanib is able to penetrate the cell membrane, 
suggests that vandetanib does not specifically inhibit receptor 
tyrosine kinases. This result shows the need for a better 
understanding of RTKI targets. It is possible that the 
multi-targeted actions of RTKIs, like vandetanib, lead to an 
inhibition of vessel dilatation, regardless of the initiating 
signalling molecule. 
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6.4.5 Conclusion 
Vandetanib and pazopanib produced no significant effect on 
vessel diameter in non-preconstricted vessels. Vandetanib has 
been shown to inhibit VEGF and ACh-mediated vessel 
dilatation. Vandetanib was also shown to elicit vasodilatation 
in the presence of a vasoconstrictor, a novel finding. Overall 
this Chapter clearly demonstrates the importance of the 
multi-targeted nature of pazopanib and vandetanib. A clearer 
understanding of the effects of RTKIs on endothelial signalling 
in vessels or in the whole animal is needed to gain a greater 
understanding of the underlying mechanisms that lead to 
hypertension.  
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Chapter 7 : General 
Discussion  
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7.1 Introduction 
One of the main side effects of anti-angiogenic VEGF therapies 
is the development of cardio-toxicity, specifically hypertension. 
The main objectives of this work were to determine the 
haemodynamic profile of VEGF therapies and to elucidate the 
possible signalling sequelae involved in the development of 
RTKI-induced hypertension. Through characterising the 
haemodynamic, cardiovascular and signalling profile of a panel 
of RTKIs in vitro and in vivo the detrimental hypertensive 
effect of these compounds and the possible mechanisms of 
action by which hypertension occurs were explored. With this 
in mind the specific aims of this project were: 
a) To determine the pharmacological characteristics of a 
panel of receptor tyrosine kinase inhibitors (RTKIs) 
(cediranib, sorafenib, pazopanib and vandetanib) in a 
whole cell system using VEGF-stimulated Nuclear Factor 
of Activated T-cell (NFAT) signalling in HEK293 cells 
expressing the human VEGFR2 and an NFAT reporter 
gene linked to firefly luciferase. The actions of the above 
RTKIs were also explored in the presence of two VEGF-A 
isoforms, VEGF165a and VEGF165b. 
b) To investigate the chronic effects of vandetanib and 
pazopanib on heart rate and blood pressure in male 
Sprague Dawley rats. 
c) To assess the effect of various concentrations of 
vandetanib and pazopanib on heart rate, mean arterial 
blood pressure, hindquarter, renal and mesenteric 
vascular conductances in male Sprague Dawley rats. 
d) To assess the action of vandetanib and pazopanib on 
isolated pressurised mesenteric arterioles, and to 
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elucidate the effect of vandetanib on VEGF and ACh-
mediated vessel dilatation. 
7.2 The Pharmacological Characteristics of a Panel of 
Receptor Tyrosine Kinase Inhibitors (RTKIs) 
(Cediranib, Sorafenib, Pazopanib and Vandetanib) 
in a Whole Cell System  
This aim was addressed in Chapter 3, where cediranib, 
sorafenib, pazopanib and vandetanib were shown to 
non-competitively inhibit VEGF165 and VEGF165b–VEGFR2 
mediated activation of the NFAT-luciferase reporter gene. Both 
VEGF165 and VEGF165b were shown to stimulate VEGFR2 -
mediated NFAT-luciferase activation; however the efficacy of 
VEGF165b at VEGFR2 was lower than VEGF165.  
The findings from the study described in Chapter 3 raised 
several questions: 
1. Do RTKIs have the same order of potency at VEGFRs in 
human tissue? 
2. Do RTKIs show a bias toward blocking certain signalling 
pathways over others, for example by blocking certain 
tyrosine kinase residues at a higher potency than 
others? 
3. Does the order of potency found in vitro translate to the 
extent and commonality of hypertension in the 
rat/human? 
Question 1 is important as it allows for the results gained here 
to be related to physiologically relevant tissue, and therefore 
give more insight onto RTKI potency. In order to answer this 
question, human primary cells from various tissues, e.g. 
resistance arterioles and the heart could be exposed to 
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cumulative concentrations of VEGF165 in the presence of 
varying concentrations of RTKI and vice versa, similar to the 
experiments performed in Chapter 3. This would allow for a 
comparison in the order of potency of cediranib, sorafenib, 
pazopanib and vandetanib in more relevant tissue types. 
An answer to question 2 would give a greater understanding of 
RTKI pathway bias. This is important as different VEGFR2 
signalling pathways have different outcomes for the cell 
(Figure 1.1), and therefore RTKI bias may be, in part, 
responsible for the differences seen between various RTKI side 
effect profiles. In order to address this question, reporter gene 
assays, such as the one used in Chapter 3 could be used. 
Rather than looking at the activation of NFAT, the activation of 
serum response element (SRE), a response element of the 
MAPK pathway (Hill et al., 2001) could be used. The MAPK 
pathway in ECs is linked to cell proliferation and vasodilatation 
(Figure 1.1): processes important for tumour growth and 
blood pressure control, respectively. 
Question 3 addresses whether the order of potency found in 
the cell line translates to the extent and commonality of 
hypertension in the rat/human. In order to investigate this, 
cediranib, sorafenib, pazopanib and vandetanib would need to 
be given to rats/humans at equivalent ED50 values. This would 
allow for a direct comparison between the severity and 
commonality of hypertension between compound populations. 
In Chapters 4 and 5, vandetanib and pazopanib were given to 
rats at equivalent ED50 values, these studies elucidated that 
although pazopanib has a greater potency at VEGFR2 in vitro it 
did not cause a greater increase in mean arterial blood 
pressure over a 21 day dosing period, but rather produced a 
more sustained increase in mean arterial blood pressure after 
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treatment. This result suggests that vandetanib and pazopanib 
may have different pharmacokinetic profiles (Section 5.4.2).  
Understanding the link between in vitro VEGFR2 receptor 
potency and the in vivo hypertensive side effect profile is 
important for new VEGF RTKI compound design. 
7.3 The Chronic Effects of Vandetanib and Pazopanib on 
Heart Rate and Blood Pressure in Male Sprague 
Dawley Rats 
In long-term telemetry studies (Chapter 4 and 5), vandetanib 
appeared to demonstrate significant hypertensive effects 
within 24 h of the first dose. This was maintained throughout 
the dosing period and for 7 days after dosing for the 
vandetanib 25 mgkg-1day-1 treatment group. In a preliminary 
staining study of the mesenteric vasculature performed on 
tissue taken from the vandetanib treatment group in the 
telemetry study, no significant signs of rarefaction were seen, 
however there was a trend toward rarefaction, suggesting that 
rarefaction may have occurred during the treatment period 
and been reversed post-treatment. In comparison pazopanib 
produced a significant increase in mean arterial blood pressure 
from day 10 day of dosing. This effect persisted throughout 
the measured post-treatment period. Patient populations 
taking pazopanib have been shown to be more likely to 
develop hypertension than those prescribed vandetanib 
(Hamberg et al., 2010; Wells et al., 2012; Bible et al., 2014). 
This knowledge, combined with the results from Chapters 4 
and 5 indicate that VEGF RTKI induced hypertension may be, 
in part, due to physiological cardiovascular changes such as 
rarefaction. It is also possible that pazopanib has a different 
kinetics profile to vandetanib (previously discussed in Section 
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5.4.2). These findings are novel and have raised multiple 
research questions: 
 
1. Do vandetanib and pazopanib cause rarefaction after 3 
weeks of treatment, and does this process reverse after 
treatment stops? 
2. Do VEGF RTKIs cause endothelial dysfunction?  
3. Are the kinetics profile between vandetanib and 
pazopanib different? 
 
In order to address the first question further mesenteric 
studies would need to be undertaken. By looking at the 
mesenteric vasculature at different stages of treatment length 
as well as post-treatment it would be possible to ascertain if 
rarefaction is a contributing factor to VEGF RTKI induced 
hypertension. 
Question 2 addresses the hypothesis that VEGF RTKIs cause 
endothelial dysfunction which consequently leads to 
hypertension. In order to explore this further, blood plasma 
concentrations of endothelial dysfunction markers and 
inflammatory molecules, such as c-reactive protein and 
interleukin 6, respectively (Lopez-Garcia et al., 2004), from 
humans/ rats which had been subject to VEGF RTKI treatment 
vs no/vehicle treatment should be measured and compared. 
Finally, the higher potency of pazopanib at VEGFR2 (IC50=8.25 
± 0.03) in comparison to vandetanib (IC50=6.72 ± 0.03; 
Carter et al., 2015) leads to the prediction that pazopanib 
would cause a greater increase in blood pressure than 
vandetanib. This hypothesis is supported by the greater 
number of patients who experience hypertension with 
pazopanib compared to vandetanib in the clinic (Hamberg et 
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al., 2010; Bible et al., 2014; Wells et al., 2012). The 
considerably shorter plasma half-life of pazopanib in 
comparison to vandetanib (Section 1.3.1.1 and 1.3.1.2) would 
also lead to the prediction that the hypertenive effects of 
pazopanib would wane prior to those of vandetanib. However 
this was not the case (Chapter 4 and 5). One explanation for 
this observation is a difference in the kinetic profile of 
pazopanib in comparison to vandetanib. Slow dissociation of a 
drug from its target can lead to a disengagement between its 
pharmacokinetic profile and the compounds pharmacodynamic 
effects, with measured efficacy significantly outlasting 
detectable plasma concentrations of drug (Vauquelin and 
Charlton, 2010). If radiolabelled versions of the compounds 
were available, their dissociation rates could be directly 
measured using scintillation proximity assays with an 
immobilised version of the catalytic domain of the VEGFR 
(Park et al., 1999), allowing further exploration of this 
hypothesis.  
7.4 The Effect of Various Concentrations of Vandetanib 
and Pazopanib on Heart Rate, Mean Arterial Blood 
Pressure, Hindquarter, Renal and Mesenteric 
Vascular Conductances in Male Sprague Dawley 
Rats. 
The dose dependent effects of pazopanib i.p and vandetanib 
i.p on heart rate, mean arterial blood pressure, and vascular 
conductance of the renal, mesenteric and hindquarter vascular 
beds were investigated over 4 days. Both vandetanib and 
pazopanib lead to hypertension and vasoconstriction of the 
mesenteric and hindquarter vascular beds, pazopanib also 
caused significant vasoconstriction of the renal vascular bed. 
None of the variables measured in the haemodynamic studies 
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significantly differed between the 30 mgkg-1day-1 pazopanib 
and 25 mgkg-1day-1 vandetanib groups. The effect of 
vandetanib and pazopanib on vascular conductance is a novel 
finding and suggests these compounds may lead to 
hypertension via a vasoactive mechanism. The results gained 
in these studies raised multiple questions: 
 
1. Are the cardiovascular effects of vandetanib and 
pazopanib persistent when rats are dosed chronically 
and are they consistent once treatment has stopped? 
2. Do vandetanib and pazopanib affect vessel tone? 
3. Are the effects of vandetanib and pazopanib on blood 
pressure and vascular conductance negated in the 
presence of a NO-donor or PGI2?  
 
Question 1 is aimed toward characterising the long term 
effects of RTKIs and will give more information about the 
incidence of permenant physiological adaptions in the 
presence of VEGF RTKIs. This question was adressed in 
Chapters 4 and 5 and was discussed in Section 7.3. 
With the evidence that vandetanib and pazopanib lead to 
reduced vascular conductance, there is a likely possibility that 
RTKI-induced hypertension, is in part, caused by their effect 
on vessel tone. In order to investigate this hypothesis further, 
and address question 2, myography studies were performed in 
Chapter 6. The results from these studies will be further 
discussed in Section 7.5. 
Finally, an understanding of the signalling processes involved 
in the hypertensive and vasoconstrictive effects of pazopanib 
and vandetanib is needed. Chapter 3 and previously discussed 
published data suggest that these effects may be due to 
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antagonism of VEGFR2, which initially leads to inhibition of 
NO-dependent vasodilatation and in turn endothelial 
dysfunction. By looking at the effects of vandetanib and 
pazopanib on heart rate, blood pressure and vascular 
conductance in the presence of an NO donor and/or 
epoprostenol (PGI2), the underlying signalling mechanisms 
behind VEGF RTKI induced hypertension can be further 
explored. 
7.5 The Action of Vandetanib and Pazopanib on Isolated 
Pressurised Mesenteric Arterioles, and the Effect of 
Vandetanib on VEGF and Acetylcholine Mediated 
Vessel Dilatation. 
This aim was addressed in Chapter 6 where pazopanib and 
vandetanib were shown to have no significant effect on vessel 
diameter in non-preconstricted vessels. Vandetanib was shown 
to inhibit VEGF- and ACh-mediated vessel dilatation, a novel 
finding. Vandetanib was also able to induce vasodilatation in 
the presence of a vasoconstrictor (U46619), a previously 
unseen finding. The results in Chapter 6 clearly demonstrate 
the importance of the multi-targeted nature of pazopanib and 
vandetanib. Finally, hVEGF165a was shown to be significantly 
more potent in rat mesenteric arterioles than in the VEGF 
NFAT recombinant HEK293 cell line, this result was expected 
due to the ability for ECs, which contain the full plethora of 
VEGFR signalling machinery, to propagate vasoactive signals 
through cell-cell interactions (discussed fully in Chapter 6). 
These results, combined with those previously discussed raise 
multiple questions:  
1. Does vandetanib and pazopanib affect vessel structure? 
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2. Do vandetanib and pazopanib exert the same effect in 
the presence of other vasoactive substances? 
3. Do class II and class III RTKIs demonstrate the same 
effect as vandetanib and pazopanib in 
non-preconstricted vessels? 
Vessel stiffness has been noted as a physiological marker of 
hypertension (Chirinos, 2012). Vessel stiffness is characterised 
by a thickening of the vessel wall and leads to the vessel being 
less responsive to vasoactive substances and haemodynamic 
stress, reducing the ability for the vessel to dilate. Whether 
this is a marker of hypertension or a cause, is currently 
disputed in the literature (Hall et al., 2012). In order to look 
for structural changes in the vessel, vessel biopsies from 
rats/humans treated with vandetanib/ pazopanib could be 
harvested and histological staining of the vascular smooth 
muscle performed. 
Previous research has shown that vandetanib and pazopanib 
are able to bind to multiple receptor tyrosine kinases as well 
as intracellular signalling kinases (Davis et al., 2011); however 
the effect of this on their hypertensive side effect profile is 
unknown. In order to address question 2, the experiments in 
Chapter 6 Sections 6.3.3 and 6.3.4 should be repeated in the 
presence of vasoactive stimuli shown to be inhibited by 
vandetanib and pazopanib. One example of this would be 
PDGF. The inhibition of PDGF signalling has been shown to 
reduce pericyte recruitment during angiogenesis, therefore 
reducing vessel stability (Heldin, 2013). Understanding the 
effects of VEGF RTKIs multi-targeted action on their vasoactive 
profile will help to further improve future drug design. 
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Finally, vandetanib and pazopanib were shown to have no 
effect on unstimulated vessel preparations. Both vandetanib 
and pazopanib are class I RTKIs. They exert their inhibitory 
effects by binding to the active conformation of the receptor, 
competitively antagonising ATP binding at various intracellular 
kinase groups (Gotink and Verheul, 2010). However, class II 
and class III RTKIs are able to bind to their targets while they 
are in the non-active conformational state (Zhang et al., 2009; 
Gotink and Verheul, 2010; Davis et al., 2011). By repeating 
the experiments in Figure 6.2, with sorafenib and neratinib a 
greater understanding of how an RTKI’s mechanism of action 
affects VEGF RTKI vasoactivity would be gained. 
7.6 Overall Conclusion 
Targeted therapeutics, as opposed to traditional cytotoxic 
therapies, were first brought to the clinic in the hope that they 
would reduce many of the side effects seen with non-specific 
cytotoxic chemotherapy. VEGF RTKIs, which are 
multi-targeted, have become a popular therapeutic tool as they 
have been shown to be relatively well tolerated in comparison 
to cytotoxic chemotherapies and drug resistance is a less 
common problem.  
The inhibition of VEGF, a potent stimulant for angiogenesis 
(Gacche and Meshram, 2014), by VEGF RTKIs has been shown 
to reduce vessel density, cancer metastasis and tumour size 
(Liang et al., 2014). Significant increases in progression free 
survival for a multitude of cancer types has lead to VEGF RTKIs 
being FDA approval for the treatment of various solid tumours. 
For example, sorafenib and pazopanib have been shown to 
significantly improve progression free survival in renal cell 
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cancer, with patients taking these compounds on average living 
3 to 9 months longer (Meadows and Hurwitz, 2012). 
However, anti-VEGF RTKIs have been shown to have class 
specific side effects such as hypertension. Hypertension can 
lead to life threatening conditions such as stroke, arterial 
thrombo-embolisms and acute heart failure (Eschenhagen et 
al., 2011). Therefore, clinicians must weigh up the cost-benefit 
ratio of prescribing these compounds, as although they extend 
a patient’s progression free survival they are also able to 
produce serious side effects for those taking them. Whether a 
chosen VEGF RTKI will be prescribed depends on the age of the 
patient, any pre-existing conditions the patient may have, the 
tumour type and its genetic profile as well as any other 
concomitant treatments prescribed eg, surgical removal of the 
tumour mass. A better understanding of how VEGF RTKIs 
cause hypertension may help to further inform clinicians about 
the best treatments to prescribe VEGF-RTKI mediated 
hypertension as well as assist the research and development of 
anti-VEGF compounds that prolong patient progression free 
survival while not being cardio-toxic. 
The body of work undertaken here has given novel insight into 
the ability for anti-VEGF RTKIs work non-competively to inhibit 
VEGF mediated effects in the cell. It has also produced a 
validated method of reproducing hypertension in a rat model, 
both in the short and long term. These models have shown 
that different anti-VEGF RTKIs have different regional 
haemodynamic and post-treatment hypertensive side effect 
profiles. Finally, an isolated vessel myography technique was 
developed that demonstrated VEGF RTKIs are able to cause 
vessel dilatation, while also inhibiting VEGF and ACh mediated 
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vessel dilatation, implying these compounds may have further 
off target effects. 
The ability to use validated in vivo models to reproduce anti-
VEGF RTKI mediated hypertension allows for future 
investigation into the mechanisms behind how hypertension 
occurs as well as how best to reverse it. The models tested 
here also allow for further study into the post-treatment 
hypertensive profile of these compounds – an important issue 
for patients who stop taking drugs like pazopanib, shown here 
to have a more sustained hypertensive effect in the rat after 
treatment in comparision to vandetanib. Finally, the 
experimental model of myography developed here enables 
further research into the direct effect of VEGF RTKIs on vessel 
diameter. This may provide an opportunity to re-define the 
proteins compounds like vandetanib interact with. Not only is 
this important for understanding the mechanisms behind the 
therapeutic and non-therapeutic effects of vandetanib but may 
also aid development of the next generation of safer 
anti-angiogenic therapies. 
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